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Abstract 
 
This thesis presents the first example of reversible photoregulation of the binding of a 
protease, α-chymotrypsin, to a surface.  A modular approach is used involving the 
azobenzene photoswitch group, a surface linker and an enzyme binding group.  This 
approach is designed to be easily extended to the photoregulation of binding of other 
proteases to surfaces by use of enzyme binding groups selective to these proteases. 
 
Chapter one gives a brief outline of some of the important areas involved in to this work, 
including molecular switches, proteases and surface modification. 
 
Chapter two describes the synthesis of azobenzene-containing boronate esters designed as 
photoswitch inhibitors of α-chymotrypsin.  Boronate esters were prepared containing the 
aminophenylboronate group or the peptidomimetic borophenylalanine group for enzyme 
binding and a range of substituents designed for enzyme affinity and/or surface attachment.  
Syntheses primarily involved peptide coupling reactions and azobenzene formation by 
condensation of nitrosobenzenes and anilines.  Coupling reactions were successfully 
carried out using EDCI or isobutyl chlorofomate in several cases where other reagents 
gave unacceptable decomposition. 
 
Chapter three describes the syntheses and HPLC stability studies of derivatives of a 
noncovalent α-chymotrypsin inhibitor.  Several dipeptide-based compounds containing 
either an amide group for surface attachment or an azobenzene group for photoswitching 
were prepared, primarily using peptide coupling reactions.  Each compound was incubated 
with α-chymotrypsin to assess its stability, and all were found by HPLC monitoring to be 
stable to α-chymotrypsin catalysed hydrolysis. 
 
Chapter four describes syntheses of azobenzene-containing trifluoromethylketones and  
α-ketoesters designed as photoswitch inhibitors of α-chymotrypsin.  
Trifluoromethylketones/α-ketoesters containing amine groups for surface attachment were 
prepared, primarily using peptide coupling reactions, but could not be isolated due to the 
incompatibility of the electrophilic ketone and primary amine groups.     
Trifluoromethylketones/α-ketoesters containing terminal alkynes for surface attachment 
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were prepared either by the attachment of an alkyne substituent group to a symmetrical 
azobenzene core or by Pd-catalysed reaction of a protected alkyne with an azobenzene 
having a halide substitutent.   
 
Chapter five describes syntheses of sulfur-containing surface linkers for use in surface 
attachment of the photoswitch inhibitors described in chapters 2-4.  A range of compounds 
containing disulfide or protected thiol groups for surface attachment and azide or 
carboxylic acid groups for inhibitor attachment were prepared.  Syntheses primarily 
involved coupling of functionalised alcohols/amides to carboxylic acid-containing 
disulfides/thioacetates.  Selected linkers were attached to azobenzenes by amide coupling 
or azide-alkyne cycloaddition for surface attachment, photoswitching and/or enzyme assay.  
Azide-alkyne cycloaddition yields were initially poor, but were improved by use of 
stoichiometric amounts of copper catalyst. 
 
Chapter six describes UV/vis photoisomerisation studies and enzyme assays carried out to 
assess enzyme photoswitching of the compounds described in chapters 2-5.  The 
trifluoromethylketones and α-ketoesters described in chapter 4 gave the best results, with 
moderate inhibition of α-chymotrypsin (μM affinity constants) and up to 5.3 fold changes 
in inhibition on UV/vis irradiation.  Many of the boronate esters described in chapter 2 
were found to inhibit α-chymotrypsin, but were somewhat unstable to irradiation.  The 
dipeptide-based compounds described in chapter 3 were inactive against α-chymotrypsin.  
Good photoisomerisation was obtained for an azobenzene containing a symmetrical 
disulfide surface linker and poor photoisomerisation was obtained for an azobenzene 
containing a lipoic acid surface linker. 
 
Chapter seven describes surface attachment of selected photoswitch inhibitors and studies 
of photoregulated enzyme binding to the resultant functional surfaces.  Self assembled 
monolayers (SAMs) of disulfides were formed on gold surfaces and characterised by 
electrochemistry and contact angle measurements.  Binding of α-chymotrypsin to SAMs 
containing a photoswitch inhibitor was detected by quartz crystal microbalance (QCM), 
but was found to be largely irreversible.  An alkyne-containing photoswitch inhibitor was 
attached to a surface plasmon resonance (SPR) chip in a two step procedure involving 
generation of an azide modified surface followed by azide-alkyne cycloaddition.  Binding 
Abstract 
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of α-chymotrypsin to the resultant modified surface was detected by SPR and successfully 
regulated by UV/vis irradiation. 
 
Chapter eight provides conclusions for the work described in this thesis and suggests 
future directions. 
 
Chapter nine gives experimental details for the work described in this thesis. 
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Abbreviations 
 
Ala  alanine 
Asp  aspartic acid 
Boc  tert-butoxycarbonyl 
BOP benzotriazol-1-yloxy-tris(dimethylamino)phosphonium 
hexafluorophosphate 
Cbz  carbobenzyloxy 
CV  cyclic voltammetry/cyclic voltammogram 
d  doublet (NMR) 
dd  doublet of doublets (NMR) 
de  diastereomeric excess 
DCM  dichloromethane 
DIBAL diisobutylaluminium hydride 
DIEA  diisopropylamine 
DMAP  dimethylaminopyridine 
DME  dimethoxyethane 
DMF  dimethylformamide 
DMSO  dimethylsulfoxide 
dq  doublet of quartets (NMR) 
dt  doublet of triplets (NMR) 
EDCI  N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride 
EDTA  ethylenediamine tetraacetic acid 
eq  equivalents 
Fmoc  9-fluorenylmethoxycarbonyl 
Gly  glycine 
HATU O-(7-azabenzotriazol-1-yl)-N,N,Nʹ,Nʹ-tetramethyluronium 
hexafluorophosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His  histidine 
HMDS  hexamethyldisilazane 
HMPA  hexamethylphosphoramide  
HOAt  N-hydroxy-7-azobenzotriazole 
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HOBt  N-hydroxybenzotriazole 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrometry 
Hyp  hydroxyproline 
LDA  lithium diisopropylamide 
Leu  leucine 
LiHMDS lithium hexamethyldisilazane 
Ms  mesyl (methanesulfonyl) 
MS  mass spectrometry 
NHS  N-hydroxysuccinimide 
NMM  N-methylmorpholine 
NMR  nuclear magnetic resonance 
OEG  oligoethylene glycol 
pet ether petroleum ether 
Phe  phenylalanine 
Pro  proline 
PSS  photostationary state 
QCM  quartz crystal microbalance 
qu  quantitative 
r.t.  room temperature 
SAM  self-assembled monolayer 
sat.  saturated 
SCE  saturated calomel electrode 
SDS  sodium dodecyl sulfate 
Ser  serine 
SPR  surface plasmon resonance 
Suc  succinyl 
t  triplet (NMR) 
TBAF  tetrabutylammonium fluoride 
TEA  triethylamine 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
Tris  tris-(hydroxymethyl)aminomethane 
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UV  ultraviolet 
Val  valine 
vis  visible 
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Introduction 
 
1.1 Overview 
 
The aim of this project was to prepare a series of photoswitch enzyme inhibitors for 
surface attachment, in order to photoregulate enzyme binding to surfaces.  To achieve this 
goal, existing classes of protease inhibitors containing an azobenzene molecular switch 
were modified to improve molecular switching and to introduce groups for surface 
attachment.  These photoswitch inhibitors were attached to surfaces and enzyme binding 
and photoswitching studies were carried out at the modified surfaces. 
 
This work is based on previous study of photoswitch inhibitors of the enzyme  
α-chymotrypsin.  The work of Harvey1-3 focused on the design of inhibitors containing an 
azobenzene group linked to a peptidomimetic α-ketoester, based on a known inhibitor.4  
This study covered a range of structures and discovered several effective photoswitch 
inhibitors, with a 2-3 fold change in enzyme activity observed on photoisomerisation. An 
example compound is shown in Fig. 1.1 that switches from an inhibition constant, Ki, of 
240 nM in the E form, 1.1, to 130 nM in the Z form, 1.2.  This represents an increase in 
activity on E to Z photoswitching. 
 
 
 
 
 
 
 
Fig. 1.1.  α-Ketoester photoswitch inhibitor of α-chymotrypsin.2 
 
The work of Alexander5 involved the study of photoswitch enzyme inhibitors containing 
the trifluoromethylketone enzyme binding group (Fig. 1.2), again based on known 
inhibitors.6  This work aimed to increase the potency and/or photoswitching of the 
compounds by increased derivatisation of the azobenzene group.  The inhibitors were less 
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active than α-ketoesters, but showed better photoswitching of up to 5 fold changes in 
activity on photoisomerisation. 
 
 
 
 
 
 
Fig. 1.2.  Trifluoromethylketone photoswitch inhibitor of α-chymotrypsin.5 
 
The work described in this thesis involves the study of related inhibitors and those with a 
third enzyme binding group, the boronate ester, as well as further derivatisation of the 
azobenzene group and surface attachment of photoswitch inhibitors. 
 
This chapter summarises the major areas involved in this thesis: molecular switching, 
protease inhibition and surface modification, and gives a brief description of the work 
presented in this thesis. 
 
1.2 Molecular Switching 
 
A single compound can often exist in different forms such as isomers and excited states 
that have significantly different molecular shape and function.  In certain cases, these 
different forms can be reversibly interconverted by non-invasive changes in external 
conditions such as pH, electron transfer, light or heat, and thus can be used as molecular 
switches.  This external control of molecular function is important both in fundamental 
research of molecular properties and as a first step towards useful molecular devices and 
technologies.  As such, it is currently of interest to develop a variety of molecular 
switching methods for a range of systems. 
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Effective, useful molecular switching has various ideal requirements: 
 
1. Efficient and complete switching – a molecular switch should be easily converted 
completely from one form to another.  
 
2. Significant change in properties on switching – a large difference in properties such as 
shape or charge should be obtained between the two forms. 
 
3. Reversibility – molecular switching should be completely reversible and stable over a 
number of switching cycles without side reactions. 
 
4. Ease of synthesis – a molecular switch should be easy to incorporate into a variety of 
different structures without extensive new synthetic design. 
 
In practice, many molecular switches do not fulfil all of these requirements.  However, the 
most useful switches satisfy most of them.  Molecular switches using pH or light control 
are two of the most important, and will be briefly described below: 
 
1.2.1 pH switching 
 
pH switching has been studied in supramolecular chemistry for the development of 
nanoscale devices.  This form of molecular switching usually requires a change in shape 
between a protonated and a deprotonated form of a molecule.  While 
protonation/deprotonation clearly has a large impact on the charge of a molecule, shape is 
not always affected.  However, a localised change in charge can significantly alter 
interactions with neighbouring groups, often leading to a change in shape.  This is 
particularly likely when coordination effects are involved. 
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Fig. 1.3.  Acid-base molecular switch.7 
 
pH switching at a coordination site has been used in the development of ‘molecular 
shuttle’ rotaxanes.7  One such shuttle, shown in Fig. 1.3, consists of a dumbbell shaped 
unit with two coordination sites, NH2+ and bipyridinium2+, and a crown ether ring which 
surrounds the dumbbell and can coordinate to either site.  The ring coordinates to the NH2+ 
site in acidic media (structure 1.6), and on deprotonation of the group to NH at higher pH 
the ring moves to the bipyridinium coordination site (structure 1.7).  An extension of this 
pH switching molecular device is the molecular ‘elevator’, which consists of three 
connected molecular shuttles.8  This large platform structure shifts up and down on pH 
switching. 
 
1.2.2 Photoswitching 
 
Photoswitching is the isomerisation of a compound resulting from irradiation with light.  
While many  molecules undergo electronic transitions under UV/visible irradiation, only a 
few reversibly isomerise as a result of a transition.   
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To fulfil the ideal molecular switching requirements, the photoisomerisation process 
should have high quantum yield and proceed to completion quickly without side reactions.  
The isomer formed should be stable to ambient light conditions and to the initial 
isomerisation wavelength, but be readily isomerised back to the initial state by 
isomerisation at a different wavelength.  Several relatively effective photoswitches that 
fulfil most of these criteria have been developed and used extensively. 
 
For studies aimed towards information storage, photoswitches are required that are very 
stable and reversible, and have some easily measurable property change (e.g. colour) rather 
than a large change in shape on switching.  For this purpose, studies have focused on such 
compounds as diarylethenes and fulgides.  Diarylethenes are developed from stilbene 1.8, 
which undergoes a photochemical reaction to form dihydrophenanthrene 1.9 (Fig. 1.4).9  
This electrocyclic reaction proceeds under UV irradiation, and the reverse reaction occurs 
thermally, as shown in Fig. 1.4.  Unfortunately, dihydrophenanthrene 1.9 is irreversibly 
oxidised in the presence of air to phenanthrene 1.10, which does not undergo 
photoisomerisation.  Stilbene has been systematically improved by the replacement of the 
phenyl rings by heterocycles, constraining the structure to prevent E/Z isomerisation about 
the double bond, and substitution of the ortho positions of the aromatic rings to prevent a 
permanent cyclisation.10  These modifications have produced stable, thermally irreversible 
compounds with effective photoswitching from a colourless to a coloured state.  For 
example, compound 1.11 (Fig. 1.4) cyclises on UV irradiation to 1.12, which is heat stable 
but reopens to 1.11 on visible irradiation. 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4. Photoswitching of diarylethenes. 
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Fulgides are another class of photoisomerisable compounds that undergo a photochemical 
transition between an ‘open’ colourless form and a ‘closed’ coloured form,11 such as 
compound 1.13, which isomerises to 1.14 on UV irradiation (Fig. 1.5).  The first fulgides 
discovered were unstable and thermally reversible due to reactions of the closed form.  
However, as for diarylethenes, modifications have improved the stability and 
photoswitching of these compounds. 
 
 
 
 
 
 
Fig. 1.5.  Photoswitching of fulgides. 
 
The most commonly studied photoswitch is azobenzene.  Azobenzenes undergo 
photoswitching by a simple E/Z isomerisation, as shown in Fig. 1.6.  E-Azobenzene 1.15 is 
the most stable form, but readily undergoes isomerisation to the Z isomer 1.16 on UV 
irradiation.  The two isomers have markedly different properties, the major difference 
being the shape of the isomers.  The E isomer is a planar molecule with extended π-
conjugation through the aromatic structure, whereas the Z isomer is a distorted non-planar 
structure, as steric repulsion between ortho hydrogen atoms on the two phenyl rings cause 
the rings to rotate out of the C-N=N-C plane.12  Due to these differences in shape, the 
isomers have different electronic and physical properties.  In general the Z isomer is more 
polar than the E isomer,13 which can be observed, for example, by the separation of the 
isomers on a chromatography column.14  The measured dipole moments for the isomers 
are 3.0 D for Z-azobenzene and zero for the E isomer.15 
 
 
 
 
 
Fig. 1.6.  Photoswitching of azobenzene. 
 
O
O
O
S O
O
O
S
UV
UV, vis
1.13 1.14
N
N
N
NUV
vis, Δ
1.15 1.16
Chapter One: Introduction 
 
20
 
The UV/vis spectra the isomers of azobenzenes are very different (see Fig. 1.7).  The E 
isomer has a strong UV absorption band at approximately 300-350 nm and a weaker 
visible absorption band at approximately 400-500 nm, which causes azobenzenes to have a 
distinctive red/orange colour.  The Z isomer lacks the strong UV band, but has a visible 
absorption band, similar to the E isomer.  Irradiation of the E isomer by wavelengths 
within its UV absorption band causes a π → π* transition to an excited state.16  This 
excited state is flexible to structural change by an inversion or rotation mechanism17 and 
thus can relax to either the E or Z isomer.  Relaxation is most likely to give the more stable 
E isomer, but any E isomer formed can then be excited by further irradiation, while any Z 
isomer formed is less likely to be excited by light of these wavelengths.  Continuous 
irradiation of an azobenzene thus eventually leads to an equilibrium photostationary state 
(PSS) that is enriched in Z isomer, usually in the order of 60-90% Z.  Irradiation by visible 
light excites both isomers, and since the excited state is most likely to relax to the more 
stable E isomer, visible irradiation gives a PSS of mainly E isomer, usually close to 80% E.  
In normal ambient lighting conditions (i.e. sunlight or indoor lighting) a PSS is obtained 
that is similar to that obtained by visible irradiation.1, 5  The Z isomer is less thermally 
stable than the E isomer and in the absence of light isomerises to the E isomer at room 
temperature.  
Fig. 1.7.  UV/visible spectra of E and Z azobenzene. 
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As a photoswitch, azobenzene has several favourable properties: a large difference in 
shape between isomers, fast photoisomerisation with high quantum yield, no significant 
photodecomposition and relatively easy synthesis of derivatives.  The drawbacks of 
azobenzene are the thermal instability of the Z isomer and the incomplete 
photoisomerisation that is usually obtained.  Despite these problems, azobenzene is an 
effective photoswitch, especially in laboratory studies where complete switching and 
thermal stability are not necessarily required, and has been applied to a variety of 
photoswitching experiments, some of which will be discussed later in this chapter.  
 
1.2.3 Biophotoswitching 
 
One of the most interesting applications of photoswitching is photocontrol of biological 
systems.  Important natural processes such as photosynthesis and vision involve 
photoreactions, and natural photoswitch proteins have been discovered.18  In order to 
mimic these natural processes or to modify biological activity in new ways, it is of interest 
to incorporate photoswitches into biomolecules such as peptides19 and proteins.20  
Alternatively, activity of biomolecules can be modulated using external photoswitches 
such as photoisomerisable enzyme inhibitors or polymers.21  Most examples of 
biophotoswitching use azobenzene as photoswitch, as it is relatively easy to incorporate 
into biological systems. 
 
A recent example of the modification of a biological structure to introduce photoswitching 
involved the cross linking of collagen with an azobenzene unit.22  Collagen consists of 
three polypeptide chains in a triple helix structure.  The azobenzene group was attached to 
these chains as a cross-linking clamp (Fig. 1.8) that was expected to disrupt the peptide 
structure in the Z form, but not affect the structure in the E form.  As expected, a triple 
helix was formed from the E-azobenzene form of the modified collagen, then  UV 
photoisomerisation to the Z-isomer disrupted the structure of the polypeptide chains, 
causing the helix to partially unfold.  Subsequent visible photoisomerisation returned the 
structure to the triple helix form.  As in many cases, the E to Z photoisomerisation did not 
proceed to completion, so only a small percentage of the collagen molecules unfolded.   
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Fig. 1.8.  An azobenzene modified collagen peptide for photoregulated helix folding and 
unfolding.22  
 
Azobenzene photoisomerisation has been used to control enzyme activity in many studies, 
generally by incorporation of azobenzene into the enzyme or an inhibitor of the enzyme.  
The former approach has been performed, for example, by the covalent attachment of an 
azobenzene compound to the exterior lysine residues of papain.23  Photoisomerisation of 
the modified enzyme led to 2.75 fold decrease in enzyme activity, presumably due to a 
change in the protein tertiary structure that affected the shape of the active site.  A more 
ambitious variation on this approach involved the genetic modification of a bacteria to 
biosynthesise proteins containing a non-natural azobenzene amino acid.20  
Photoisomerisation of this bacteria modulated the biological activity of the modified 
protein.  Recently, the thiooxopeptide bond has been used as an alternative photoswitch.24  
This group is nearly isosteric with a normal peptide bond but is easily photoisomerised 
between cis and trans forms.  Replacement of a normal peptide bond in Ribonuclease S 
with a thiooxopeptide bond gave an enzyme which retained activity in its normal form, but 
became inactive on photoisomerisation. 
 
The approach of most interest to our group is the incorporation of the azobenzene group 
into enzyme inhibitors.  This indirect approach may lead to useful molecular devices and 
applications, such as those that this work begins to investigate.  The first photoswitch 
enzyme inhibitor, 4-azophenyldiphenylcarbamyl chloride 1.1814 (Fig. 1.9), was developed 
in 1969, by modification of known irreversible α-chymotrypsin inhibitor 
diphenylcarbamyl chloride 1.19.  The E and Z isomers of 1.18 were isolated, assayed, and 
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photoisomerisation was studied.  The E isomer was found to inactivate chymotrypsin 5 
times faster than the Z isomer, and in situ photoisomerisation during an assay was found to 
change the rate accordingly.   
 
 
 
 
 
 
Fig. 1.9.  Photoswitch α-chymotrypsin inhibitor 1.1814 and related inhibitor 1.19. 
 
Since this first example, a variety of photoswitch inhibitors for different enzymes have 
been developed.  The approach used in development of 1.18 (modification of previously 
known inhibitors) led to the development of photoswitchable irreversible inhibitors for 
acetylcholine esterase25 and photoswitchable substrates for trypsin.26  Photoswitchable 
reversible inhibitors were later developed, such as those for papain and chymotrypsin27 
consisting of an azobenzene group linked to an aldehyde (1.20) and a boronic acid 
warhead† (1.21), respectively, as shown in Fig. 1.10.  Both inhibitors showed a significant 
difference in activity between the E and Z forms.  In situ photoisomerisation of the papain 
inhibitor gave a reversible 6 fold decrease in enzyme activity, while only a 13% decrease 
in activity was observed for the α-chymotrypsin inhibitor.  This study was the initial basis 
for our group’s work, which has mainly involved making systematic structural changes to 
increase the enzyme inhibition, photoswitching and practical use of photoswitch  
α-chymotrypsin inhibitors. 
   
 
 
 
 
 
Fig. 1.10.  Photoswitch reversible inhibitors of papain and α-chymotrypsin.27 
 
                                                 
† ‘Warhead’ in this context refers to an electrophilic group that is able to bind to the nucleophilic amino acid 
residue in the enzyme active site. 
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In a recent study, a photoswitch inhibitor of mitochondrial complex I was designed to 
mimic the structure of an effective known inhibitor in the E form (1.22, Fig. 1.11) and an 
ineffective known inhibitor in the Z form (1.23).28  Despite containing two azobenzene 
groups, this compound isomerised remarkably well to the Z,Z form.  An initial state of 
100% E,E (obtained by thermal Z to E reaction in the dark) was isomerised to 95% Z,Z and 
5% E,Z by UV irradiation.  However, visible irradiation of the Z,Z isomer with visible 
light only returned 60% E,E isomer (and 35% E,Z, 5% Z,Z).  This suggests that the Z 
isomer of these azobenzene groups has high stability, possibly due to hydrophobic 
interactions of the alkyl substituents.  Photoisomerisation and enzyme assays showed that 
the E,E enriched state resulting from visible irradiation inhibited the enzyme twice as 
strongly as the Z,Z enriched state. 
 
Fig. 1.11.  Photoswitch inhibitor of mitochondrial complex I.28 
 
1.3 Proteases  
 
In this thesis, photoswitch inhibitors for the serine protease α-chymotrypsin were studied.  
This enzyme was chosen for study as it is a simple, well characterised enzyme that was 
expected to be relatively easy to work with, and because proteases are an important class 
of enzymes that are of much significance in modern medicinal chemistry. 
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Proteases are enzymes that catalyse the hydrolysis of amide bonds in peptides and proteins.  
They are involved in many important physiological processes such as digestion, growth, 
immune response and blood coagulation.29, 30  As a result, proteases are also involved in a 
variety of diseases such as cancers, malaria and HIV.  Inhibition of proteases has been 
found to be an effective treatment for some medical conditions.  As such, protease 
inhibitors have been developed into useful drugs.31, 32 
 
1.3.1 Serine proteases 
 
α-Chymotrypsin belongs to the serine protease family, the most widely studied family of 
proteases.  These enzymes cleave peptide bonds by the attack of an activated serine residue 
on the carbonyl group of the bond.29  Serine proteases are usually classified into several 
major groups according to their substrate specificity.  ‘Chymotrypsin-like’ serine proteases, 
the largest group, contain a deep hydrophobic pocket in the S1 position (by the notation of 
Schechter and Berger33), which results in the enzymes specifically binding to 
substrates/inhibitors containing an aromatic group that can fit into this pocket, such as the 
side chains of the amino acids phenylalanine and tryptophan.  Other types of serine 
protease require a positively charged or small hydrophobic group in this position.30 As a 
result of these specificities, serine proteases cleave peptides in a position adjacent to a 
certain type of amino acid residue.  α-Chymotrypsin is present in the pancreas and plays a 
role in digestion by cleaving peptides adjacent to aromatic amino acids.   
 
The generally accepted mechanism of serine protease catalysed amide bond hydrolysis is 
as follows (Scheme 1.1):29, 30  Starting from structure 1.24, first the hydroxyl group of the 
Ser195 residue attacks the carbonyl group of the substrate amide bond.  This step is aided 
by the ‘catalytic triad’ of the Ser195, His57, and Asp102 residues.  The His57 residue acts 
as a base to deprotonate the Ser195 hydroxyl group and increase its nucleophilicity.  The 
Asp102 residue hydrogen-bonds to His57, in order to orient it with the Ser195 hydroxyl 
and the substrate.  After nucleophilic attack (structure 1.25), the negatively charged 
oxygen atom of the substrate is stabilised by hydrogen bonding to the ‘oxyanion hole’ – 
the NH groups of the Ser195 and Gly193 residues.  The next step is the cleavage of the  
C-N bond of the substrate with loss of an amine and the formation of an acyl-enzyme 
intermediate, shown in structure 1.26.  This step is aided by the His57 residue, this time 
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acting as an acid to protonate the amine and increase its leaving group ability.  Next, a 
water molecule attacks the newly formed acyl group, activated by deprotonation by the 
His57 residue.  Similar to the first attack, the oxyanion hole stabilises the negatively 
charged oxygen atom, and the His57 residue acts a base.  The enzyme-substrate C-O bond 
is cleaved, and a carboxylic acid is formed.  This is aided again by the His57 residue, 
acting as an acid to protonate the Ser195 hydroxyl group in order to improve its leaving 
group ability.  The overall result of the reaction is the cleavage of the amide substrate into 
an amine and a carboxylic acid, with restoration of the enzyme catalyst, as shown in 
structure 1.27. 
 
 
Scheme 1.1.  Mechanism of chymotrypsin catalysed amide hydrolysis. 
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1.3.2 Reversible chymotrypsin inhibitors 
 
The inhibition of α-chymotrypsin has been studied extensively, and a range of reversible 
and irreversible inhibitors have been designed.  This project involves the study of 
reversible inhibitors only, so these will be the focus of this discussion. 
 
Usually, there are two major components of reversible chymotrypsin inhibitors: 
 
i) The ‘warhead’ group – This is an electrophilic group that covalently (but reversibly) 
binds to the highly nucleophilic Ser195 residue, in place of the amide bond of substrates 
that normally bind to the enzyme (see sections 1.3.3-1.3.5 for examples).  While it is 
preferable not to use a warhead group due to potential selectivity and reactivity problems, 
the use of a warhead significantly improves enzyme binding affinity. 
 
 ii) The active site recognition domain – The remainder of the molecule is required to fit 
well into the active site, in particular the S1 and S2 subsites.  This can be carried out by 
mimicking the structure of substrates that are known to be hydrolysed by α-chymotrypsin. 
 
As mentioned above, α-chymotrypsin binds to substrates and inhibitors containing an 
aromatic group in the P1 position.  It also contains a large hydrophobic S2 pocket, which 
preferentially binds large hydrophobic groups such as the side chains of the amino acids 
leucine and valine.  Beyond the S2 subsite, α-chymotrypsin has little selectivity,29 although 
extended peptidic inhibitors containing four amino acids improve binding over compounds 
that bind only to the S1 pocket,34 possibly due to hydrogen bonding interactions. 
 
There are several major types of reversible chymotrypsin inhibitors, including boronic 
acids, trifluoromethylketones and α-ketoesters.  These, and an example of a group of 
effective non-warhead inhibitors, will be summarised in the following sections. 
 
1.3.3 Boronic acid and boronate ester based inhibitors 
 
Boronic acids are a class of compounds that are used extensively in synthetic organic 
chemistry;35 however, they are also effective as electrophilic enzyme binding groups.  
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Boron groups are naturally electron deficient, as boron has three valence electrons and can 
normally form only three covalent bonds in a neutral state.  As a result, these groups are 
electrophilic and can be attacked by nucleophiles such as the activated hydroxyl group of 
the α-chymotrypsin Ser195 residue.  As such, an α-chymotrypsin inhibitor can be 
produced by combination of a boronic acid or boronate ester† and appropriate active site 
recognition groups. 
 
The earliest boronic acid inhibitor of α-chymotrypsin was 2-phenylethaneboronic acid,36 
which inhibits α-chymotrypsin with a Ki of 40 μM.  This compound is probably the 
simplest possible boronic acid inhibitor, containing only the boronic acid group and a 
phenyl group to bind to the S1 subsite.  It was proposed to bind well to the enzyme as it 
mimics of the transition state of substrate hydrolysis, as shown in Fig. 1.12.  When the 
boron is covalently bound to the enzyme, it is thought that a hydroxyl group of the boronic 
acid hydrogen bonds to the oxyanion hole. This theory is supported by the crystal structure 
of the enzyme-inhibitor complex.37  
 
 
 
 
 
 
 
 
Fig. 1.12.  Transition state inhibition by 2-phenylethaneboronic acid.36 
 
Since report of this compound, more sophisticated boronic acid inhibitors have been 
developed.  The compounds of most interest here are those designed by replacement of the 
carboxylic acid group of phenylalanine by a boronic acid.  First synthesised by Matteson, 
these compounds are effective inhibitors of α-chymotrypsin, the simplest (1.28, Fig. 1.13) 
having a Ki of 2.1 μM.38  Extension of this compound to short peptides such as 1.29 was 
carried out to obtain more potent inhibitors,34 the best having a Ki of 3.4 nM due to more 
                                                 
† Boronic acids are compounds of the formula RB(OH)2, where R is any group.  Boronate esters are 
compounds of the formula RBORʹORʹʹ, where R is any group, Rʹ and Rʹʹ are alkyl groups. 
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effective binding to the extended active site domain.  Other work has produced boronic 
acid analogues of other amino acids, to inhibit different proteases.31 
 
 
 
 
 
 
Fig. 1.13.  Peptidomimetic boronic acid inhibitors of α-chymotrypsin.34, 38 
 
Boronate esters are a protected form of boronic acids, and in many cases inhibit proteases 
with similar inhibition constants to the corresponding boronic acids.34, 39  These 
compounds were studied in this project, because it was expected that they might be more 
stable and easier to synthesise than boronic acids and inhibitors containing electrophilic 
ketone groups. 
 
1.3.4 Trifluoromethylketone based inhibitors 
 
Similar to boronic acids, trifluoromethylketones are electrophilic compounds that can form 
reversible covalent bonds to the α-chymotrypsin Ser195 hydroxyl, as shown in Fig. 1.14.  
α-Fluorinated ketones are highly electrophilic due to the electron withdrawing effect of the 
electronegative fluorine atoms.  As such, they are effective protease inhibitiors.  Various 
mono-, di-, and tri- fluorinated ketones have been synthesised and assayed.6, 40, 41  As 
would be expected, trifluoromethylketones are the most active of these fluorinated ketones, 
due to the greater electron withdrawing effect imparted by a larger number of fluorine 
atoms.  On the other hand, α-difluorinated ketones are of interest as they can be extended 
in the S′ direction to improve enzyme binding.  This approach has been used to produce 
very potent α-chymotrypsin inhibitors.41 Trifluoromethylketones containing the 
azobenzene group have been found to be effective photoswitch inhibitors of α-
chymotrypsin.5 
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Fig. 1.14.  Transition state inhibition by peptidyl trifluoromethylketones. 
 
1.3.5 α-Ketoester based inhibitors 
 
α-Ketoesters bind to serine proteases in a similar manner to trifluoromethylketones, as the 
electron withdrawing ester group increases the electrophilicity of the ketone.  These 
compounds have been found to exhibit very potent inhibition of α-chymotrypsin.  For 
example, compound 1.30 (Fig. 1.15) has a Ki of 150 nM.4 
 
 
 
 
 
 
Fig. 1.15. α-Ketoester α-chymotrypsin inhibitor.4 
 
A range of α-ketoesters containing the azobenzene group have been found to be effective 
photoswitch inhibitors of α-chymotrypsin.1-3 
 
1.3.6 Non-covalent inhibitors 
 
Inhibitors containing an electrophilic warhead group can often bind to a range of similar 
enzymes and other biomolecules, reducing specificity and biostability.  Consequently, it is 
preferable to develop non-covalent inhibitors lacking an electrophilic group.   
α-Chymotrypsin accepts a range of peptide substrates with specificity primarily relying on 
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interaction with the S1 subsite.  This creates difficulties in the design of non-covalent 
inhibitors; however, important exceptions have been reported using a D-Leu, L-Phe, 
benzylamine sequence.42  These peptides bind to chymotrypsin in an unusual inhibitory 
conformation, with the D-Leu and L-Phe side chains both placed in the large S2 subsite and 
the benzylamine group in the narrow hydrophobic S1 pocket, as shown in Fig. 1.16.  This 
binding is proposed to be stabilised by hydrophobic interactions between the D-Leu and L-
Phe side chains, and is observed in the crystal structure of the enzyme-inhibitor complex.43 
 
 
 
 
 
 
 
Fig. 1.16 Binding of a non-covalent inhibitor to the chymotrypsin active site.42 
 
We envisaged that the benzylamine group of this inhibitor could be replaced by an 
azobenzene to create a simple photoswitch inhibitor. 
 
1.4 Surface modification for development of functional surfaces 
 
In this thesis, photoswitch inhibitors of α-chymotrypsin were attached to surfaces to 
generate functional surfaces for photoregulated enzyme binding.  The attachment of 
organic molecules to surfaces is currently an important area of research with potential 
applications in areas such as sensor science, medicine, and the development of nanoscale 
devices.  As a result, the modification of a variety of surfaces has been studied, in 
particular carbon,44, 45 silicon,46, 47 and gold.48, 49 Gold surfaces have received the most 
attention in studies of biological interactions and the development of complex molecular 
devices.  This is due to the relative ease of attachment of a variety of compounds to SAMs 
on gold, and the use of techniques such as SPR that can be used to monitor interactions of 
molecules at gold surfaces.   
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1.4.1 Modification of gold surfaces 
 
The formation of SAMs of alkyl thiols/disulfides on gold was chosen for use in this project 
for surface attachment of photoswitch enzyme inhibitors.  SAMs have been extensively 
studied and excellent reviews are available,50 so only aspects most relevant to the work in 
this thesis are reviewed here.  SAMs spontaneously form on immersion of a gold surface 
in a solution of an alkyl thiol or disulfide, and are relatively stable and ordered structures 
due to: 
 
a) The covalent bond that is formed between sulfur and gold atoms.51 
 
b) Hydrophobic interactions between alkyl groups.  These groups are found to pack 
together, standing upright on an angle of 20-30º from perpendicular to the surface (Fig. 
1.17).52  This well ordered structure requires a long alkyl chain; short chains (less than 9 
methylene groups) tend to form less ordered assemblies. 
 
 
 
 
 
 
 
 
 
Fig. 1.17.  Structure of an alkyl thiol SAM on a gold surface. 
 
As these SAMs are densely packed and ordered such that the thiol ‘head’ group is bound 
to the gold, the ‘tail’ end of the alkyl chain is presented at the surface of the SAM.  The 
properties of the tail group thus have a large impact on the character of the modified 
surface.  However, this group generally has little impact on the formation or stability of the 
SAM unless sterically bulky and therefore is able to be freely derivatised to modify the 
properties of the surface.   
 
 
Au
S S S SSS S SS
Chapter One: Introduction 
 
33
 
An example of a surface property that can be controlled through the use of SAMs is 
wettability.  Alkyl thiols with a range of tail groups have been used to form surfaces of 
varying hydrophilicities.53 Surface hydrophilicity is measured using contact angles, the 
angles that droplets of water (or other liquids) make at a surface (see Fig. 1.18).  Small 
water contact angles (<50º) are obtained on hydrophilic surfaces, as the droplets spread out 
to maximise contact with the surface.  Very hydrophobic surfaces give high contact angles 
(>100º), as the water droplets bead on the surface to minimise contact with the surface.  
SAMs with hydrophobic tail groups such as CH3 and CF3 give very high contact angles, 
whereas hydrophilic tail groups such as OH and CONH2 give low contact angles.  
Modification of this type is of interest for the development of highly water resistant 
surfaces (hydrophobic), and surfaces that resist adsorption of biomolecules (hydrophilic). 
 
 
 
 
 
Fig. 1.18.  Contact angles: low at hydrophilic surfaces (left) and high at hydrophobic 
surfaces (right). 
 
In order to produce SAMs presenting complex structures at the surface, molecules can be 
linked to the tail groups of alkyl thiols.  There are two general approaches used: 
 
a) Synthesis of a thiol with the complex structure attached to the alkyl group.  This 
approach has the advantage that the desired SAM can be directly formed from this thiol; 
the disadvantage is that it can be synthetically challenging.  This approach has been used 
for a variety of systems such as the surface attachment of ferrocenes54 and calixarenes.55  
 
b) Formation of a SAM containing a reactive linker tail group, followed by attachment of 
the complex structure to this SAM.  This approach is potentially more versatile; however, 
carrying out a reaction at a surface can be difficult due to steric crowding and the 
difficulties of establishing the yield and identity of products.  Several linker groups have 
been used for this approach, including carboxylic acids,56 biotin,57 and azides/alkynes.58 
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In this thesis, both approaches were used to attach photoswitch enzyme inhibitors to 
surfaces.   
 
1.4.2 Photoswitching at surfaces 
 
The final goal of this thesis was to achieve photoswitching of azobenzene-containing 
inhibitors at a surface.  Photoisomerisation of surface modifiers has been extensively 
studied; however, most previous studies used simpler systems designed for optical 
information storage or control of the physical properties of the surface.   
 
SAMs of azobenzene-containing alkyl thiols on gold have been studied.  In many of these 
studies the azobenzene group was used for structural studies only and photoisomerisation 
was not attempted.59-61 These structural studies generally found that the azobenzene groups 
tend to pack tightly together in SAMs in a similar way to alkyl chains, as shown in Fig. 
1.19, structure 1.31.  This suggests that photoisomerisation would be difficult in these type 
of SAMs, as there is little free space for the isomerisation.  A detailed study of 
photoswitching in densely packed azobenzene SAMs using UV/vis and electrochemistry 
found that only a small proportion of the azobenzene groups was isomerised by UV 
irradiation.62  In other studies, successful photoisomerisation was obtained by increasing 
the free volume in the SAM using asymmetrical disulfides.63, 64  These disulfides contain 
two different alkyl chains, one containing an azobenzene group.  SAMs formed from these 
compounds contain space for the azobenzene isomerisation, as shown in structure 1.32.  
Photoisomerisation has been obtained more easily on silicon surfaces,65 which are 
presumably less densely packed than SAMs on gold.  In one example, light was used to 
switch an azobenzene-modified surface between hydrophilic (contact angle <5º) and super 
hydrophobic (contact angle 153º).66   
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Fig. 1.19. Comparison of structures of azobenzene SAMs formed from a thiol (1.31) and 
an asymmetrical disulfide after cleavage of the disulfide bond (1.32) 
 
Some work has been carried out towards more complex photoisomerisable surfaces.  For 
example, a light controlled molecular shuttle has been developed.67  This system contains a 
surface-attached rotaxane-like structure, similar to the pH switching shuttle mentioned 
previously in section 1.3.  The ‘ring’ of the rotaxane, a cyclodextrin molecule, is 
associated with the azobenzene group as the E isomer and moves to a different location on 
E to Z photoisomerisation. 
 
1.4.3 Studies of biological interactions at surfaces using SPR and QCM 
 
The recently developed SPR and QCM technologies were used in this thesis for the 
detection of enzyme binding to photoswitch surfaces.  These methods allow direct label-
free monitoring of the binding of biomolecules to surfaces, and are currently of much 
interest for use in advanced biological assays.   
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SPR detects binding of molecules to a surface by monitoring changes in the absorption of 
light at a gold surface.68  A light beam is directed at the underside of a surface consisting 
of a gold layer on a glass substrate, as shown in Fig. 1.20, and an electrical field (the 
evanescent wave) is formed at the interface between the glass and the gold.  This field 
interacts with the gold surface by the excitation of surface plasmons, leading to absorption 
of the incident light.  A solution is flowed over the gold surface, and the absorbance is 
measured at a range of incident angles, θ.  The angle of maximum absorbance (the 
resonance angle) is dependent on the refractive index of the interface between the gold and 
the solution, which is in turn dependent on the properties of the gold surface.  When 
molecules attach to the surface, the resonance angle changes.  Monitoring the resonance 
angle thus allows detection of surface binding events.  SPR is relatively easy to use in 
study of biomolecular interactions, partly due to the commercial availability of surfaces 
with a dextran polymer layer attached to the gold.  This polymer layer contains carboxylic 
acid groups for binding of biomolecules and resists non-specific protein adsorption.69 
 
 
 
 
 
 
 
Fig. 1.20. Surface plasmon resonance apparatus involving the reflection of a light beam 
from a gold/glass surface interface.   
 
QCM utilises the piezoelectric effect of AT-cut quartz crystals.70  When an alternating 
current is applied to such a crystal, it vibrates.  The resonance frequency of this vibration 
depends on the mass of the crystal, so changes in the mass of the crystal can be detected by 
changes in the resonance frequency.  Very small mass changes in the order of ng cm-2 can 
be detected in this way, which allows attachment of molecules to the surface of the crystal 
to be studied.  The Sauerbrey equation71, 72 can be used to calculate the mass change from 
the observed frequency change: 
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Where Δf is the change in frequency, Δm is the change in mass, and f0, A, ρq, μq, and υq are 
constants.  While this equation is not strictly correct for non-rigid surfaces such as a layer 
of enzyme, it was considered sufficiently accurate for the mass changes studied in this 
work.  Commercially available crystals for use in QCM usually have a layer of gold on the 
surface for formation of SAMs.  QCM has been used in some studies of biological 
interactions.73, 74 
 
Studies of enzyme binding to SAMs have been carried out using SPR.  A simple example 
involved monitoring of non-specific protein adsorption to surfaces.68, 75 Non-specific 
binding occurs when proteins in aqueous solutions come into contact with hydrophobic 
surfaces.  As the interior of proteins is hydrophobic, proteins can denature and spread out 
on surfaces to maximise hydrophobic interactions.  These studies measured this binding to 
SAMs comprising of two components -  an ethylene glycol compound known to block 
non-specific adsorption and a hydrophobic compound that was expected to promote non-
specific adsorption.  It was found that SAMs with a low proportion of small hydrophobic 
groups (CH3) completely resist protein adsorption, whereas SAMs with a low proportion 
of large hydrophobic groups (CPh3) only partially resist adsorption.  As would be expected, 
larger amounts of non-specific adsorption were measured for SAMs with greater 
proportions of either hydrophobic group. 
 
A more complex study involved measurement of specific enzyme binding to a SAM 
containing an enzyme inhibitor.76  Mixed SAMs were formed using two components – a 
diluent thiol containing a triethylene glycol group to block non-specific binding and a thiol 
containing a known inhibitor of carbonic anhydrase, as shown in Fig. 1.21.  The SAMs 
were able to selectively bind carbonic anhydrase from solution but effectively block non-
specific adsorption of other proteins.   
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Fig. 1.21.  A SAM for biospecific adsorption of carbonic anhydrase.76 
 
Some studies of photoregulated binding of biomolecules to surfaces have been carried out.  
For example, an antibody sensor has been developed using the spiropyran photoswitch.77  
This system contains a spiropyran attached to a gold surface by a thiol linker, as shown in 
Fig. 1.22.  The spiropyran was derivatised to bind anti-dinitrophenyl antibody, and can be 
converted between isomers 1.33 and 1.34 by UV/vis photoisomerisation.  QCM and SPR 
analysis was used to monitor binding of the antibody to the surface-attached ligand.  The 
antibody attaches to surface 1.33, but can be washed off the surface after UV 
photoisomerisation to 1.34.  Visible irradiation returns the active form 1.33 and antibody 
again binds to the surface. 
 
 
 
 
 
 
 
 
Fig. 1.22.  A SAM for photocontrolled antibody binding.77 
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More recently, a study has reported photocontrolled cell binding to a surface using an 
azobenzene-containing integrin-binding peptide attached to a polymer surface.78  The E 
isomer of this peptide binds to integrin, an enzyme which promotes cell growth to the 
surface.  UV photoisomerisation to the Z isomer reduces the rate of cell growth to the same 
as that observed at an unmodified surface.   
 
1.5 Work described in this thesis 
 
The major goal of this thesis was to develop photoswitch protease inhibitors for attachment 
to surfaces, with a secondary goal being to improve knowledge of biological 
photoswitching. 
 
This work was carried out to as a step towards the development of functional surfaces that 
bind and release a range of biomolecules in a controlled manner.  Study of such surfaces 
may lead to the development of new technologies such as reversible biosensors, advanced 
medical implants and biomolecular computers.  The initial development of these functional 
surfaces requires approaches for the controlled binding of families of biomolecules to 
surfaces.  Towards this goal, a modular approach was developed here for photoregulated 
surface binding of the protease family of enzymes, initially targeting the serine protease α-
chymotrypsin. 
 
This approach involved the synthesis and surface attachment of photoswitch inhibitors 
containing an azobenzene photoswitch core with substituent surface linker and enzyme 
binding groups, as shown schematically in Fig. 1.23 below.  Photoisomerisation of the 
photoswitch group then allows modulation of the enzyme binding properties of the surface.  
The modular system allows a variety of groups to be used as each of the three components, 
in order to evaluate the best for each function.  Enzyme binding groups known to bind  
α-chymotrypsin were used in this thesis.  Modification to target other proteases should be 
possible by use of alternative enzyme binding groups specific to these enzymes. 
 
  
 
 
Chapter One: Introduction 
 
40
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.23.  Modular design of photoswitch inhibitors for surface attachment. 
 
More specifically, the inhibitors developed in this thesis can be represented as compound 
1.35, Fig. 1.24.  The 4-position of the azobenzene group contains an electrophilic enzyme 
binding warhead group W, and the 4′ position contains a surface linker group R.  
 
 
 
 
 
 
R = a group for surface attachment,  W = an electrophilic enzyme binding warhead group. 
Fig. 1.24.  General structure of photoswitch inhibitors. 
 
There were several major components of this work: 
 
a) Synthesis of azobenzenes containing a range of electrophilic enzyme binding groups 
and a range of surface attachment groups.  Boronic acids (chapter 2), 
trifluoromethylketones (chapter 4) and α-ketoesters (chapter 4) were studied as enzyme 
binding groups.  Potential inhibitors lacking an electrophilic enzyme binding group were 
also synthesised (chapter 3).  Primary amines and alkynes were studied as surface 
attachment groups. 
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b) Evaluation of the photoswitching and enzyme binding properties of the azobenzenes by 
photoisomerisation studies and enzyme assays (chapter 6). 
 
c) Synthesis of alkyl disulfides for surface modification (chapter 5), surface attachment of 
the inhibitors, and photoregulated enzyme binding to the modified surfaces (chapter 7). 
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Synthesis of boronate esters 
 
2.1 Introduction 
 
The first major goal of this thesis was the development of photoswitch enzyme inhibitors 
for surface attachment.  Azobenzene-containing boronate esters were initially prepared for 
this purpose.  The boronate ester group (see chapter 1, section 1.3.3) was chosen due to its 
apparent ease of synthesis and thus potential for use in complex disubstituted azobenzenes 
for surface attachment.  For example, the related azobenzene-containing boronic acid 1.21 
(Fig. 2.1) exhibits photoregulated inhibition of α-chymotrypsin and was prepared in a 
relatively simple synthesis1 compared to other reported photoswitch α-chymotrypsin 
inhibitors.  Extension of this compound in the 4′-position of the azobenzene group was 
considered a simple method to obtain a photoswitch inhibitor for surface attachment. 
 
 
 
 
 
 
Fig. 2.1.  Reported photoswitch inhibitor of α-chymotrypsin 1.21. 
 
This chapter describes the synthesis of a range of boronate esters 2.1-2.11 (figs. 2.2 and 
2.3) designed to act as photoswitch inhibitors of α-chymotrypsin.  These compounds 
contain the azobenzene photoswitch group and an enzyme binding group containing a 
boronate ester.  The boronate esters 2.10-2.11 additionally contain a group for surface 
attachment.  Compounds 2.1-2.9 lacking a surface attachment group were synthesised so 
that the best enzyme binding structures could be identified without the added complication 
of an additional substituent.   
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Fig. 2.2.  Azobenzenes 2.1-2.6 containing aminophenylboronate ester for enzyme binding. 
 
The aminophenylboronate compounds 2.1-2.6 are based on known photoswitch inhibitor 
1.21.  The simplest, 2.1, is structurally very similar to 1.21, differing only in the 
replacement of the sulphonamide group by an amide and the use of a boronate ester rather 
than a boronic acid group.  While sulfonamides are generally more stable than amides, 
they are comparatively difficult to introduce synthetically.  The amide group was chosen 
as it is formed in a simple, versatile coupling reaction between an amine and a carboxylic 
acid.  Synthetic versatility is highly important here, as more complex syntheses were 
required for the preparation of inhibitors for surface attachment, such as amine 2.11.  
Derivatives 2.2-2.6 contain a hydrophobic amino acid adjacent to the 
aminophenylboronate group, designed to improve enzyme binding by targeting the S2 
subsite of the α-chymotrypsin active site.  Assuming that the aminophenylboronate group 
binds to the S1 subsite, this amino acid side chain should bind to the S2 site, which is 
known to accommodate large hydrophobic groups.2  Compounds 2.2, 2.3 and 2.6 contain 
amino acids that are known to have affinity for the S2 site (Val, Leu).  A smaller 
hydrophobic amino acid was used in compounds 2.4 and 2.5 to partially fill the S2 pocket 
so that free space remains in this pocket that might be filled by part of the azobenzene 
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group.  Compound 2.6 contains a sulphonamide group in place of the amide group of 
analogue 2.2, in order to compare the effects of these groups on enzyme binding and 
photoswitching. 
 
Fig. 2.3.  Azobenzenes 2.7-2.11 containing borophenylalanine for enzyme binding. 
 
Compounds 2.7-2.11 (Fig. 2.3) contain the peptidomimetic borophenylalanine group for 
enzyme binding.  This group has been used successfully in inhibitors of  
α-chymotrypsin,3, 4 as discussed in chapter 1, but has not previously been used in 
photoswitch inhibitors.  Compounds 2.7-2.11 contain similar design features to the 
aminophenylboronate compounds.  As previously, amide bonds are used to link the 
enzyme binding group to the azobenzene photoswitch, due to the synthetic versatility of 
the amide coupling reaction.  The simplest analogue, 2.7, contains borophenylalanine 
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directly attached to the azobenzene group.  Derivatives 2.8 and 2.9 contain the amino acid 
leucine between these two groups to investigate the influence of an amino acid in the P2 
position, as above for compounds 2.2-2.6.  In this case, the chiral centre of the amino acid 
leads to the formation of two separable diastereomers instead of a racemic mixture of 
enantiomers.  The azobenzenes 2.10 and 2.11 contain an amine group for surface 
attachment and a Gly residue to increase peptidic character for improved enzyme binding. 
  
In addition, the synthesis of the previously reported α-chymotrypsin inhibitor 2.124 (Fig. 
2.4) for assay validation is described.  This compound is an acetylated derivative of the 
borophenylalanine peptidomimetic group used in azobenzenes 2.7-2.11. 
 
  
 
 
 
 
Fig. 2.4.  Compound 2.12, a reported inhibitor of α-chymotrypsin. 
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2.2 Synthesis of aminophenylboronate based compounds 
 
Synthesis of boronate ester 2.1 
 
The boronate ester 2.1 was prepared as shown in Scheme 2.1.  Following a reported 
synthesis,5 nitrosobenzene 2.13 was condensed with 4-aminobenzoic acid 2.14 in AcOH to 
give azobenzene 2.15 in 53% yield.  The azobenzene 2.15 was then coupled to 
aminophenylboronate ester 2.16 in the presence of HATU to give 2.1 in 53% yield.  
 
Reagents and conditions:  i) 2.14, AcOH,  53%  ii) 2.16, HATU, DIEA, DMF, 53% 
Scheme 2.1.  Synthesis of compound 2.1. 
 
Synthesis of boronate esters 2.2-2.5 
 
The boronate esters 2.2-2.5 were prepared as shown in Scheme 2.2.  First, azobenzene 2.15 
was coupled to an amino acid methyl ester (glycine, alanine, valine or leucine) in the 
presence of HATU to give 2.17-2.20 in 85-96% yields.  The esters were then deprotected 
by basic hydrolysis to give carboxylic acids 2.21-2.24.  Coupling of 2.21 to amine 2.16 in 
the presence of HATU was initially attempted, but a colour change from orange to black 
was observed on mixing of the reactants, and the desired product 2.2 could not be detected 
in a 1H NMR spectrum of the reaction products after 16 h.  However, coupling of amine 
2.16 to carboxylic acids 2.21-2.24 in the presence of EDCI did give 2.2-2.5 in 32-43% 
yields. 
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Reagents and conditions: i) Amino acid methyl ester, HATU, DIEA, DMF, 85-96%  ii) LiOH, THF, H2O, 
63-100%  iii) 2.16, EDCI, HOBt, DCM, 32-43%  
Scheme 2.2.  Synthesis of compounds 2.2-2.5. 
 
Synthesis of sulfonamide 2.6 
 
The boronate ester 2.6 was synthesised by a similar route, as shown in Scheme 2.3.   
Initially sulfonyl chloride 2.256 (obtained from Nathan Alexander7) was coupled to  
H-Leu-OMe in the presence of base (DIEA) to give sulphonamide 2.26.  This compound 
was deprotected by basic hydrolysis with LiOH to give carboxylic acid 2.27, which was 
then coupled to amine 2.16 in the presence of HATU to give 2.6.  Interestingly, the use of 
HATU in this reaction was successful, but caused problems in the synthesis of the close 
analogue 2.2.   
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Reagents and conditions: i) H-Leu-OMe, DIEA, DCM, 91%  ii) LiOH, THF, H2O, 63%  iii) 2.16, HATU, 
DIEA, DMF, 28%. 
Scheme 2.3.  Synthesis of compound 2.6. 
 
2.3 Synthesis of borophenylalanine based compounds 
 
Synthesis of borophenylalanine precursor 2.33 
 
The synthesis of boronate esters 2.7-2.11 required borophenylalanine 2.33 as key precursor, 
which was synthesised following a reported route (Scheme 2.5).3  Initially, benzyl chloride 
2.28 was reacted with Mg in ether to form the Grignard reagent benzylmagnesium chloride.  
This reagent was added to trimethylborate to give a methyl boronate intermediate, which 
was hydrolysed by the addition of sulphuric acid to give boronic acid 2.29.  Next, 2.29 was 
stirred with pinacol in ether to give the boronate ester 2.30.  A 63% yield was obtained 
over these first two steps.  The boronate ester was then reacted with dichloromethyllithium 
(formed in situ from DCM and LDA) to give chloride 2.31 as an impure (by TLC and 1H 
NMR) brown oil.  This material was reportedly purified by spinning band distillation, but 
this was not available.  Fractional distillation using a packed column was attempted 
without success and column chromatography resulted in decomposition.  Thus, the next 
reaction was attempted using crude 2.31, with the intention of purifying after further 
reaction steps.  The chloride 2.31 was reacted with LiHMDS to give protected amine 2.32, 
which was detected in the reaction products by 1H NMR, but again the crude material 
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could not be purified by distillation or column chromatography.  Again a further step was 
carried out before purification.  The crude amine 2.32 was treated with TFA to give 
borophenylalanine trifluoroacetate 2.33.  This compound precipitated from the reaction 
solution and was collected as a white solid, pure by 1H NMR.  An acceptable yield (19%) 
was obtained for these three steps. 
 
Reagents and conditions: i) 1. Mg, ether, 0ºC → r.t.  2. B(OMe)3, -30ºC → r.t.  3. H2SO4 0ºC → r.t.   
ii) pinacol, ether, 63% over 2 steps  iii) LDA, DME, DCM, -78ºC → r.t.  iv) LiHMDS, THF, -78ºC → r.t.  
v) TFA, ether, 0ºC, 19% over 3 steps. 
Scheme 2.5.  Synthesis of borophenylalanine 2.33. 
 
Synthesis of boronate ester 2.7 
 
The boronate ester 2.7 was prepared from precursor 2.33, as shown in Scheme 2.6.  
Initially, coupling of carboxylic acid 2.15 and amine 2.33 in the presence of EDCI was 
attempted, but a mixture of compounds was formed from which 2.7 could not be identified 
by 1H NMR.  The reaction was repeated using BOP coupling reagent, but the same result 
was obtained.  Finally, the mixed anhydride coupling method with isobutyl chloroformate 
was carried out to give 2.7 in 51% yield.   
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Reagents and conditions: 2.33, i-BuOCOCl, NMM, THF, 51% 
Scheme 2.6.  Synthesis of boronate ester 2.7. 
 
While the mixed anhydride method is not often used in modern amide coupling reactions, 
good results have been previously reported in the synthesis of peptides containing 
borophenylalanine.3  It is known that the free base form of amine 2.33 is unstable,4 so it is 
likely that decomposition of this amine occurs during reaction with EDCI or BOP.  
However, in the mixed anhydride method, the carboxylic group is initially converted to an 
anhydride, then the amine is added to react with this activated intermediate.  Presumably 
the unstable amine 2.33 is able to react rapidly with the intermediate before decomposition 
occurs. 
 
Synthesis of diastereomeric boronate esters 2.8 and 2.9 
 
The boronate esters 2.8 and 2.9 were synthesised as shown in Scheme 2.7.  The carboxylic 
acid 2.21 was coupled to amine 2.33 using the mixed anhydride method to give 
diastereomers 2.8 and 2.9 in 76% combined yield.  These compounds were separable by 
chromatography, but are partially unstable to silica gel.  As such, poor recovery was 
obtained at each purification step.  After several chromatography attempts using normal 
silica, satisfactory separation was obtained using deactivated silica (consisting of 30% H2O 
and 70% silica).  Each isomer was purified to 86% diastereomeric excess (de, measured by 
1H NMR), but with poor recovery (3% and 5%).  The  observed decomposition may 
involve cleavage of the boronate ester to form the free boronic acid, which would have 
eluted very slowly from the silica gel. 
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Reagents and conditions: i) 2.33, iBuOCOCl, NMM, THF, 76% combined yield 
Scheme 2.7.  Synthesis of diastereomeric boronate esters 2.8 and 2.9. 
 
Synthesis of boronate esters 2.10 and 2.11 for surface attachment 
 
The boronate esters 2.10 and 2.11 were synthesised by a more complex method, as shown 
in Scheme 2.8.  Initially, the amine salt 2.34 was reacted with Fmoc-Cl to give protected 
amine 2.35, which was then reduced to aniline 2.36 by catalytic hydrogenation with PtO2 
in 86% yield.  Next, ethyl-4-aminobenzoate 2.37 was oxidised using catalyst 
Mo(O2)2O(H2O)HMPA and hydrogen peroxide to give nitrosobenzene 2.38, which was 
condensed with aniline 2.36 in AcOH to give azobenzene 2.39.  This compound was 
treated with 20% piperidine in DMF to give deprotected amine 2.40, which was then 
coupled to Boc-Gly-OH in the presence of HATU to give 2.41 in 88% yield (over two 
steps).  The deprotection of ester 2.41 was carried out by basic hydrolysis to give 
carboxylic acid 2.42.  This step was initially attempted under mild hydrolysis conditions 
(LiOH, THF/H2O, 0 ºC, 16 h) but no reaction was observed by TLC.  The reaction was 
repeated at an elevated temperature (50 ºC) and compound 2.42 was obtained in 
quantitative yield.  Next, carboxylic acid 2.42 was coupled to amine 2.33 using the mixed 
anhydride method to give boronate ester 2.10 in 60% yield.  Finally, 2.10 was treated with 
TFA to give trifluoroacetate salt 2.11 in 49% yield.   
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Reagents and conditions: i) Fmoc-Cl, DIEA, DCM, 0ºC → r.t., 52%  ii) H2, PtO2, EtOAc, 86%   
iii) Mo(O2)2O(H2O)HMPA, DCM, H2O2  iv) HOAc, 100ºC, 22% over 2 steps  v) DMF, piperidine  vi) Boc-
Gly, HATU, DIEA, DMF, 88% over 2 steps  vii) LiOH, THF, H2O, 50 ºC, qu  viii) 2.33, iBuOCOCl, NMM, 
DMF, 0 ºC → r.t., 60%  ix) TFA, DCM, 49% 
Scheme 2.8.  Synthesis of compounds 2.10 and 2.11. 
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Synthesis of known inhibitor 2.12 for validation of assays 
 
The boronic acid 2.12 was synthesised as shown in Scheme 2.9, following a reported 
method.4  The amine 2.32 was acetylated with acetic anhydride to obtain amide 2.43, 
which was then deprotected using boron trichloride to give boronic acid 2.12.  This 
inhibitor was purified by recrystallisation to obtain a pure sample for assay. 
 
Reagents and conditions: i) Ac2O, AcOH, THF, -78 ºC → r.t., 47% over 3 steps (see Scheme 2.5)  ii) BCl3, 
DCM, -78 ºC → r.t., 23% 
Scheme 2.9.  Synthesis of 2.12. 
 
2.4 Summary 
 
The azobenzene containing boronate esters 2.1-2.11 designed as photoswitch inhibitors of 
α-chymotrypsin were synthesised.  An amine group was included in compounds 2.10 and 
2.11 for surface attachment. 
 
Aminophenylboronate based compounds 2.1-2.6 were synthesised using peptide coupling 
methods.  The boronate esters 2.1 and 2.6 were successfully prepared using the HATU 
coupling reagent, but the final step in the synthesis of 2.2-2.5 was unsuccessful using this 
reagent, so instead EDCI was used with acceptable results.  For the synthesis of 
borophenylalanine derivatives, precursor 2.33 was prepared according to a literature 
method.3  However, some purification steps could not be carried out successfully, so the 
purification of two intermediates was omitted.  Using this precursor, boronate esters 2.7-
2.9 were synthesised by the coupling of 2.33 to carboxylic acids 2.15 and 2.21.  The use of 
standard coupling reagents (EDCI or BOP) was unsuccessful in these reactions, but the 
mixed anhydride method was successful.  The diastereomers 2.8 and 2.9 were somewhat 
unstable on silica gel, but were successfully separated by chromatography on deactivated 
silica.  Disubstituted azobenzenes 2.10 and 2.11 were synthesised by a more complex route, 
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involving the key step of condensation of a nitrosobenzene containing a protected amine 
substituent with an aniline containing an ester substituent. 
 
Enzyme assays of selected boronate esters from this chapter (2.1-2.2 and 2.6-2.12) are 
described in chapter 6. 
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Synthesis and stability studies of derivatives of a noncovalent  
α-chymotrypsin inhibitor 
 
3.1 Introduction 
 
Development of α-chymotrypsin photoswitch inhibitors lacking a warhead group was 
attempted as an alternative to the boronate esters prepared in chapter 2 and in order to 
improve inhibitor stability and selectivity (see chapter 1, section 1.3.6 for a discussion of 
noncovalent inhibitors).  Modification of known noncovalent inhibitors 3.1 and 3.21 was 
carried out in an attempt to introduce photoswitching and allow surface attachment. 
 
 
 
 
 
 
 
Fig. 3.1.  Noncovalent dipeptide inhibitors of α-chymotrypsin 3.1 and 3.2. 
 
It was considered that photoswitching activity could be introduced by replacement of the 
C-terminal phenyl group by azobenzene and that surface attachment could be carried out 
by extension of the N-terminal amine group.  In order to test these predictions, model 
compounds 3.3-3.5 (Fig. 3.2) containing either a C-terminal azobenzene or an N-terminal 
amide were synthesised and assayed (assays described in chapter 6).  The crystal structure 
of a complex of known inhibitor 3.2 with chymotrypsin shows that the amine group of 3.2 
appears to form a hydrogen bond to the Gly216 carbonyl group of the enzyme.  As 
modification of this amine group is required for surface attachment, it was important to 
determine its importance in enzyme binding.  The amine group of 3.1 was replaced by a 
simple acetamide group in 3.3, and by an extended amino acid group (Boc-Gly) in 3.4, in 
order to investigate whether or not the replacement of the amine group by an amide alters 
the enzyme affinity of the inhibitor.  The extended peptide functionality of 3.4 was 
additionally designed for use in surface attachment and to improve enzyme binding by 
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targeting the α-chymotrypsin S3 subsite.  The amine 3.5 containing a C-terminal 
azobenzene group was investigated to determine if the large azobenzene group is 
accommodated in the S1 subsite, and whether or not a significant difference in activity is 
observed between the E and Z isomers of 3.5, as is required for enzyme photoswitching. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2.  N- and C-terminally extended derivates of 3.1 for surface attachment and 
photoswitching. 
 
The inhibitors 3.1 and 3.2 were observed to show high stability to α-chymotrypsin 
catalysed hydrolysis,1 a feature not normally observed in simple peptides.  This stability is 
presumably due to the presence of the D-Leu residue in the P2 position, which is unlikely 
to bind well to the S2 subsite in the normal substrate conformation (where phenylalanine 
binds to S1).  As discussed in chapter 1, an unusual enzyme binding conformation is 
observed instead.  For the use of compounds 3.3-3.5 as inhibitors, similar stability is 
required.  The stability of these compounds to enzymatic hydrolysis was assessed by 
incubation of each compound with α-chymotrypsin, monitored by HPLC. 
 
3.2 Synthesis of 3.3-3.5 
  
Compounds 3.3-3.5 were synthesised using solution peptide coupling methods, as shown 
in Scheme 3.1 (compounds 3.3 and 3.4) and Scheme 3.2 (compound 3.5).    
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Synthesis of 3.3 and 3.4 
 
The syntheses of 3.3 and 3.4 (Scheme 3.1) were carried out in a similar manner to the 
reported synthesis of 3.1, which involved coupling of H-Phe-benzylamine 3.82, 3 with Boc-
D-Leu-OH, followed by acidic cleavage of the Boc group.   
 
Initially, Boc-Phe-OH 3.6 was coupled to benzylamine in the presence of HATU to give 
amide 3.74, 5 in 41% yield.  This compound was then treated with TFA to give the free 
amine 3.8, which was separately coupled to Ac-D-Leu-OH and Boc-D-Leu-OH to give 
amides 3.3 and 3.9, respectively.  The Boc group of 3.9 was removed on treatment with 
TFA to give amine 3.10, the free base equivalent of 3.1, in 65% yield.  This amine was 
then coupled to Boc-Gly-OH to give 3.4. 
 
Reagents and conditions: i) benzylamine, HATU, DIEA, DMF, 41%  ii) TFA, DCM, 65%  iii)  Ac-D-Leu-
OH, HATU, DIEA, DMF, 72%  iv) Boc-D-Leu-OH, HATU, DIEA, DMF, 76%  v) TFA, DCM, 65%   
vi) Boc-Gly-OH, HATU, DIEA, DMF, 55%. 
Scheme 3.1. Synthesis of compounds 3.3 and 3.4.  
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Synthesis of 3.5 
 
The azobenzene 3.5 was synthesised using a different route, involving the attachment of 
the C-terminal azobenzene group in the final stages of the synthesis, as shown in Scheme 
3.2.  This convergent route was used with the aim of improving the overall yield.  Here, 
reported carboxylic acid 3.156 and amine 3.127 were the key precursors. 
 
Reagents and conditions: i) nitrosobenzene 2.13, AcOH, 71%  ii) piperidine, DMF, 76%  iii) H-Phe-OEt, 
HATU, DIEA, DMF, 92%  iv) LiOH, THF, H2O, 43%  v) 3.12, HATU, DIEA, DMF, 72%  vi) TFA, DCM, 
89%. 
Scheme 3.2. Synthesis of compound 3.5. 
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The aniline 2.36 (used in the synthesis of azobenzenes 2.10 and 2.11) was condensed with 
nitrosobenzene 2.13 in AcOH to give azobenzene 3.118 in 71% yield.  This Fmoc-
protected amine was then treated with 20% piperidine in DMF to give amine 3.12.  Boc-D-
Leu-OH 3.13 was coupled to H-Phe-OEt in the presence of HATU to give amide 3.14, 
which was then deprotected by basic hydrolysis to give carboxylic acid 3.15 in 43% yield.  
The acid 3.15 was coupled to amine 3.12 to give amide 3.16, which was then treated with 
TFA to give 3.5 in 89% yield.  
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3.3 Stability studies  
 
HPLC studies were carried out to investigate the stability of 3.3-3.5 on incubation with 
α-chymotrypsin, to ensure that these peptides are sufficiently stable for use as inhibitors. 
 
Solutions of 3.3-3.5 in acetonitrile (1 mg mL-1) were initially injected onto a reverse phase 
HPLC column to check purity and determine the retention time for each compound.  Using 
solvent A: water with 0.05% TFA, and solvent B: acetonitrile, and the following elution 
gradient: 0-1 min 20% solvent B, 1-10 min gradient 20-100% B, 10-12 min 100% B, 12-
14 min gradient 100-20% B, 14-20 min 20% B, good chromatograms were obtained (Fig. 
3.3).  Two peaks are evident in the chromatogram of compound 3.5, corresponding to the Z 
isomer (minor peak) and E isomer (major peak), as determined by UV/vis spectra. 
Fig. 3.3.  HPLC of compounds 3.3-3.5. 
 
Next, an aliquot from each solution (50 μL) was diluted with Tris buffer (1020 μL) and  
α-chymotrypsin (30 μL of a 0.24 μM solution) was added.† HPLC of these solutions was 
immediately carried out, then the solutions were incubated for 24 h at 25 ºC and HPLC 
was repeated in order to determine whether or not enzyme catalysed hydrolysis had 
                                                 
† The Tris buffer and enzyme solutions were as used in assays described in chapter 6, and in the experimental 
chapter, section 9.6. 
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occurred.  Peaks for compounds 3.3-3.5 were observed in the chromatograms obtained, at 
similar retention times to those recorded in acetonitrile.  Representative chromatograms for 
compound 3.4 are shown in Fig. 3.4, and the integrals of the peaks for all compounds are 
shown in Table 3.1. 
Fig. 3.4.  HPLC chromatograms for a solution of 3.4 and α-chymotrypsin in Tris buffer, 
before and after 24 h incubation. 
 
Table 3.1.  HPLC retention times and integrals for compounds 3.3-3.5. 
Compound Retention time 
(min) 
Peak integral at t = 0 h 
(mAU min) 
Peak integral at t = 24 h 
(mAU min) 
3.3 10.1 66.1 66.8 
3.4 11.2 71.5 71.6 
Z-3.5 8.4 7.3 8.4 
E-3.5 9.3 44.3 53.2 
 
A comparison of the peak integrals in Table 3.1 reveals no significant decrease in the 
amounts of 3.3-3.5 present after 24 h.  Therefore, these compounds are stable to α-
chymotrypsin catalysed hydrolysis and thus are appropriate for use as inhibitors.  The 
integrals for 3.5 appear to increase slightly after 24 h, probably due to evaporation of 
solvent or slow dissolution of 3.5. 
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3.4 Summary 
 
The peptidomimetics 3.3-3.5, derivatives of known non-covalent α-chymotrypsin inhibitor 
3.1, were synthesised for initial studies towards the development of non-covalent 
photoswitch inhibitors of α-chymotrypsin.  Compounds 3.3-3.4 contain an N-terminal 
amide group to investigate extension for surface attachment and 3.5 contains a C-terminal 
azobenzene group for photoswitching.  
 
HPLC stability studies showed that peptidomimetics 3.3-3.5 are stable to α-chymotrypsin 
catalysed hydrolysis, so are appropriate for inhibition studies.   
 
Enzyme assays of 3.3-3.5 are described in chapter 6. 
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Synthesis of trifluoromethylketones and α-ketoesters 
 
4.1 Introduction 
 
The photoisomerisable boronate esters described in chapter 2 for attachment to surfaces 
were found to be partially unstable to photoisomerisation and the dipeptide derivatives 
described in chapter 3 were found to be inactive against α-chymotrypsin (see chapter 6).  
Consequently, alternative photoswitch inhibitors were required.  Trifluoromethylketones 
and α-ketoesters were chosen for this purpose, since stable photoswitch inhibitors 
containing these groups are known.1, 2  Both classes of inhibitor contain a ketone activated 
by an adjacent electrophilic group that binds to the active site serine of chymotrypsin (see 
chapter 1).  However, α-ketoesters generally exhibit much stronger binding affinities 
(usually high nM inhibition constants)3 than do trifluoromethylketones (low μM)4.  In 
addition, trifluoromethylketones often exhibit slow-tight binding characteristics,5 whereas 
α-ketoesters usually exhibit simple competitive binding.  Trifluoromethylketones linked to 
azobenzenes also tend to exhibit a greater difference in activity between the E and Z 
isomers than do related α-ketoesters,1, 6 although this observation is yet to be 
systematically studied.  Given these differences, we chose to investigate the potential of 
each for use as surface attached photoswitch inhibitors.   
 
A linker group for surface attachment was included in these inhibitors.  Two such groups 
were studied.  Firstly, the primary amine group, as in boronate ester 2.11 (see chapter 2), 
which is commonly used for surface attachment using the simple and versatile amide 
coupling reaction.  Secondly, the alkyne group, which reacts with azides in a copper(I) 
catalysed 3 + 2 cycloaddition reaction.  This reaction was chosen as recent studies show 
that it is unaffected by the presence of most functional groups,7 and has been used 
successfully in various systems, including surface attachment.8   
 
The copper catalysed azide-alkyne cycloaddition has been labelled a ‘click chemistry’ 
reaction due to its simple reaction conditions, high yields, and broad applicability.9  
Cycloaddition of alkynes and azides to form triazoles can occur either thermally or with 
Cu(I) catalysis (Scheme 4.1).  Thermal reaction requires high temperatures and gives rise 
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to a mixture of 1,4- and 1,5-regioisomers, whereas the recently reported copper catalysed 
reaction proceeds efficiently at room temperature and forms only the 1,4 isomer.   
 
 
 
 
 
 
 
Scheme 4.1.  Azide-alkyne cycloaddition. 
 
This chapter describes the synthesis of a series of trifluoromethylketones 4.1-4.4 (Fig. 4.1) 
and α-ketoesters 4.5-4.7 (Fig. 4.2) designed to act as photoswitch inhibitors of 
α-chymotrypsin.  These compounds contain an enzyme binding group, an azobenzene 
photoswitch core, and a linker for surface attachment.  A range of compounds was 
synthesised in order to identify the most effective groups for photoswitch enzyme binding 
and surface attachment.  The enzyme binding groups are phenylalanine derivatives 
containing an electrophilic ketone, synthesised from reported trifluoromethylalcohol 4.8 or 
α-hydroxyester 4.9 (Fig. 4.3).  The phenylalanine structure was used since it is known to 
bind strongly to the α-chymotrypsin active site.11  The surface attachment linker consists 
of an alkyne (compounds 4.2-4.4 and 4.6-4.7) or protected amine (compounds 4.1 and 4.5) 
and an appropriate scaffold to attach this functional group to the azobenzene core.  The 
protected amines are designed for surface attachment by amide coupling after liberation of 
the free amine group, and are analogous in structure to boronate ester 2.10.  A long chain 
oligoethylene glycol (OEG) group was included in compounds 4.2, 4.4 and 4.7 as a spacer 
to separate the enzyme binding group from the surface, to improve α-chymotrypsin 
binding.  Two different groups were used to link the OEG group to the azobenzene group, 
amide (in compound 4.2) and internal alkyne (in compounds 4.4 and 4.7) to compare the 
impact of these groups on enzyme activity and photoswitching.  
 
 
 
 
R1
N
NN
R2
N
N
N R2
R1
N
N
N R2
R1
N
N
N R2
R1
Δ
Cu(I)
++
1,4 1,5
1,4
Chapter Four: Synthesis of trifluoromethylketones and α-ketoesters 
 
71
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 4.1.  Trifluoromethylketones 4.1-4.4 described in this chapter. 
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Fig. 4.2. α-Ketoesters 4.5-4.7 described in this chapter. 
 
 
 
 
 
 
 
Fig. 4.3.  Alcohols 4.8 and 4.9, precursors to trifluoromethylketones and α-ketoesters. 
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4.2 Synthesis of precursor 4.9 
 
Compound 4.9 was prepared by modification of reported syntheses,12-17 involving acidic 
hydrolysis of a cyanohydrin to the key α-hydroxyester group, as shown in Scheme 4.2.  
Initially Cbz-Phe-OMe 4.10 was reduced to aldehyde 4.11 in 90% yield using DIBAL.  
The aldehyde 4.11 was then reacted with NaHSO3 and KCN to give cyanohydrin 4.12 as 
an inseparable mixture of diastereomers, obtained in a 3:2 ratio (by 1H NMR) after 
purification by column chromatography.  Hydrolysis of the mixture of cyanohydrins was 
carried out by stirring in a solution of HCl in MeOH/ether for 70 h, with addition of water 
after 24 h.  The resulting diastereomeric α-hydroxyesters were separated by column 
chromatography to give 4.13 (33%) and 4.14 (19%).  However, much poorer yields were 
obtained in repeats of this reaction (8% then 11% combined yield of 4.13 and 4.14).  
Finally, the Cbz group of 4.13 was removed by catalytic hydrogenolysis to give 4.9 in 
quantitative yield. 
 
 
Reagents and conditions: i) DIBAL, toluene, -78ºC, 90%  ii) KCN, NaHSO3, EtOAc, H2O, 0ºC → 4ºC → r.t., 
79%  iii) HCl, MeOH, ether, H2O, 0ºC → 4ºC, 8-52% combined yield  iv) Pd/C, H2, EtOAc, qu. 
Scheme 4.2.  Synthesis of α-hydroxyester 4.9. 
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4.3 Synthesis of trifluoromethylketone and α-ketoester derivatives of 
boronate ester 2.10 
 
Trifluoromethylketone 4.1 and α-ketoester 4.5 were synthesised as shown in Scheme 4.3.  
The carboxylic acid 2.42 was separately coupled to 4.9 and trifluoromethylalcohol 4.818 
(obtained from Nathan Alexander1) in the presence of EDCI to give 4.15 and 4.16, 
respectively.  The alcohols 4.15 and 4.16 were then oxidised using Dess-Martin 
periodinane to give ketone 4.5 in 83% yield and 4.1 in 44% yield.  Dess-Martin 
periodinane was used since it has been reported to be the most reliable reagent for 
oxidation of trifluoromethylalcohols to ketones, when used in a 3.7 equivalent excess.19 
Therefore, 3.7 equivalents were used in the oxidation of trifluoromethyl alcohol 4.16.  Two 
equivalents were used in the oxidation of α-hydroxyester 4.15.  Treatment of 4.1 with TFA 
gave the amine salt 4.17 which was unstable to chromatography, presumably due to the 
conflicting reactivities of the electrophilic trifluoromethylketone group and the 
nucleophilic amine group.  This is surprising, as the related boronate ester 2.11 was 
successfully isolated by chromatography.  As this reaction was unsuccessful, deprotection 
of related ketone 4.5 was not carried out. 
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Reagents and conditions  i) 4.9, EDCI, HOAt, DIEA, DMF, 69% ii) Dess-Martin periodinane, DCM, 83%  
iii) 4.8, EDCI, HOBt, DIEA, DMF, 50%  iv) Dess-Martin periodinane, DCM, 44%  v) TFA, DCM 
Scheme 4.3.  Synthesis of 4.1 and 4.5, and attempted synthesis of 4.17. 
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4.4 Synthesis of azobenzenes with alkyne substituents for surface 
attachment by ‘click’ chemistry 
 
Two different approaches were carried out to synthesise azobenzenes containing terminal 
alkyne substituents, as detailed in sections 4.4.1 and 4.4.2, below. 
 
4.4.1 Synthesis of photoswitch inhibitor 4.2 from a symmetrical azobenzene precursor 
 
Azobenzene 4.2 was synthesised by the sequential reaction of symmetrical azobenzene 
4.2120 (Scheme 4.4) with trifluoromethylalcohol 4.8 and alkyne 4.28 followed by oxidation 
(Schemes 4.5-4.8).  Initially, synthesis of the related trifluoromethylketone 4.18 lacking 
the alanine residue (Fig. 4.4) was also attempted (schemes 4.5-4.6).  These syntheses were 
carried out without use of protecting groups in order to eliminate protection/deprotection 
steps and thus decrease the number of reaction steps.  
 
Fig. 4.4.  Trifluoromethylketone 4.2 and the related target, trifluoromethylketone 4.18. 
 
Synthesis of symmetrical azobenzene 4.21 
 
Following reported syntheses of 4.21,20, 21 nitrosobenzoic acid 4.19 was reduced with 
glucose to azobenzene 4.20 in 33% yield, followed by reaction with PCl5 to give acid 
chloride 4.21 in 47% yield (scheme 4.4). 
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Reagents and Conditions: i) glucose, NaOH, H2O, 50ºC, 33%  ii) PCl5, 1,2-dichloroethane, reflux, 47%   
Scheme 4.4.  Synthesis of symmetrical azobenzene 4.21. 
 
Synthesis of alkyne 4.23 and attempted reaction with 4.21 
 
The alkyne 4.23 was prepared in 38% yield by reaction of propargyl bromide with a large 
excess of tetraethylene glycol 4.22 (scheme 4.6).  The alcohol 4.23 was then reacted with 
acid chloride 4.21 in the presence of base (TEA) in an attempt to obtain ester 4.24, a 
precursor to 4.18, but this product was not obtained.  The 1H NMR of the crude product 
instead suggested the formation of a symmetrical disubstituted derivative resulting from 
reaction of two equivalents of alcohol 4.23 with both acid chloride groups of 4.21. 
 
 
Reagents and Conditions i) propargyl bromide, NaH, THF, 0ºC → r.t., 38%  ii) 4.21, THF, TEA 
Scheme 4.5.  Synthesis of alkyne 4.24 and attempted synthesis of azobenzene 4.24. 
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Reaction of 4.21 with trifluoromethylalcohol 4.8 and subsequent attempted reaction with 
alkyne 4.23 
 
As an alternative approach for the synthesis of 4.18, the reaction of amine 4.8 with 4.21 
was carried out (Scheme 4.6) in order to attach the enzyme binding substituent (4.8) to the 
azobenzene core before attachment of the alkyne substituent (4.23).  The amine 4.8 and 
acid chloride 4.21 were reacted in the presence of base (DIEA) to give amide 4.25 in 
acceptable yield (38%).  However, subsequent reaction of acid chloride 4.25 with alcohol 
4.23 gave returned starting material only.  
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: i) 4.8, DIEA, DCM, 38%  ii) 4.23, DIEA, DCM 
Scheme 4.6.  Synthesis of azobenzene 4.25 and attempted reaction with alkyne 4.23. 
 
Synthesis of alkyne 4.28 and attempted reaction with 4.21 
 
Efforts were then focused towards synthesis of trifluoromethylketone 4.2 rather than 4.18.  
The primary amine 4.28 was synthesised, which was expected to be more reactive than 
alcohol 4.23 for nucleophilic attack on acid chloride 4.21 or 4.25. 
  
The alcohol 4.23 was coupled to Boc-Ala-OH to obtain amide 4.27 in 94% yield, which 
was then treated with TFA to give amine 4.28 (scheme 4.7).  This amine was reacted with 
acid chloride 4.21 in the presence of base (DIEA).  Again, products were formed but 
analysis of these compounds by TLC, 1H NMR, and MS showed only traces of the desired 
product 4.29.   
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Reagents and conditions: i) Boc-Ala-OH, EDCI, DMAP, DCM,  94%  ii) TFA, DCM  iii) 4.21, DIEA, DCM. 
Scheme 4.7.  Synthesis of alkyne 4.28 and attempted reaction with azobenzene 4.21. 
 
Synthesis of 4.2 involving reaction of alkyne 4.28 and azobenzene 4.25 
 
The amine 4.28 was reacted with acid chloride 4.25 to successfully obtain disubstituted 
azobenzene 4.30 (Scheme 4.8).  This compound was then oxidised by Dess-Martin 
periodinane to give trifluoromethylketone 4.2 in quantitative yield.   
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: i) 4.28, DIEA, DCM, 70% over 2 steps  ii) Dess-Martin periodinane, DCM, qu. 
Scheme 4.8.  Successful synthesis of trifluoromethylketone 4.2. 
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It is unclear why the reactions of amine 4.28 with acid chloride 4.25 (Scheme 4.8) and of 
amine 4.8 with acid chloride 4.21 (Scheme 4.6) were successful but the reaction of amine 
4.28 with 4.21 (Scheme 4.7) was not.  However, as a result the synthesis of 
trifluoromethylketone 4.2 requires the use of key precursor 4.8 at an early stage of the 
synthesis.  As precursors 4.8 and 4.9 are difficult to obtain in large quantities, it is 
preferable to introduce these compounds at a late stage of synthesis.  Consequently, an α-
ketoester analogue of 4.2 was not synthesised. 
 
4.4.2 Synthesis of alkyne substituted azobenzenes utilising Pd catalysed coupling 
 
The alkynes 4.3, 4.4, 4.6, and 4.7 were synthesised by palladium catalysed coupling of an 
alkyne to an azobenzene with a halide substituent.  This synthetic method has been 
previously reported for a simple bromobenzoate structure, as shown in Scheme 4.9.22  First, 
bromide 4.31 was reacted with the alkyne 2-methyl-3-butyn-2-ol and catalysts 
PdCl2(PPh3)2 and CuI to give aryl alkyne 4.32.  Deprotection was then carried out by 
reflux with NaOH to give terminal alkyne 4.33. 
 
Reagents and conditions: i) 2-methyl-3-butyn-2-ol, PdCl2(PPh3)2, PPh3, CuI, TEA, 98%  ii) NaOH, BuOH, 
99% 
Scheme 4.9.  Reported synthesis of an aryl alkyne utilising Pd catalysis.  
 
A directly analogous synthesis was used here in the synthesis of ketones 4.3 and 4.6, 
involving reaction of known bromoazobenzene 4.36 with 2-methyl-3-butyn-2-ol followed 
by deprotection to give alkynylazobenzene 4.40 (Schemes 4.10-4.11).   
 
Synthesis and Pd-catalysed coupling of 4.36 
 
The azobenzene 4.36 was initially prepared following a reported method23 (Scheme 4.10).  
Methyl aminobenzoate 4.34 was oxidised with Oxone to the corresponding nitrosobenzene 
4.35 in 62% yield.  Next, condensation of 4.35 with bromoaniline in AcOH was carried out 
OMe
O
Br
OH
OMe
O
OH
O
i ii
4.31 4.32 4.33
Chapter Four: Synthesis of trifluoromethylketones and α-ketoesters 
 
81
 
to give 4.36 in 30% yield.  This is surprising, since the reported yield for this reaction is 
98%.   
 
Reagents and conditions:  i) Oxone, DCM, H2O, 90%  ii)  bromoaniline 4.36, AcOH, 98% 
Scheme 4.10.  Synthesis of 4.37 following a reported method. 
 
An alternative route to 4.37 was carried out to improve yields, as shown in Scheme 4.11.  
Bromoaniline 4.36 was oxidised to bromonitrosobenzene 4.38 in 98% yield, which was 
then condensed with methyl aminobenzoate 4.34 in AcOH to give azobenzene 4.36 in 
improved yield (52%).  The azobenzene 4.36 was then reacted with the protected alkyne 2-
methyl-3-butyn-2-ol in the presence of PdCl2(PPh3)2 and CuI to give alkyne 4.39 in 93% 
yield.  Finally, both protecting groups were removed by basic hydrolysis to give terminal 
alkyne 4.40.   
 
 
 
 
 
 
 
 
 
Reagents and conditions i) Oxone, H2O, DCM, 98%  ii) 4.34, AcOH, 52%  iii) 2-methyl-3-butyn-2-ol, 
PdCl2(PPh3)2, PPh3, CuI, TEA, reflux, 93%  iv) NaOH, BuOH, reflux, 71% 
Scheme 4.11.  Synthesis of azobenzene 4.40 containing an alkyne substituent. 
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Synthesis of ketones 4.3 and 4.6 
 
The ketones 4.3 and 4.6 were then synthesised from compound 4.40, as shown in Scheme 
4.12.  The carboxylic acid 4.40 was separately coupled to amines 4.8 and 4.9 to give 4.41 
and 4.42, respectively.  The alcohols 4.41 and 4.43 were then oxidised using Dess-Martin 
periodinane to obtain trifluoromethylketone 4.3 and α-ketoester 4.6, respectively. 
Reagents and conditions i) 4.8, EDCI, HOAt, DIEA, DMF, 56%  ii) Dess-Martin periodinane, DCM, 91%  
iii) 4.9, EDCI, HOBt, DIEA, DMF, 61%  iv) Dess-Martin periodinane, DCM, 91%. 
Scheme 4.12.  Synthesis of 4.3 and 4.6. 
 
Synthesis of ketones 4.4 and 4.7 
 
Derivatives 4.4 and 4.7 containing a long chain OEG group were synthesised in a similar 
manner to 4.3 and 4.6, using alkyne 4.47 as the key precursor in place of compound 4.40.  
The alkyne 4.47 was synthesised by Andrew Muscroft-Taylor24 (Scheme 4.13).  In brief, 
alkyne 4.44 was coupled to iodide 4.45 to give 4.46, which was deprotected to obtain 
carboxylic acid 4.47.   
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Reagents and conditions: i) n-BuLi, TMS-Cl  ii) PdCl2(PPh3)2, DMF, TEA  iii) NaOH, THF, H2O, MeOH 
Scheme 4.13.  Synthesis of alkyne 4.47 (carried out by Andrew Muscroft-Taylor). 
 
Using this precursor, trifluoromethylketone 4.4 was synthesised (Scheme 4.14) by the 
coupling of carboxylic acid 4.47 and amine 4.8 using EDCI coupling reagent to give 4.48 
in 80% yield, followed by Dess-Martin periodinane oxidation to give 4.4 in 90% yield.  
Similarly, α-ketoester 4.7 was synthesised by the coupling of carboxylic acid 4.47 and 
amine 4.9 to give 4.49 in 58% yield, followed by oxidation to give 4.7 in 51% yield. 
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Reagents and conditions: i) 4.8, EDCI, HOBt, DIEA, DMF, 80%  ii) Dess-Martin periodinane, DCM, 90%  
iii) 4.9, EDCI, HOBt, DIEA, DMF, 58%  iv) Dess-Martin periodinane, DCM, 51%   
Scheme 4.14.  Synthesis of 4.4 and 4.7. 
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4.5 Summary 
 
Azobenzene-containing trifluoromethylketones 4.1-4.4 and α-ketoesters 4.5-4.7 were 
synthesised as photoswitch inhibitors of α-chymotrypsin.  A terminal alkyne group for 
surface attachment by azide-alkyne cycloaddition was included in compounds 4.2-4.4 and 
4.6-4.7.  
 
Precursor 4.9 was synthesised following previously reported methods.12, 13, 18  While poor 
yields were obtained, sufficient material was obtained for use in synthesis of inhibitors 4.5-
4.7.  The protected amines 4.1 and 4.5 were readily synthesised by coupling of carboxylic 
acid 2.42 to amines 4.8 and 4.9, respectively, followed by oxidation with Dess-Martin 
periodinane.  Acidic hydrolysis of 4.1 gave amine 4.17, which was unstable to 
chromatography.  The alkyne 4.2 was synthesised from symmetrical azobenzene precursor 
4.21 by direct reaction of the desired substituent groups with 4.20 without use of 
protecting groups.  Several synthetic routes to 4.2 and alternative target 4.18 were 
attempted, with the coupling of acid chloride 4.21 to amine 4.8 followed by coupling of 
the product to amine 4.28 to give 4.2 being successful.  Alkynes 4.3-4.4 and 4.6-4.7 were 
synthesised by Pd-catalysed coupling of an alkyne to an azobenzene with a halide 
substituent, followed by deprotection, amide coupling to 4.8 or 4.9 then oxidation. 
 
Enzyme assays and photoisomerisation studies carried out on the trifluoromethylketones 
and α-ketoesters described in this chapter (4.1-4.7) are described in chapter 6.  Surface 
attachment and SPR studies of photoregulated surface enzyme binding to surface-attached 
trifluoromethylketone 4.4 are described in chapter 7. 
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Synthesis of sulfur-containing surface linkers 
 
5.1 Introduction 
 
The formation of SAMs of alkyl thiols/disulfides on gold was chosen for the surface 
attachment of photoswitch enzyme inhibitors (see chapter 1, section 1.4).  However, as the 
inhibitors described in chapters 2-4 do not contain thiol or disulfide groups, linker 
molecules containing a sulfur group for surface attachment and a carboxylic acid or azide 
group for attachment to inhibitors were used, as shown in Fig. 5.1.  This chapter describes 
the synthesis of these linkers. 
 
 
Key: R1 and R2 are groups that can be linked together e.g. amine and carboxylic acid, E is an electrophilic 
group for enzyme binding 
Fig. 5.1.  Molecular components used to attach photoswitch inhibitors to gold surfaces. 
 
Various thiol/disulfide linkers have been used similarly for the surface attachment of 
complex molecules.  Here, lipoic acid derivatives, acetyl protected alkyl thiols and 
symmetrical alkyl disulfides were synthesised, in order to obtain a range of surface linker 
groups for evaluation of the most appropriate for use in surface attachment of photoswitch 
inhibitors.   
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Lipoic acid 5.11 (Fig. 5.2) has been used previously as a linker for attachment to surfaces 
and nanoparticles,2-4 and was chosen for use here due to its apparent synthetic versatility.  
In particular, the disulfide group of 5.1 is part of a 5-membered dithiolane ring, and hence 
both alkyl groups attached to the disulfide group converge into a single chain.  
Consequently, syntheses involving lipoic acid do not require complex transformations to 
derivatise both alkyl chains, as can be required in the syntheses of other disulfides.  
 
 
 
 
Fig. 5.2. Lipoic acid 5.1. 
 
Longer chain alkyl thiols containing carboxylic acid groups are also used often as surface 
linkers, such as compounds 5.2 and 5.35 (Fig. 5.3).  It was considered that these linkers 
would form higher quality SAMs on gold than lipoic acid derivatives, as they consist of 
more symmetrical, longer chain molecules that should pack well in a SAM.  The thiol 5.2 
was chosen for use here as a precursor to protected thiols and symmetrical disulfides for 
surface attachment.   
 
Fig. 5.3.  Alkyl thiols 5.2 and 5.3. 
 
Non-specific protein binding to hydrophobic surfaces (discussed in chapter 1, section 
1.4.3) can be problematic in the study of specific enzyme binding to surface-attached 
ligands.  To reduce this problem, studies of specific binding usually use hydrophilic 
surface components that block non-specific attachment.  In particular, mixed SAMs can be 
formed containing an enzyme binding component and a hydrophilic diluent that blocks 
non-specific binding.6, 7  This inert diluent may have the additional beneficial function of 
spacing out (‘diluting’) the active functionality on the surface, improving accessibility for 
enzyme binding.  Here, OEG diluents were used as the hydrophilic component.  
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This chapter describes the design and synthesis of surface linkers and diluents 5.4-5.11  
(figs. 5.4 and 5.5), model compounds 5.12-5.13 for photoswitching studies (Fig. 5.6), 
photoswitch inhibitors 5.14-5.16 for surface attachment (Fig. 5.7) and inhibitors 5.17-5.18 
for enzyme assay that mimic surface-attached inhibitors (Fig. 5.8).  A range of linkers 
(amide, triazole) and sulfur groups (protected thiol, disulfide) were used in order to obtain 
compounds with varying properties for surface attachment studies.   
 
Fig. 5.4.  Lipoic acid based surface linkers 5.4-5.5 and diluent 5.6. 
 
The disulfides 5.4-5.6 (Fig. 5.4) were synthesised from lipoic acid 5.1.  The surface linkers 
5.4-5.5 contain an azide group for inhibitor attachment, and the diluent 5.6 contains a 
terminal OEG group to block non-specific enzyme binding.  Longer OEG groups are 
included in surface linkers 5.4-5.5, so that these compounds can form mixed SAMs with 
diluent 5.6 but extend further into solution for optimum enzyme binding.  Azides 5.4 and 
5.5 contain OEG groups of differing lengths, in order to investigate the influence of chain 
length on enzyme binding. 
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Fig. 5.5.  Surface linkers and diluents synthesised from thiol 5.2. 
 
The surface linkers 5.7-5.9 and diluents 5.10-5.11 (Fig. 5.5) are synthesised from alkyl 
thiol 5.2.  These compounds are similar in structure to lipoic acid derivatives 5.4-5.6,  but 
contain longer alkyl chains and symmetrical disulfides or protected thiols for surface 
attachment.  In addition, 5.7 contains a carboxylic acid group for inhibitor attachment 
rather than an azide group.  While the protected thiols 5.7, 5.8 and 5.10 may form SAMs 
on gold,8 disulfides 5.9 and 5.11 are expected to be more reliable for SAM formation. 
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Azobenzenes 5.12 and 5.13 (Fig. 5.6) were designed for use in photoswitching studies to 
assess the potential of the surface linkers for use in surface photoswitching.  Both 
compounds consist of a surface linker (lipoic acid 5.1 or protected thiol 5.7) attached to an 
azobenzene. 
 
Fig. 5.6.  Model compounds 5.12 and 5.13 for photoswitching studies of surface linkers. 
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Compounds 5.14-5.16 (Fig. 5.7) consist of photoisomerisable trifluoromethylketones 
attached to selected surface linkers, for use in surface attachment and photoswitching 
studies.   
 
 
Fig. 5.7.  Surface-attachable photoswitch inhibitors 5.14-5.16. 
 
Many of the inhibitors that were synthesised in chapter 4 and found to be excellent 
photoswitch inhibitors (see chapter 6 for photoisomerisation and assay results) were not 
attached to surface linkers.  This is simply due to the chronological order in which this 
research was performed, since later studies involved SPR, which does not require 
thiol/disulfide linkers for surface attachment. 
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Compounds 5.15-5.16 contain triazole groups linking the azobenzene to the alkyl disulfide 
group.  As the azobenzene group is expected to bind to the S2 subsite of the  
α-chymotrypsin active site, these triazole groups should be associated with the S2 and/or S3 
subsites.  Consequently, the triazole group is likely to affect the binding and 
photoswitching properties of inhibitors 5.15-5.16.  To test this prediction, it was of interest 
to carry out enzyme assays for compounds 5.15-5.16 to assess their enzyme binding and 
photoswitching properties.  However, these compounds are insufficiently water soluble for 
assays to be carried out, so water soluble model compounds 5.17 and α-ketoester analogue 
5.18 (Fig. 5.8) were synthesised by cycloaddition of an OEG azide to alkynes 4.3 and 4.6, 
respectively.  These compounds mimic the structure of surface-attached alkynes 4.3 and 
4.6, and thus assay and photoisomerisation of these compounds provides information 
about surface binding and photoswitching of 4.3 and 4.6 (and 5.15-5.16).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.8.  Photoswitch inhibitors 5.17-5.18 designed to mimic surface attached 4.3 and 4.6. 
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5.2 Synthesis of lipoic acid derivatives 
 
Synthesis of 5.4 
 
The azide surface linker 5.4 was prepared by coupling of known azide 5.219 to lipoic acid 
5.1, as shown in Scheme 5.1.  Triethylene glycol 5.19 was reacted with mesyl chloride in 
the presence of silver oxide to give mesylate 5.205, which was then reacted with sodium 
azide to give azide 5.21 in quantitative yield.  Finally, 5.21 was coupled to lipoic acid 5.1 
in the presence of HATU to give 5.4 in 38% yield. 
 
Reagents and conditions: i) MsCl, Ag2O, DCM, 65%  ii) NaN3, DMF, 110ºC, qu.  iii) 5.1, HATU, DIEA, 
DMF, 38% 
Scheme 5.1.  Synthesis of azide surface linker 5.4. 
 
Synthesis of 5.5 
 
The azide 5.5 was prepared as shown in Scheme 5.2.  Initially, hexaethylene glycol 5.22 
was reacted with mesyl chloride to give mesylate 5.23, using alternative reaction 
conditions (NaH, THF) to those used to prepare 5.20.  Poorer yield was obtained than in 
the synthesis of 5.20; however, the reaction time was much shorter (16 h rather than 68 h).  
The mesylate 5.23 was then reacted with sodium azide to obtain 5.24 in 81% yield.  
Finally, azide 5.24 was coupled to 5.1 to give 5.5 in 77% yield.  Here, EDCI coupling 
reagent was used, since use of HATU gave a poor yield in the synthesis of 5.4. 
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Reagents and conditions: i) MsCl, NaH, THF, 0ºC → r.t., 45%  ii) NaN3, DMF, 110ºC, 81%  iii) 5.1, EDCI, 
DMAP, DCM, 77% 
Scheme 5.2.  Synthesis of azide surface linker 5.5. 
 
Synthesis of 5.6 
 
The diluent 5.6 was synthesised as shown in Scheme 5.3.  Lipoic acid 5.1 was coupled to 
diethylene glycol in the presence of EDCI and DMAP to give ester 5.6 in 78% yield.  
 
 
 
 
Reagents and conditions:  i) diethylene glycol, EDCI, DMAP, DCM, 78% 
Scheme 5.3. Synthesis of surface diluent 5.6. 
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5.3 Synthesis of thiols and symmetrical disulfides 
 
Surface linkers and diluents 5.7-5.11 were synthesised from thiol 5.2, which was initially 
protected as a thioester to reduce the reactivity of this group for amide coupling reactions. 
 
Synthesis of 5.7 
 
The carboxylic acid 5.7 was synthesised as shown in Scheme 5.4.  Thiol 5.2 was reacted 
with acetyl chloride to give thioester 5.25.  Bromide 5.26 was coupled to triethylene glycol 
5.19 in the presence of base (NaH) to give alcohol 5.27 in 38% yield, which was then 
coupled to carboxylic acid 5.25 in the presence of EDCI and DMAP to give ester 5.28 in 
64% yield.  This ester was treated with TFA to give carboxylic acid 5.7.   
 
Reagents and conditions: i) AcCl, AcOH, DCM, 0ºC → r.t., 63%  ii) triethylene glycol 5.19, NaH, THF, 0ºC 
→ r.t., 38%  iii) 5.25, EDCI, DMAP, DCM, 63%  iv) TFA, DCM, 74% 
Scheme 5.4.  Synthesis of carboxylic acid surface linker 5.7. 
 
Synthesis of 5.8 and 5.9 
 
The azides 5.8 and 5.9 were prepared as shown in Scheme 5.5.  First, carboxylic acid 5.25 
was reacted with azide 5.24 to give 5.8 in 38% yield.  The thioacetate 5.8 was then treated 
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with hydrazine acetate to give disulfide 5.9 in quantitative yield.  Hydrazine acetate was 
used since mild hydrolysis conditions were required to avoid cleavage of the ester group.  
Deprotection of a similar thioester has been reported using this reagent.10 
 
 
Reagents and conditions: i) 5.24, EDCI, DMAP, DCM, 38%  ii) N2H4.AcOH, DMF, qu. 
Scheme 5.5.  Synthesis of azide surface linkers 5.8 and 5.9. 
 
Synthesis of 5.10 and 5.11 
 
The diluents 5.10 and 5.11 were prepared as shown in Scheme 5.6.  First carboxylic acid 
5.25 was reacted with diethylene glycol in the presence of EDCI and DMAP to obtain 5.10 
in 63% yield.  The thioester 5.10 was then treated with hydrazine acetate to give disulfide 
5.11 in 67% yield.   
 
Reagents and conditions: i) diethylene glycol, EDCI, DMAP, DCM, 63%  ii) N2H4.AcOH, DMF, 67% 
Scheme 5.6.  Synthesis of surface diluents 5.10 and 5.11. 
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5.4 Attachment of azobenzenes to thiol/disulfide linkers 
 
Synthesis of 5.12 
 
Compound 5.12 was synthesised as shown in Scheme 5.7.  Initially, azobenzene 2.41 was 
treated with TFA to give amine 5.29 in 99% yield.  This amine was then coupled to lipoic 
acid 5.1 in the presence of EDCI to give amide 5.12 in 36% yield. 
 
 
Reagents and conditions: i) TFA, DCM, 99%  ii) 5.1, EDCI, HOBt, DIEA, DMF, 36% 
Scheme 5.7.  Synthesis of azobenzene 5.12 for photoswitching studies. 
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Synthesis of 5.13 
 
The azobenzene 5.13 was synthesised as shown in Scheme 5.8, by coupling of amine 5.29 
and carboxylic acid 5.7 in the presence of EDCI to give 5.13 in 53% yield. 
 
Reagents and conditions: i) 5.29, EDCI, HOBt, DIEA, DCM, 53% 
Scheme 5.8.  Synthesis of model azobenzene 5.13 for photoswitching studies. 
 
5.5 Attachment of photoswitch inhibitors to surface linkers 
 
Synthesis of 5.14 
 
The protected thiol 5.14 was prepared as shown in Scheme 5.9.  Trifluoromethylalcohol 
4.16 was treated with TFA to obtain amine 5.30, which was then coupled to carboxylic 
acid 5.7 in the presence of EDCI to give amide 5.31 in 99% yield.  Finally, 5.31 was 
oxidised to trifluoromethylketone 5.14 using Dess-Martin periodinane. 
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Reagents and conditions: i) TFA, DCM, 60%  ii) 5.7, EDCI, HOAt, DIEA, DMF, 99%  iii) Dess-Martin 
Periodinane, 38% 
Scheme 5.9. Synthesis of azobenzene 5.14 for enzyme binding and photoswitching at 
surfaces. 
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Synthesis of 5.15 
 
The azobenzene 5.15 was prepared by azide-alkyne cycloaddition of alkyne 4.3 and azide 
5.8, as shown in Scheme 5.10.  The reaction was initially carried out using the conditions 
shown in Table 5.1, entry (i).  Very poor yield of 5.15 (4%) was obtained, which was 
surprising considering the reported ease of this reaction.  Normally, t-BuOH is used as 
solvent, but EtOH was used here since it would be the preferred solvent for use in 
attachment of alkyne 4.3 to an azide SAM.  Furthermore, higher reactant concentrations 
are normally used.  However, as relatively low amounts of reactants were available for use 
here, and practical solvent volumes were required (> 1 mL), the resulting concentrations 
were low.  The reactants dissolved poorly in the first attempt, so the reaction was repeated 
using an increased solvent volume and a greater proportion of ethanol, as shown in table 
5.1, entry (ii).  A greater amount of reactants dissolved under these conditions and triazole 
5.15 was obtained in 26% yield. 
 
Reagents and conditions: i) 5.8, CuSO4, sodium ascorbate, EtOH, H2O, 35% 
Scheme 5.10.  Synthesis of azobenzene 5.15 for enzyme binding and photoswitching at 
surfaces. 
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Table 5.1.  Reaction conditions† and yields for reaction of alkyne 4.3 with azide 5.8. 
Entry Concentrations of alkyne 
4.3 and azide 5.8 (mM) 
Solvent Yield of 5.15 
i 11 1:1 EtOH/H2O 4% 
ii 2.0 9:8 EtOH/H2O 26% 
†All reactions were carried out in the presence of catalysts CuSO4 (1 mol%) and  sodium ascorbate (5 mol%) 
at r.t. for 16 h. 
 
Optimisation of azide-alkyne cycloadditions using a model system 
 
As the cycloaddition gave a maximum yield of 26%, reaction conditions were optimised 
using a model system.  The reaction of benzyl azide 5.32 with nitrophenyl propargyl ether 
5.34 (see Scheme 5.12 below) was chosen as a model reaction, since it has been previously 
reported as a simple azide-alkyne cycloaddition.11  The alkyne starting material 5.34 was 
synthesised as shown in Scheme 5.11.  Nitrophenol 5.33 was reacted with propargyl 
bromide and base (K2CO3) to give 5.34 in 40% yield. 
 
 
 
 
Reagents and conditions: i) propargyl bromide, K2CO3, DMF, 40% 
Scheme 5.11.  Synthesis of alkyne 5.34. 
 
Cycloaddition of 5.32 and 5.34 to give triazole 5.35 (scheme 5.12) was then carried out 
under previously reported conditions,11 as shown in Table 5.2, entry (i), to give 5.35 in 
78% yield.  The elevated temperature and high concentration in this reaction are 
undesirable for reactions of the surface linkers and inhibitors used here, so the reaction was 
repeated at lower concentration and temperature and with a longer reaction time, as shown 
in Table 5.2, entry (ii).  Under these conditions 1H NMR of the reaction mixture after 16 h 
showed only 11% product present.  To improve yield, the reaction was repeated using 
stoichiometric amounts of CuSO4 and sodium ascorbate (instead of catalytic amounts), as 
shown in Table 5.2, entry (iii).  1H NMR of the reaction mixture after 16 h showed 80% 
product, a significant improvement.   
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Reagents and conditions: i) 5.34, t-BuOH, H2O, 60ºC, 78% 
Scheme 5.12.  Model azide-alkyne cycloaddition. 
 
Table 5.2.  Reaction conditions† and yields for reaction of alkyne 5.34 with azide 5.32. 
Entry Concentration of 
alkyne 5.34 and 
azide 5.32 (mM) 
Catalysts Temperature 
(ºC) 
Reaction 
time (h) 
Yield 
of 5.35 
i 500 5 mol% CuSO4, 
10 mol% sodium 
ascorbate 
60 1.25 78% 
ii 50 5 mol% CuSO4, 
10 mol% sodium 
ascorbate 
r.t. 16 11 
iii 50 1 eq CuSO4, 1 eq 
sodium ascorbate 
r.t. 16 80 
†All reactions were carried out in 1:1 tBuOH/H2O. 
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Synthesis of 5.16 
 
Having determined an acceptable method using this model system, similar conditions were 
used in the reaction of surface linker 5.9 with photoswitch inhibitor 4.3, as shown in 
Scheme 5.13.  The alkyne 4.3 was reacted with azide 5.9 in the presence of 2.2 equivalents 
of CuSO4 and sodium ascorbate to give triazole 5.16 in 82% yield. 
 
Reagents and conditions: i) 4.3, CuSO4, sodium ascorbate, t-BuOH, H2O, 82% 
Scheme 5.13.  Synthesis of azobenzene 5.16 for enzyme binding and photoswitching at 
surfaces. 
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5.6 Synthesis of analogues of surface-attached inhibitors for assay 
 
Synthesis of 5.17 
 
The alkyne 4.3 was reacted with azide 5.24 in the presence of 1.1 equivalents of CuSO4 
and sodium ascorbate to give triazole 5.17 in 68% yield (Scheme 5.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: i) 5.24, CuSO4, sodium ascorbate, t-BuOH, H2O, 68% 
Scheme 5.13.  Synthesis of model triazole 5.17 for enzyme assay. 
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Synthesis of 5.18 
 
The alkyne 4.6 was reacted with azide 5.24 in the presence of 1.1 equivalents of CuSO4 
and sodium ascorbate to give triazole 5.18 in 37% yield (Scheme 5.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: i) 5.24, CuSO4, sodium ascorbate, t-BuOH, H2O, 37% 
Scheme 5.14.  Synthesis of model triazole 5.18 for enzyme assay. 
 
5.7 Summary 
 
A range of thiol/disulfide surface linkers was synthesised for surface attachment of 
photoswitch enzyme inhibitors.  The disulfides 5.4-5.5 containing azide groups for surface 
attachment of inhibitors and diluent 5.6 for blocking of non-specific protein adsorption 
were synthesised from lipoic acid 5.1.  Analogous protected thiols 5.7-5.8 containing 
carboxylic acid or azide groups and diluent 5.10 were synthesised from thiol 5.2.  The 
symmetrical disulfides 5.9 and 5.11 were prepared by deprotection of thioesters 5.8 and 
5.10. 
 
The azobenzene 5.29 was coupled to lipoic acid 5.1 and to protected thiol 5.7 to give 
azobenzenes 5.12 and 5.13 for photoswitching studies.  The trifluoromethylalcohol 4.16 
was attached to surface linker 5.7 by deprotection and amide coupling to give 5.14 for 
enzyme binding and photoswitching studies, and trifluoromethylketone 4.3 was attached to 
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surface linkers 5.8 and 5.9 by azide-alkyne cycloaddition to give 5.15 and 5.16 for the 
same purpose.  The trifluoromethylketone 4.3 and α-ketoester 4.6 were reacted with OEG 
azide 5.24 to form model compounds 5.17 and 5.18 for enzyme assay that mimic the 
structure of surface-attached 4.3 and 4.6. 
 
Photoisomerisation studies of azobenzenes 5.12-5.13 and 5.17-5.18 and enzyme assays of 
trifluoromethylketone 5.17 and α-ketoester 4.18 are described in chapter 6.  Surface 
attachment of disulfides 5.9, 5.11 and 5.16 and QCM studies of enzyme binding to 
surface-attached trifluoromethylketone 5.16 are described in chapter 7. 
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Photoisomerisation and enzyme inhibition studies 
 
6.1 Introduction 
 
Photoregulated enzyme binding to a surface required a surface-bound enzyme inhibitor 
that exhibits a significant change in potency on photoisomerisation.  This chapter describes 
UV/visible photoisomerisation experiments and enzyme assays that were carried out on the 
compounds described in chapters 2-5 to assess their photoswitching and enzyme inhibition 
properties, in order to select the best compounds for surface photoswitching studies. 
 
As discussed in chapter 1, the E and Z isomers of azobenzenes are excited by UV/visible 
irradiation, allowing controlled E/Z isomerisation.  Methods were thus required to irradiate 
azobenzenes and to characterise and quantify the isomers obtained from irradiation.  
Irradiation was carried out using a Hg arc lamp with filters to select UV or visible light and 
characterisation of E and Z isomers was performed by analysis of 1H NMR spectra, based 
on reported methods.1-3 
 
Inhibition of α-chymotrypsin was measured using a spectrophotometric assay that 
measures the rate of hydrolysis of substrate MeO-Suc-Ala-Ala-Pro-Phe-4-nitroanilide,4 as 
shown in Scheme 6.1.  The increase in the visible absorption of released 4-nitroaniline was 
measured at 405 nm and plotted against reaction time to obtain a linear graph with slope 
proportional to the rate of hydrolysis.  Determining hydrolysis rates at a range of substrate 
and/or inhibitor concentrations then allowed calculation of kinetic parameters Km and Vmax 
and/or inhibition constants IC50 or Ki.†   
 
                                                 
† The IC50 inhibition constant represents the concentration of inhibitor required to halve the rate of reaction, 
and the Km, Vmax and Ki parameters are constants in the following Michaelis-Menten equation for the initial 
rate of an enzymatic reaction with competitive inhibition: 
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Where V0 is the initial rate, [S] is the concentration of substrate and [I] is the concentration of inhibitor.  Here 
Vmax represents the maximum possible rate of enzyme hydrolysis at saturation of all enzyme sites, Km 
represents the substrate concentration that gives rise to a rate equal to half of Vmax, and Ki represents the 
concentration of inhibitor required to give an apparent doubling of Km. 
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Scheme 6.1.  α-Chymotrypsin catalysed hydrolysis of MeO-Suc-Ala-Ala-Pro-Phe-pNA. 
 
6.2 Optimisation of photoisomerisation studies 
 
Photoisomerisation of model azobenzene 2.26 
 
Initially, photoisomerisation of simple azobenzene 2.26 (Fig. 6.1) was carried out to 
optimise irradiation conditions.  A solution of E-2.26 (2 mg) in d3-acetonitrile (500 μL) 
was placed in a quartz NMR tube and a 1H NMR spectrum of the sample was obtained.  
The spectrum (Fig. 6.2) shows only E isomer.  This sample was then irradiated with UV 
light to induce E to Z photoisomerisation. 
 
 
 
 
 
 
Fig. 6.1.  Azobenzene 2.26 for initial photoisomerisation studies. 
 
Fig. 6.2. 1H NMR spectrum of E-2.26. 
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Irradiation was initially carried out using a Schott UG11 UV filter to select UV 
wavelengths from a Hg arc lamp and a water filter to remove heat from the UV beam.  The 
NMR tube containing E-2.26 was irradiated for 90 min, obtaining 1H NMR spectra after 
30, 60 and 90 min.  The spectrum obtained after 30 min irradiation is given in Fig. 6.3, 
showing a series of new upfield peaks assigned to the Z isomer.  The sample was then 
irradiated with visible light (using a Corning 0-51 visible filter) for 60 min to induce Z to E 
isomerisation.  A further 1H NMR spectrum was obtained (not shown), which revealed a 
decrease in the integrals of peaks corresponding to the Z isomer.  Finally, the sample was 
left in ambient lighting conditions (fluorescent indoor lighting) for 24 h in order to reach 
an ambient light PSS, and a 1H NMR spectrum was obtained.  E/Z isomeric proportions 
were determined from each spectrum by comparison of the integrals of peaks 
corresponding to the amide protons at 6.1 ppm (Z) and 6.2 ppm (E), as shown in Table 6.1. 
 
 
 
Fig. 6.3.  1H NMR spectrum of Z-enriched azobenzene 2.26 (44% Z) resulting from 30 min 
UV irradiation.  Arrows show new peaks assigned to Z-2.26. 
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Table 6.1.  E:Z ratios for azobenzene 2.26 before/after UV/vis irradiation. 
Irradiation(s) carried out E:Z ratio determined by 1H NMR 
None >95 : <5 
UV 30 min 56 : 44 
UV 60 min 54 : 46 
UV 90 min 53 : 47 
UV 90 min, visible 60 min 85 : 15 
UV, visible, ambient lighting 16 h 80 : 20 
 
A maximum Z isomer enrichment of 47% was obtained from UV irradiation (after 90 min).  
This represents relatively poor photoisomerisation compared to previous studies, which 
generally report 70-90% Z isomer after UV irradiation.2, 3 Visible irradiation gave 15% Z, 
similar to previous studies.  The PSS obtained in ambient lighting contained 20% Z, 
similar to that obtained by visible irradiation.  This is as expected, since ambient indoor 
lighting should contain similar wavelengths to the visible light produced by the lamp.  To 
improve the E to Z photoswitching, experimental conditions (solvent, substrate, 
wavelength filter) were systematically modified: 
 
Photoisomerisation of 2.26 in DMSO 
 
First, solvent was varied, since use of a solvent that stabilises the Z isomer over the E 
isomer would improve E to Z photoswitching.  A sample of E-2.26 was dissolved in d6-
DMSO and irradiated with UV.  NMR analysis showed Z-enrichment to 49% Z isomer 
after 30 min, and no further enrichment after 60 or 90 min.  This result is similar to the 
maximum Z enrichment obtained in acetonitrile (47%).  Therefore, the change in solvent 
does not significantly improve photoswitching.   
 
Photoisomerisation of alternative model azobenzene 2.41 
 
It was considered that azobenzene 2.26 might simply be a poor photoswitch, due to 
possible instability of the Z isomer.  A solution of alternative azobenzene 2.41 (Fig. 6.4) in 
d3-acetonitrile was irradiated with UV for 90 min, obtaining 1H NMR spectra after 
irradiation times of 30, 60 and 90 min.  58% Z isomer was obtained after 30 min, and no 
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further enrichment was observed after 60 or 90 min.  Visible irradiation of this sample for 
60 min then gave 14% Z isomer.  This azobenzene gave improved Z enrichment on UV 
irradiation as compared to 2.26 (58% vs. 47%), but the amount of Z isomer obtained was 
still not as high as desired (preferably > 70%). 
 
 
 
 
 
 
Fig. 6.4.  Alternative azobenzene 2.41 for optimisation of photoisomerisation studies. 
 
Assessment of UV filters used in irradiation 
 
Next, the UV filter was assessed, in order to determine whether or not selective excitation 
of azobenzene could be performed at the wavelengths transmitted by the UG11 filter.  To 
give selective E to Z isomerisation, the transmittance wavelengths of the UV filter are 
required to coincide with absorbance bands of the E azobenzene isomer, but not with those 
of the Z isomer (in order to excite the E isomer only).  A UV/vis transmittance spectrum of 
the filter was obtained, and absorbance spectra of ethanol solutions of the E and Z isomers 
of azobenzene 2.7† were measured for comparison.  All three spectra are shown in Fig. 6.5.  
The absorbance spectra of E- and Z-2.7 are not to scale with the transmittance spectrum of 
the UV filter, but allow comparison of the wavelength ranges of the major absorbance and 
transmittance bands.  The spectrum of the UV filter shows transmittance over a large 
wavelength range (at least 250-400 nm).  This range overlaps the major absorbance band 
of E-2.7 (~260-370 nm), as is required for E to Z isomerisation.  However, the 
transmittance range also significantly overlaps the major absorbance bands of the Z isomer 
(< 320 nm and ~370-500 nm).  This is undesirable, as the UV irradiation may also excite 
the Z isomer, leading to the reverse Z to E isomerisation.  The overlap may explain why 
relatively poor Z enrichment was obtained on UV irradiation using this filter.   
                                                 
† See section 6.3, below, for details of the chromatographic separation of E- and Z-2.7 
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 Fig. 6.5.  UV/vis spectra of the UG11 UV filter and E- and Z-2.7. 
 
Irradiation of 2.41 using the alternative Corning 7-37 UV filter 
 
A UV filter that only transmits light in the narrow range 320-380 nm (Corning 7-37 UV 
filter) was obtained with the aim of improving photoisomerisation.  A sample of 2.41 in 
d3-acetonitrile was irradiated with UV using this filter to give 65% Z after 30 min and 90% 
Z after 60 min, with no further enrichment after 90 min.  The NMR spectra of E-2.41 and 
the Z-enriched PSS resulting from 60 min irradiation are shown in Fig. 6.4.  This 
photoswitching is a significant improvement on the result obtained using the UG11 filter 
(maximum 58% Z).  Consequently, the Corning 7-37 filter was used in the enzyme 
photoswitching studies. 
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Fig. 6.6.  NMR spectra of E-2.41 and a sample of Z-2.41 obtained by UV irradiation.  
Integrals of peaks at 4.38, 4.46, 7.48, 7.95, 8.18 ppm (E) and 4.26-4.33, 6.82, 6.90 ppm (Z) 
were used to determine E/Z compositions. 
 
6.3 Photoisomerisation of inhibitors and surface linkers 
 
Photoisomerisation of boronate ester 2.7 
 
The potential photoswitch inhibitor 2.7 (Fig. 6.7) was photoisomerised using the 7-37 UV 
filter.  A solution of 2.7 in d3-acetonitrile was irradiated with UV light for 30 min to give 
50% Z isomer.  However, the NMR spectrum showed an usually large peak at 1.20 ppm 
E-2.41 
Z-2.41 
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(Fig. 6.8), suggesting decomposition.  The peaks at 1.18 and 1.20 ppm correspond to the 
pinacol group of E-2.7, and the upfield peaks at 1.14 and 1.16 correspond to the Z isomer.  
However, the integral of the E peak at 1.20 ppm appears slightly larger than the peak at 
1.18 ppm.  The sample was irradiated for a further 60 min, after which the peak at 1.20 
ppm was clearly larger than the peak at 1.18 ppm (see Fig. 6.8), and appeared to be a 
doublet.  The large size and unexpected structure of the peak at 1.20 ppm suggest that this 
peak corresponds to a new compound formed by irradiation.  TLC of the irradiated sample 
was carried out.  A spot was observed on the TLC plate that was not present in a pure 
sample of E and Z-2.7, confirming the presence of a new compound formed from 
irradiation.  This decomposition product was not further characterised. 
 
 
 
 
 
 
Fig. 6.7. Boronate ester 2.7 for photoswitching and enzyme assays. 
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Fig. 6.8.  Observed changes to the pinacol peaks of 2.7 on UV irradiation. 
A third UV filter was used (Edmund Optics 340 nm interference filter) in an attempt to 
reduce the apparent decomposition.  This filter transmits a narrower range of wavelengths 
than the 7-37 filter, so allows irradiation at lower intensity and greater selectivity for the 
major absorbance band of E azobenzenes.  Irradiation of azobenzene 2.7 was carried out 
for 90 min to give 74% Z isomer.  Inspection of the pinacol NMR peaks for this sample 
revealed the presence of the decomposition product peak at 1.20 ppm.  However, the 
relative integral of this peak was less than was observed after irradiation with the 7-37 
filter, showing less decomposition. 
 
Samples of 2.7 irradiated with the Edmund Optics filter were assayed to assess the impact 
of the decomposition on α-chymotrypsin inhibition (see section 6.5 for details and assay 
results).  In addition, a sample of Z-2.7 was obtained by column chromatography to 
compare with the partially decomposed irradiated samples.  A solution of E-2.7 was left in 
ambient lighting for 24 h, then the resultant mixture of E- and Z-2.7 was separated by 
silica column chromatography in dim lighting conditions to obtain a sample of Z-2.7 (> 
95% Z). 
30 min irradiation 
90 min irradiation 
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Photoisomerisation of boronate ester 2.10 
 
A solution of boronate ester 2.10 (Fig. 6.9) in d3-acetonitrile was irradiated with UV light 
for 120 min using the Edmund Optics filter to give 50% Z after 60 min and 68% Z after 
120 min.  However, 1H NMR spectra revealed decomposition by the appearance of a new 
peak at 1.20 ppm.  Irradiated samples of this compound were assayed to assess the impact 
of decomposition on α-chymotrypsin inhibition (see section 6.5).   
 
 
 
 
 
 
Fig. 6.9.  Boronate ester 2.10 for photoswitching and enzyme assays. 
 
 
Photoisomerisation of trifluoromethylketones and α-ketoesters 
 
The trifluoromethylketone and α-ketoester inhibitors 4.1-4.7 and 5.17-5.18 were 
photoisomerised using a fixed set of irradiation conditions (7-37 UV filter, 0-51 visible 
filter, 90 min UV irradiation followed by 60 min vis irradiation) in order to directly 
compare the photoisomerisation of these compounds.  1H NMR of these samples after 
irradiation showed good photoisomerisation (see Table 6.2), from initial states of <10% Z 
isomer to 66-93% Z after UV irradiation and back to 8-21% Z after visible irradiation, with  
no observed decomposition. 
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Table 6.2.  Photoisomerisation of trifluoromethylketones and α-ketoesters. 
Compound Structure Amount of Z 
isomer before 
irradiation 
Amount of 
Z isomer 
after UV 
irradiation 
Amount of Z 
isomer after 
visible 
irradiation 
4.1  
 
 
<5% 93% 16% 
4.2 
 
5% 66% 9% 
4.3  
 
 
5% 87% 12% 
4.4 
 
6% 85% 8% 
5.17  
 
 
7% 76% 18% 
4.5  
 
 
 
5% 94% 14% 
4.6  
 
 
<5% 85% 7% 
4.7 
 
6% 88% 14% 
5.18  
 
 
7% 74% 15% 
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The pairs of compounds containing the same azobenzene 4ʹ-substituent and differing only 
in the enzyme binding group (4.1 and 4.5, 4.3 and 4.6, 4.4 and 4.7, 5.17 and 5.18) exhibit 
very similar photoswitching properties.  This suggests that the electrophilic enzyme 
binding group does not significantly affect photoswitching.  However, the 4ʹ-substituent 
appears to have a large influence on photoswitching, as can be seen in the difference 
between the UV PSS compositions of compounds 4.1 and 4.2 (93% and 66%, respectively).  
The properties of this substituent presumably influence photoisomerisation by affecting 
one or both of the following factors: 
 
i) The difference between the stability of the E and Z isomers in solution – i.e. substituents 
that increase the steric or electronic stability of the Z isomer over the E isomer are likely to 
promote E to Z isomerisation, and substituents that increase the stability of the E isomer 
over the Z isomer are likely to promote Z to E isomerisation. 
 
ii) The UV/visible absorbance of the azobenzene group.  Substituents that donate/withdraw 
electron density to/from the azobenzene group may alter the energy levels involved in 
electronic excitation of azobenzene to the excited state that allows isomerisation (see 
chapter 1, section 1.2.2).  Changes to these energy levels causes a shift of the 
corresponding UV/vis absorbance bands of the azobenzene.  Assuming irradiation is 
carried out using a fixed wavelength range, a shift of the azobenzene absorbance bands 
may lead to increased (or decreased) excitation of either the E or Z isomer by the 
irradiation wavelengths, leading to increased (or decreased) isomerisation of this isomer. 
 
Photoisomerisation of model surface linkers 
 
Irradiation experiments were also carried out to assess the photoisomerisation properties of 
model surface compounds 5.12 and 5.13 (Fig. 6.10).  A sample of disulfide 5.12 was 
irradiated with UV to, unexpectedly, give only trace amounts (< 5%) of Z isomer after 90 
min.  Irradiation was carried out for a further 90 min to give 20% Z isomer.  This poor 
photoisomerisation suggests that the UV absorbance of the constituent dithiolane group 
interferes with the UV absorbance of the azobenzene group.  Based on this result, lipoic 
acid derivatives were not used in surface attachment studies.  
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Fig. 6.10.  Model azobenzenes 5.12 and 5.13 for photoswitching studies. 
 
A sample of compound 5.13 (initially < 5% Z isomer) was irradiated with UV light for 90 
min, to obtain 91% Z isomer.  Visible irradiation for 60 min returned the sample to 15% Z 
isomer.  Related compounds were thus used in surface attachment studies (see chapter 7). 
 
6.4 Assay setup and validation 
 
α-Chymotrypsin assays were carried out as described in section 6.1. 
 
Assay conditions 
 
Solutions of Tris buffer (0.1 M, pH 7.8, containing CaCl2 and Triton X-100 surfactant),  
α-chymotrypsin (in Milli-Q water containing HCl and Triton X-100), substrate (in Tris 
buffer), and inhibitor (in DMSO or acetonitrile) were made up.  Inhibitor and substrate 
were mixed, incubated for 5 min at 25 ºC, then enzyme was added and the UV/vis 
absorbance of the solution was monitored at 405 nm for 5 or 10 min.  The experiment was 
repeated over a range of substrate and/or inhibitor concentrations, and the initial or final 
rate was calculated for each.  The uncertainty in affinity constants is estimated at ± 20%, 
and the uncertainty of affinity increases/decreases on photoisomerisation is estimated at ± 
10%.  Further details are given in the experimental chapter, section 9.6, and in the 
descriptions of particular assays in this chapter. 
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Αssay without addition of inhibitor 
 
Initially, assays were carried out without inhibitor to ensure that the enzyme exhibited 
normal activity.  Initial rate data was obtained for a range of substrate concentrations (83-
420 μM) and plotted in a double reciprocal plot† (Fig. 6.11) to determine kinetic 
parameters of Km = 40 μM and Vmax = 1.2 μmol s-1 mg-1.  These results are comparable to 
previous studies.5, 6 
Fig. 6.11.  Double-reciprocal plot for calculation of kinetic parameters for α-chymotrypsin. 
 
As inhibitor assays involved addition of acetonitrile or DMSO to the assay solution, 
preliminary assays with addition of solvent were also carried out.  Kinetic constants of 
Vmax = 1.2 μmol s-1 mg-1 and Km = 19 μM were obtained with the addition of acetonitrile, 
and Vmax = 1.1 μmol s-1 mg-1 and Km = 33 μM with the addition of DMSO.  The Km in these 
assays is decreased, as compared to the assay containing no organic solvent.  This suggests 
that acetonitrile and DMSO enhance the rate of α-chymotrypsin catalysed hydrolysis.   
 
 
 
                                                 
† 1/V0 vs 1/[S], where [S] is the substrate concentration.  The x-intercept is equal to 1/Km and the y-intercept 
is equal to 1/Vmax. 
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Validation of assay with reported inhibitor 2.12 
 
The racemic form of reported inhibitor 2.12 (Fig. 6.12) was assayed in order to validate the 
assay procedure.  Assays of both the L and D enantiomers have been previously reported, 
with inhibition constant, Ki, of 2.1 μM7 and 3.8 μM8 reported for the L isomer and 537 and 
80 μM8 reported for the D isomer.   
 
 
 
 
 
Fig. 6.12.  Known inhibitor 2.12 for assay validation. 
 
Initial rate data was obtained at a range of substrate concentrations (80-410 μM) and 
inhibitor concentrations (17-69 μM) and a Dixon plot† was used (Fig. 6.13) to obtain a Ki 
inhibition constant of 7 μM.  This result for racemic 2.12 compares well with the literature, 
where the active L enantiomer is reported to give approximately half this value (2-4 μM).  
As such, this result validates the assay, ensuring that inhibition constants obtained here can 
be compared with other studies. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
† 1/V0 vs [I], where [I] is the inhibitor concentration.  Lines are drawn through sets of points of the same 
substrate concentration, the intersection of these lines occurring at (–Ki, 1/Vmax).   
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Fig. 6.13.  Dixon plot for determining Ki of inhibitor 2.12. 
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6.5 Assay of boronate esters described in chapter 2 
 
Assays of E azobenzenes and chromatographically separated Z-2.7 
 
Samples of the E isomers (< 5% Z) of boronate esters 2.1-2.2 and 2.6-2.11 and the sample 
of Z-2.7 obtained by chromatography were assayed at a range of inhibitor concentrations 
[I] as appropriate for each compound and a fixed substrate concentration [S] of 190 μM, in 
order to obtain IC50 inhibition constants.  The percentage inhibition was calculated at each 
[I] then plotted against log[I].  From these plots, log(IC50) was interpolated at 50% 
inhibition and used to calculate IC50 values.  As the plots were found to be non-linear at 
high and low percentage inhibition, the line of best fit for interpolation was drawn through 
the linear points, usually in the range 20-80% inhibition.  Fig. 6.14 shows a representative 
IC50 plot using data obtained from assay of 2.7.  Here, poor solubility of the inhibitor 
prevented assay at high inhibitor concentrations (>3.3 μM), but the three linear points were 
sufficient to obtain an IC50 value.  The measured IC50 values of the boronate esters are 
shown in Table 6.3, below.   
 
Fig. 6.14.  IC50 plot for 2.7. 
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Table 6.3.  IC50 inhibition constants for inhibition of α-chymotrypsin by boronate esters. 
Compound ( < 5% Z unless 
specified) 
Structure IC50 (μM) 
2.1  
 
> 15 
2.2 
 
> 25 
2.6 
 
> 200 
E-2.7  3.0 
Z-2.7 (> 95% Z, obtained by 
chromatography) 
 4.7 
2.8/2.9 (92 : 8 ratio) 
 
18 
2.8/2.9 (7 : 93 ratio) 
 
1.3 
2.10 
 
10 
2.11 
 
11 
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The azobenzenes 2.1-2.2 and 2.6 containing an aminophenylboronate ester group were 
found to be inactive against α-chymotrypsin up to their solubility limits (15-200 μM).  
This is surprising, as these compounds are structurally very similar to the reported 
photoswitch inhibitor 1.21 (Fig. 6.15), which inhibits α-chymotrypsin with inhibition 
constant, Ki, of 11 μM.3  This suggests that the fit of 1.21 into the enzyme active site is 
significantly enhanced by the shape and/or hydrogen bonding attributable to the 
sulfonamide group.  However, replacing the amide of 2.2 with a sulfonamide to give 2.6 
did not replicate this effect, as sulphonamide 2.6 was also inactive.  It is possible that the 
incorporation of the boronate ester group into 2.1-2.2 and 2.6 (instead of the boronic acid 
group) might account for the reduction in potency relative to 1.21.  However, the observed 
1.4-18 fold decreases in activity are not consistent with literature, where boronate esters 
and their corresponding free acids are reported to give very similar activities in enzyme 
assays.9, 10  Our results suggest that 1.21, although an effective photoswitch, cannot be 
simply extended as a peptide analogue.  As such, the related boronate esters 2.3-2.5 were 
not assayed and efforts were focussed on the borophenylalanine derivatives 2.7-2.11, 
which inhibited α-chymotrypsin with low micromolar IC50 values. 
 
 
 
 
 
Fig. 6.15.  Known α-chymotrypsin inhibitor 1.21. 
 
Encouragingly, the potency of compounds 2.7 and 2.9 (3.0 and 1.3 μM, respectively) is 
similar to the activity of acetylborophenylalanine 2.12 (Ki = 7 μM). This result implies that 
activity is not significantly impaired by the presence of the azobenzene group or the 
protection of the boronic acid as the pinacol ester. It is possible that the azobenzene group 
may even enhance activity by providing either a good fit into the shallow hydrophobic S2 
subsite, or an extended mimic of a β-strand, the preferred conformation of peptide 
substrates of proteases.11 This could then offset any possible reduction in activity due to 
the boronic acid protection.  The absolute configuration of diastereomers 2.8 and 2.9 could 
not be assigned from NMR data.  However, the more active isomer 2.9 is tentatively 
assigned the (R) configuration, as this corresponds to (i) the configuration of natural 
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phenylalanine and (ii) that commonly found in the more active isomers of related 
inhibitors.8  Interestingly, the most active diastereomer 2.9 was found to have 
approximately twice the potency of racemic 2.7.  This suggests that incorporation of 
leucine into the inhibitor structure does not significantly enhance binding through 
interaction of leucine with the S2 subsite. It is, however, possible that any increase in 
binding conferred by leucine is off-set by the affinity of the hydrophobic azobenzene 
group for the S2 subsite (as in 2.7) rather than the S3 subsite (as in 2.9). 
 
The azobenzenes 2.10 and 2.11 containing a surface attachment group in the 4ʹ position 
gave inhibition constants that are not significantly different (10 and 11 μM), several times 
weaker than monosubstituted azobenzene 2.7, but significantly more potent than 2.1-2.2 
and 2.6.  This suggests that the extra substitution of the azobenzene group only slightly 
impairs the fit of the inhibitor into the active site.  The extra bulk of the Boc group in 2.10 
is tolerated, suggesting that the specificity of the enzyme binding site does not extend 
further than the glycine in these inhibitors.  Consequently, it is likely that the primary 
amine group of 2.11 protrudes from the active site and thus may be used for surface 
attachment. 
 
The azobenzene E-2.7 exhibits more potent inhibition than chromatographically separated 
Z-2.7 (IC50 values of 3.0 vs. 4.7 μM).  This is consistent with the reported photoswitching 
of azobenzene 1.21, where the E isomer was also found to be the most active. 
 
Assay of irradiated boronate esters 2.7 and 2.10 
 
To compare with the chromatographically separated samples of E- and Z-2.7, assays were 
carried out on UV/vis irradiated samples.  A solution of E-2.7 was irradiated for 90 min, an 
aliquot was removed and assayed, and the remainder of the solution irradiated with visible 
light for 60 min with subsequent assay.  Two further irradiations (UV then visible) and 
assays were carried out, with the resulting IC50 values after each irradiation shown in Fig. 
6.16.  
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Fig. 6.16.  Assay of irradiated 2.7 showing decomposition. 
 
A decrease in inhibition was observed after each irradiation.  In addition, the samples 
irradiated two or more times were less potent than the chromatographically isolated sample 
of Z-2.7 (4.7 μM).  Combined with the NMR and TLC results in section 6.3, these results 
show that decomposition of 2.7 occurred on irradiation, with a loss of activity. 
 
A similar set of irradiations and assays was carried out for boronate ester 2.10.  
Photoswitching was observed with limited decomposition at each cycle.  The assay results 
recorded over three irradiations are shown in Fig. 6.17.  The activity increased from 10 μM 
(for sample containing <5% Z isomer) to 7.0 μM after UV isomerisation to give 60% Z 
isomer.  Subsequent visible irradiation reduced activity to 13 μM (85% E isomer), and a 
further UV irradiation increased activity to 10 μM.  The Z isomer of this boronate ester is 
the more potent isomer, contrasting with the results obtained for the simpler compounds 
2.7 and 1.21, where the E isomer is more potent. Consequently, there appears to be no 
direct correlation between the nature of the enzyme binding group and the relative 
activities of the E and Z isomers.  Rather, it is dependent on the shape of the inhibitor and 
hence the nature of its overall fit into the α-chymotrypsin active site. 
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Fig. 6.17. Photoswitching of boronate ester 2.10 with limited decomposition. 
 
As boronate esters 2.7 and 2.10 decomposed on irradiation, these compounds are not 
sufficiently stable for surface photoswitching, and photoisomerisation of other boronate 
esters was not carried out. 
 
6.6 Assay of compounds described in chapter 3 
 
Assays were carried out to obtain IC50 values for compounds 3.3-3.5 (Fig. 6.18), 
derivatives of reported non-covalent inhibitor 3.1 (see chapter 3) further substituted to 
introduce photoswitching activity (3.5) or a surface attachment group (3.3 and 3.4). 
 
Fig. 6.18.  Derivatives 3.3-3.5 of a non-covalent α-chymotrypsin inhibitor. 
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The azobenzene 3.5 was assayed as a mixture of E and Z isomers (83% E, 17% Z, 
determined by HPLC) for an initial screening assay.  All compounds 3.3-3.5 were found to 
be inactive against α-chymotrypsin up to their solubility limits (25-91 µM).  To confirm 
the previously reported activity of compound 3.1,12 intermediate 3.10 was assayed to 
obtain a Ki value.  This compound is essentially identical to 3.1, simply lacking the HCl 
salt.  A result of 4 µM was obtained, comparable to the reported value of 3.6 µM for 3.1.   
 
The reduced potency of compounds 3.3 and 3.4 (compared to 3.1) suggests that either the 
amine group of 3.1 is involved in important hydrogen bonding interactions with the active 
site of α-chymotrypsin or there is simply insufficient space in the active site for the 
replacement of the amine by the larger amide group.  Consequently, inhibitor 3.1 cannot be 
simply extended at the N-terminus for surface attachment.  The crystal structure of the 
enzyme-inhibitor complex of 3.2 with chymotrypsin shows that the D-Leu side chain 
extends from the binding pocket.  Modification of this side chain might be a more effective 
approach for surface attachment. 
 
The inactivity of the mixture of E- and Z-3.5 suggests that the azobenzene group is too 
large to fit into the S1 subsite of α-chymotrypsin.  Consequently, photoswitching activity 
cannot be introduced to compound 3.1 by replacement of the P1 phenyl group by 
azobenzene.  As an alternative photoswitching strategy, the P2 phenyl group (the Phe side 
chain) could be replaced with azobenzene, as the large azobenzene group is more likely to 
be tolerated in the shallow S2 pocket than the deep, narrow S1 pocket. 
 
6.7 Assay of trifluoromethylketones and α-ketoesters described in 
chapters 4 and 5 
 
Potential photoswitch inhibitors containing trifluoromethylketone or α-ketoester groups 
4.1-4.7 and 5.17-5.18 were assayed to obtain IC50 values.  As these compounds all 
appeared to be stable to UV/visible irradiation (by 1H NMR), all were assayed as: i) the E 
isomer before irradiation ii) the Z enriched PSS resulting from UV irradiation iii) the E 
enriched PSS from visible irradiation.  The E:Z compositions are as given previously in 
Table 6.3, section 6.5. 
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All compounds were found to be inhibitors of α-chymotrypsin, with IC50 values as shown 
in Table 6.4.  While the α-ketoesters exhibited normal inhibition characteristics, the 
inhibition of the trifluoromethylketones appeared to increase over time.  This slow increase 
in binding strength is consistent with the ‘slow-tight’ binding mode involving the initial 
formation of a weakly bound enzyme-inhibitor complex followed by rearrangement to a 
more tightly bound complex.13  To record a steady state hydrolysis rate, 
trifluoromethylketones were allowed to incubate with enzyme and substrate for 8 minutes 
before rate data was collected.  Consequently, the IC50 values given for 
trifluoromethylketones reflect the final ‘tight’ binding.  In all cases, the initial binding of 
trifluoromethylketones was too weak to obtain an accurate IC50 value. 
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Table 6.4.  Inhibition constants (IC50) for trifluoromethylketones and α-ketoesters. 
Compound Structure IC50 before 
irradiation 
(μM) 
IC50 after 
UV 
irradiation 
(μM) 
IC50 after 
visible 
irradiation 
(μM) 
4.1  32 13 29 
4.2 
 
20 17 21 
4.3  
 
>85 16 >85 
4.4 
 
>51 14 >51 
5.17  
 
 
19 12 21 
4.5  
 
 
 
0.71 0.23 0.59 
4.6  
 
 
1.0 0.47 0.85 
4.7 
 
2.0 0.73 2.2 
5.18  
 
0.47 0.19 0.43 
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A range of structure-activity-photoswitching comparisons can be drawn from the data in 
Table 6.4.  The α-ketoesters are more potent inhibitors than the trifluoromethylketones, 
with inhibition constants ranging from 0.23 to 2.2 μM for the α-ketoesters and 12 to 85 
μM for the trifluoromethylketones.  This suggests that the α-ketoester group binds more 
rapidly and/or strongly to the Ser195 residue of the active site.  Both α-ketoesters and 
trifluoromethylketones are more active as the Z-enriched PSS obtained from UV 
irradiation, as previously reported for these classes of photoswitch inhibitors,2, 5 and 
observed for the related boronate ester 2.10 (see section 6.5).   
 
It is clear that the structural requirements for potent binding of trifluoromethylketones are 
very different to those of α-ketoesters, despite the close similarity of these classes of 
inhibitor.  For example, the Z enriched forms of the trifluoromethylketones exhibit a 
narrow range of inhibition constants (12-17 μM) and the E enriched forms vary 
considerably (19-85 μM), whereas the inhibition constants of both the E and Z enriched 
states of the α-ketoesters vary significantly between compounds.  Therefore, it appears that 
the 4ʹ substituent has little impact on the potency of Z-trifluoromethylketones, but has a 
major effect on the potency of E-trifluoromethylketones and of both E- and Z-α-ketoesters.  
 
Furthermore, the difference in activity between the E and Z isomers of an inhibitor (i.e. the 
extent of enzyme photoswitching) varies more between trifluoromethylketones than it does 
between α-ketoesters.  For example, the best and worst photoswitching results are 
observed for trifluoromethylketones (4.3 and 4.2, respectively), while all of the  
α-ketoesters exhibit intermediate photoswitching of 2-3 fold changes in activity between 
isomers.   
 
In comparison of the 4ʹ azobenzene substituents, the strongest binding is exhibited by 
triazoles 5.17 and 5.18 and the weakest binding is exhibited by alkynes 4.3, 4.6, 4.4 and 
4.7.  This suggests that the triazole group fits better into the α-chymotrypsin active site 
than the alkyne group does.  However, the best photoswitching is exhibited by alkynes 4.3 
and 4.4, which give >5.3 and >3.6 fold changes in activity on photoswitching.  As the E 
isomers of these compounds were inactive up to their solubility limits, the exact extent of 
photoswitching may be greater than that reported.  As the Z-trifluoromethylketones all 
exhibit similar potencies, the excellent photoswitching of 4.3 and 4.4 is due to the 
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particularly weak binding of the E isomers of these compounds, as compared to other 
E-trifluoromethylketones.   
 
For surface photoswitching, it should be considered that alkynes 4.3 and 4.6 would form 
triazoles on surface attachment, resembling triazoles 5.17 and 5.18, respectively.  
Therefore, the activities of these model triazoles are the best measures of the activity of 
surface attached 4.3 and 4.6.  While alkyne 4.3 is an excellent photoswitch, triazole 
analogue 5.17 is a poor photoswitch, which suggests that 4.3 would give poor results after 
surface attachment.  Conversely, alkyne 4.6 and triazole 5.18 give similar photoswitching 
results.  As the best photoswitch (4.3) is likely to give poor results after surface attachment, 
the trifluoromethylketone 4.4 is a better candidate for surface enzyme photoswitching.  
This alkyne contains an extended OEG group, so reaction to give a triazole is unlikely to 
significantly affect enzyme binding or photoswitching. 
 
6.8 Summary 
 
Photoisomerisation of azobenzenes 2.26 and 2.41 was carried out to optimise irradiation 
conditions.  The best E to Z irradiation was obtained using a UV filter with a relatively 
narrow wavelength range.  Subsequently, compounds 2.7, 2.10, 4.1-4.7, 5.12-5.13 and 
5.17-5.18 were photoisomerised.  Good photoisomerisation was obtained for all 
azobenzenes except the boronic acids, which partially decomposed on irradiation, and 
lipoic acid derivative 5.12, which did not isomerise well. 
 
α-Chymotrypsin assays were carried out, initially for reported inhibitor 2.12 to validate the 
assay, then for compounds 2.1-2.2, 2.6-2.11, 3.3-3.5, 3.10, 4.1-4.7 and 5.17-5.18.  The 
aminophenylboronate-based compounds 2.1-2.2 and 2.6 and dipeptide derivatives 3.3-3.5 
were inactive, but the borophenylalanine based compounds, trifluoromethylketones, α-
ketoesters, and dipeptide 3.10 were all micromolar inhibitors of the enzyme.   
 
Reversible photoswitching of inhibition was obtained for trifluoromethylketones and α-
ketoesters, but boronic acids exhibited a decrease in activity on irradiation due to 
decomposition.  α-Ketoesters were found to be the most potent inhibitors, while 
trifluoromethylketones 4.3 and 4.4 gave the greatest changes in potency on 
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photoisomerisation.  Alkyne 4.4 was determined to be the best inhibitor for surface 
attachment studies. 
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Surface modification and study of photoregulated enzyme 
binding to surfaces 
 
7.1 Introduction 
 
The final goals of this thesis were the attachment of photoswitch inhibitors to surfaces and 
photoregulated enzyme binding to the resultant modified surfaces.  The most appropriate 
inhibitors to use in these studies were selected from those described in chapters 2-5.  The 
trifluoromethylketone-based inhibitors (chapter 4) gave the best enzyme photoswitching, 
and the symmetrical disulfide surface linkers (chapter 5) gave good photoswitching and 
are likely to form high quality SAMs.  Therefore, the trifluoromethylketone 5.16 
containing a disulfide surface linker was chosen for initial surface attachment and enzyme 
binding studies.  In addition, related diluent 5.11 and azide 5.9 were chosen for blocking of 
non-specific enzyme attachment and initial SAM characterisation, respectively.  The 
trifluoromethylketone 4.4 was chosen for final SPR studies of surface enzyme binding and 
photoswitching due to its excellent photoswitching properties.  These surface compounds 
are shown in Fig. 7.1. 
 
This chapter describes the formation of SAMs from disulfides 5.9, 5.11, and 5.16, 
characterisation of these SAMs by cyclic voltammetry (CV) and contact angle 
measurements, and QCM enzyme binding studies using 5.16/5.11 mixed SAMs.  Finally, 
SPR studies of photoregulated enzyme binding to surface-attached inhibitor 4.4 are 
described. 
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Fig. 7.1.  Surface attachment compounds used in this chapter.  
 
7.2 Preparation of SAMs of azide 5.9 and diluent 5.11 
 
Contact angle measurements at SAMs of disulfides 5.9 and 5.11 on gold films 
 
SAMs of azide 5.9 and the corresponding OEG diluent 5.11 were formed for initial SAM 
characterisation studies.  Six gold film substrates were immersed in ethanol solutions of 
each of the disulfides (0.5 mM), and a further six substrates were immersed in ethanol as 
control samples.  After 24 h, three substrates were removed from each solution, rinsed 
thoroughly with ethanol and dried under a stream of nitrogen gas.  After 48 h, the 
remaining substrates were removed from the solutions as above.  Contact angle 
measurements were made immediately after removal to assess changes in surface 
hydrophobicity due to SAM formation.  The results are listed in Table 7.1.  Further details 
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of the preparation of gold substrates and the procedure used for contact angle measurement 
are given in the experimental chapter, section 9.7. 
 
Table 7.1.  Contact angle measurements† for SAMs of disulfides 5.9 and 5.11. 
Solution Averaged contact angle after 
24 h immersion (º) 
Averaged contact angle 
after 48 h immersion (º) 
Control 71 71 
Azide 5.9 59 62 
Diluent 5.11 53 64 
† Averaged results obtained using two drops of water on each of three surfaces.  All values are ±3º. 
 
First, it is clear that the substrates immersed in disulfide solutions are more hydrophilic 
than the control substrates, as the water contact angles of these substrates are lower than 
those of the control surfaces.  This indicates the successful formation of SAMs on these 
substrates, since the disulfides contain hydrophilic OEG groups and polar terminal groups 
that would be expected to give hydrophilic surfaces. 
 
There was no significant change in the contact angles of the SAM of azide 5.9 between 24 
and 48 h, which suggests that this SAM was well formed and stable after 24 h.  However, 
the contact angles for the SAM of diluent 5.11 increased between 24 and 48 h.  This 
increase is unexpected, as the formation of the hydrophilic SAMs initially decreased 
contact angles.  It is tentatively suggested that on the shorter timescale (24 h) a relatively 
disordered SAM was formed that traps water or ethanol molecules at the surface.  Denser 
packing of such a SAM (after 48 h) could result in a decrease in trapped solvent and thus a 
decrease in hydrophilicity.   
 
CV of SAMs of disulfides 5.9 and 5.11 on a gold plug electrode 
 
SAMs of 5.9 and 5.11 were also formed on a gold plug electrode in order to study these 
surfaces by electrochemistry.  The electrode was immersed in a solution of 5.9 (0.5 mM) 
or 5.11 (0.25 mM) in ethanol for 40 h, then rinsed with ethanol and dried under a stream of 
nitrogen gas.  CV was then carried out at each electrode in a solution of K3Fe(CN)6  
(1 mM) and NaClO4 (1 M) (Fig. 7.2).  A potential scan rate of 300 mVs-1 was used for all 
CVs unless specified otherwise, and all data is reported vs. a saturated calomel electrode 
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(SCE).  As a control, the same experiments were carried out using a gold electrode lacking 
attached disulfide.  The control surface shows an electrochemical response due to the 
ferricyanide/ferrocyanide redox couple (peaks at 0.18 V and 0.26 V).  Both modified 
surfaces lack this response, with only very small current increases observed below 0 V in 
the negative scan and above 0.35 V in the positive scan.  Clearly, these surfaces are 
blocking to electron transfer, suggesting that SAMs are formed as expected.  Further 
details of the procedures used for CV are given in the experimental chapter, section 9.7. 
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Fig. 7.2.  CVs of ferricyanide (1 mM) in NaClO4 (1 M) obtained at a bare gold plug 
electrode, and at SAMs of 5.9 and 5.11. 
 
CV of SAMs of 5.9 and 5.11 on gold films 
 
The same electrochemical analysis was carried out on SAMs of diluent 5.11 formed on 
gold film substrates, to ensure that the contact angle results and the electrochemical studies 
were carried out at comparable surfaces.  Two solutions of 5.11 (0.25 mM and 0.025 mM) 
were prepared, and a substrate was immersed in each for 40 h, then rinsed with ethanol and 
dried under a stream of nitrogen gas.  CVs were recorded for each of these surfaces (Fig. 
7.3) in ferricyanide solutions as above.  Here, both surfaces are blocking to electron 
transfer, implying that SAMs are formed from both 0.25 mM and 0.025 mM solutions of 
5.11.  This is consistent with the CV obtained for a SAM of 5.11 on a gold plug electrode 
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(Fig. 7.2) and shows that relatively densely packed SAMs are formed both on the gold 
plug electrode and the gold films.  Thus, the contact angle measurements at gold films and 
the CV results obtained more conveniently at the gold plug electrode can be assumed to 
probe essentially the same surfaces.  Furthermore, similarly blocking surfaces were formed 
from 0.25 mM and 0.025 mM solutions, which suggests that changes to the disulfide 
concentration in this range do not significantly affect the quality of SAMs formed.  
Fig. 7.3.  CVs of ferricyanide (1 mM) in NaClO4 (1 M) obtained at a bare gold film 
electrode, and at SAMs of 5.11 formed from 0.025 or 0.25 mM solutions of the disulfide. 
 
7.3 Preparation of SAMs of 5.16 and 5.11 for enzyme binding 
 
Following the successful formation of simple SAMs on gold, mixed SAMs of photoswitch 
enzyme inhibitor 5.16 and diluent alcohol 5.11 were formed on gold electrodes and gold 
coated QCM crystals. 
 
CV of mixed SAMs of disulfides 5.11 and 5.16 on a gold plug electrode 
 
Initial studies were carried out on a gold plug electrode to characterise surfaces by CV.  
The electrode was immersed in a solution of 5.16 and 5.11 (total disulfide concentration 
0.25 mM, proportion of 5.16 (χ5.16) = 1, 0.7, 0.4, 0.2, 0.1, 0 in separate experiments) for 40 
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h, then rinsed with ethanol and dried under a stream of nitrogen.  The SAMs were analysed 
by CV (figs. 7.4-7.8).  Fig. 7.4 shows a CV at a SAM with χ5.16 = 1 (i.e. no diluent) in 
ferricyanide solution.  This surface is highly blocking to electron transfer compared to the 
control surface shown, suggesting that a SAM is present. 
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Fig. 7.4.  CVs of ferricyanide (1 mM) in NaClO4 (1 M) obtained at a bare gold plug 
electrode and at a SAM of 5.16. 
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Fig. 7.5 shows CVs at the same SAM in a solution of NaClO4 (1 M) lacking ferricyanide, 
scanning over a wider potential range from 0.4 or 0.5 V to -0.7, -0.8, -0.9 or -1.0 V, then 
back to the starting potential.  Here, a pair of redox peaks are identified at -0.9 and 0.3 V.  
These peaks are assigned to the reduction of the azobenzene group to hydrazobenzene and 
the reoxidation process, respectively.1  The observation of azobenzene redox chemistry 
might seem surprising given the length of the linker.  However, redox chemistry arising 
from groups at a similar distance from the electrode has been reported previously;2 the 
mechanism for electron transfer is not clear.  The scan to -1.0 V also shows the beginning 
of a larger reduction current that is assigned to reductive desorption of disulfide from the 
surface.3, 4 
Fig. 7.5 CVs of a SAM of 5.16 in NaClO4 solution (1 M), sequentially scanning to more 
negative potentials (-0.7, -0.8, -0.9, -1.0 V). 
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A similar CV experiment was carried out for a SAM of 5.11 (χ5.16 = 0), to compare with 
the SAM of 5.16.  Fig. 7.6 shows the CVs for both SAMs.  As expected, the SAM of 5.11 
does not show the redox peaks assigned to azobenzene, but there is an increase in current 
below -0.8 V that is assigned to disulfide reduction. 
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Fig. 7.6.  CVs of SAMs of 5.16 and 5.11 in NaClO4 (1 M) solution. 
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Further CVs of the 5.16 SAM were carried out at scan rates of 100, 200 and 300 mVs-1, 
scanning first in the negative potential direction from 0.6 to -1.1 V to ensure complete 
reduction of the azobenzene group, then back to 0.6 V to reoxidise to azobenzene.  The 
integrals of the oxidation peaks were calculated using a curve fitting program5 and plotted 
against scan rate (Fig. 7.7).  The plot shows a linear relationship between scan rate and 
peak area, indicating that the same amount of charge is transferred at each scan rate.  This 
is consistent with the redox response of a surface species, because it can be assumed that 
the surface attached species will be completely oxidised and reduced in each scan, and 
hence the charge should be independent of scan rate.6  Therefore, it is confirmed that the 
observed azobenzene redox peaks arise from the redox reactions of a SAM at the surface.   
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Fig. 7.7.  Hydrazobenzene oxidation peak integral vs. scan rate for a SAM of 5.16 in 
NaClO4 solution (1 M). 
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The mixed SAMs (χ5.16 = 0.1, 0.2, 0.4 and 0.7) were also analysed.  CVs recorded in 
ferricyanide solutions (not shown) showed that all of these surfaces were highly blocking 
to electron transfer, suggesting that dense SAMs were formed.  CVs were also obtained in 
NaClO4 solution (1 M) in the absence of ferricyanide, scanning to -1.0 V to reduce the 
azobenzene group, as described above for the SAMs with χ5.16 = 0 and 1.  As previously 
for χ5.16 = 1, the CVs for these SAMs showed azobenzene redox peaks at -0.9 V and 0.3 V.  
The integrals of the oxidation peaks were calculated and plotted vs. χ5.16 (Fig. 7.8) to 
determine the relationship between the proportion of azobenzene disulfide in the SAM 
formation solution and the proportion attached to the surface.  This plot shows a linear 
relationship between χ5.16 and peak area for hydrazobenzene oxidation.  Therefore, the 
proportions of 5.16 and 5.11 present in a SAM at the surface are the same as the 
proportions of these compounds present in the solution used to form the SAM.  This is 
surprising, as longer chain length thiols/disulfides normally adsorb preferentially to a 
shorter chain analogue at a surface.7  However, both disulfides used here contain an alkyl 
chain of the same length, which is likely to be the molecular structure most important in 
stabilisation of the SAM.  The major structural difference between 5.16 and 5.11 involves 
extended OEG chains, which are known to form disordered structures at surfaces and thus 
may not significantly affect SAM formation.   
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Fig. 7.8. Hydrazobenzene oxidation peak area for mixed SAMs of 5.16 and 5.11 vs. χ5.16.  
Each data point represents an different SAM. 
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CV of mixed SAMs of disulfides 5.11 and 5.16 formed from dilute deposition solutions 
 
As SAMs formed from 0.25 mM solutions required milligram quantities of disulfides 5.16 
and 5.11 for each experiment, it was preferable in some cases to use more dilute solutions 
for SAM formation.  Hence, SAMs of 5.16 and 5.11 were formed from 0.025 mM 
solutions and compared with those formed from 0.25 mM solutions (a 0.025 mM SAM on 
gold film was also studied, see section 7.3, Fig. 7.3).  A gold plug electrode was immersed 
in a solution of 5.16 and 5.11 (total disulfide concentration 0.025 mM, χ5.16 = 0.5 or 1) for 
40 h, rinsed with ethanol and dried under a stream of nitrogen.  CVs were recorded for 
these surfaces in ferricyanide solution (not shown).  All were highly blocking to electron 
transfer, indicating that well-packed SAMs were formed.  Scans were also carried out in 
NaClO4 (1 M), giving CVs (Fig. 7.9) with similar shape and oxidation peak areas to SAMs 
formed from 0.25 mM solutions (see Fig. 7.6).  However, the oxidation peaks in Fig. 7.9 
are broader and shifted to a higher potential (peak potential, Ep = 0.4 V compared with Ep 
= 0.3 V for the 0.25 mM SAMs).  The broader peaks suggest that the azobenzene group 
may be present in a range of environments, indicating less ordered SAMs compared to 
those formed from 0.25 mM solutions. 
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Fig. 7.9.  CVs of 5.16/5.11 SAMs in NaClO4 (1 M) formed on a gold plug electrode from 
0.025 mM disulfide solutions. 
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CV of SAMs of disulfide 5.11 on QCM crystals 
 
As the above results show that SAMs of 5.16 and 5.11 can be successfully formed on gold 
surfaces, similar SAMs were formed on QCM crystals† and briefly studied by CV and 
contact angle measurements.  Initially, a gold-coated QCM crystal was immersed in a 
solution of 5.11 (0.025 mM) for 40 h, then rinsed with ethanol and dried under a stream of 
nitrogen gas.  A CV was recorded for this SAM in a solution of ferricyanide (1 mM) and 
NaClO4 (1 M).  The crystal was then cleaned with piranha solution‡, another SAM of 5.11 
was formed, and the CV was repeated.  To compare, a CV of the same gold surface with 
no SAM was recorded in the same solution.  The three CVs (5.11 SAM on a new QCM 
crystal, 5.11 SAM on a piranha cleaned QCM crystal, control) are shown in Fig. 7.10.   
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Fig. 7.10.  CVs of ferricyanide (1 mM) and NaClO4 (1 M) obtained at SAMs of 5.11 on 
gold coated QCM crystals prepared before and after piranha cleaning of the surface, and at 
a control QCM crystal with no SAM. 
 
The control CV shows ferricyanide redox peaks, as expected.  At the SAM formed without 
prior piranha cleaning, the ferricyanide response has lower peak currents and larger 
potential difference between the reduction and oxidation peaks, compared to the control.  
                                                 
† Commercially available crystals designed for use in a Q-sense QCM instrument; further QCM details are 
given in section 7.4 and the experimental chapter, section 9.7. 
‡ 1:3 H2O2/H2SO4.  Surfaces were cleaned by immersion in piranha solution for several minutes followed by 
rinsing with water. 
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This is consistent with slower electron transfer due to the presence of the SAM of 5.11.  
The SAM formed after piranha cleaning leads to even slower electron transfer for the 
ferrocyanide/ferrocyanide redox couple.  Neither of the SAMs is as blocking to electron 
transfer as the SAMs formed on gold film substrates and the gold plug electrode.  However, 
the SAM formed after piranha cleaning is more blocking than that formed without cleaning.  
Therefore, more densely packed SAMs form on the cleaned surface. 
 
Contact angle measurements of SAMs of 5.11 on QCM crystals 
 
Contact angle measurements were also carried out at a SAM of 5.11 on a gold coated 
QCM crystal.  The SAM was formed by soaking the crystal in a solution of 5.11 (0.025 
mM, ethanol) for 40 h after cleaning of the gold surface by immersion in piranha solution 
for 4 minutes and rinsing with water and ethanol.  Contact angle measurements were taken, 
then the surface was again cleaned in piranha solution for 3 min to remove the SAM, 
rinsed with water and dried under a stream of nitrogen.  Contact angle measurements were 
repeated at the cleaned surface as a control.  To confirm that the SAM was removed by 
this cleaning process, piranha cleaning was repeated for a further 3 min and further contact 
angle measurements were taken.  The averaged measurements are shown in Table 7.2.  
 
Table 7.2.  Contact angle measurements† at a 5.11 SAM on a gold coated QCM crystal and 
the same surface after piranha cleaning. 
Surface Averaged contact angle (º) 
SAM of 5.11 38 
Au after 3 min piranha soak 86 
Au after 2 × 3 min piranha soak 83 
† Averaged results obtained using three drops of water on one surface.  All values are ±3º. 
 
The contact angle after soaking in the 5.11 solution is significantly lower than that of the 
cleaned surface, suggesting that a SAM of 5.11 has formed on the surface.  The results for 
the piranha treated surfaces are not significantly different, which suggests that soaking in 
piranha solution for 3 min is sufficient to remove a SAM from the surface.  It should be 
noted that the contact angles here are significantly different to those measured at SAMs of 
5.11 on evaporated gold substrates (Table 7.1).  In particular, a larger difference between 
the contact angles of SAMs and bare gold surfaces is observed.  This might indicate that 
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better quality SAMs are formed here, due to the use of piranha treatment to prepare the 
surfaces.  However, this interpretation is inconsistent with the electrochemistry results 
(compare figs. 7.2 and 7.10), where more blocking SAMs are obtained at evaporated gold 
substrates.  Alternatively, the larger change in contact angles may be attributable to greater 
surface roughness.8  Nevertheless, it appears that SAMs are successfully formed on QCM 
crystals, and the best quality SAMs are obtained after piranha treatment of the surfaces. 
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7.4 QCM studies of enzyme binding to a surface 
 
Having shown that SAMs with low contact angles can be successfully formed on QCM 
crystals, QCM experiments were carried out to analyse enzyme binding at these surfaces.  
Details of the QCM apparatus are given in the experimental chapter, section 9.7. 
 
QCM study of blocking of enzyme binding to SAMs of 5.11 
 
 Initially, a SAM of 5.11 was formed on a QCM crystal, as described above.  This surface 
was monitored in the QCM instrument, with a solution of Tris buffer flowing at  
100 μL min-1 over the surface.  The QCM frequency response initially drifted significantly 
over time, but became relatively stable after 2.5 hours of buffer flow.  A solution of  
α-chymotrypsin (4 μM) in Tris buffer was then injected over the surface for 15 min, 
followed by buffer flow.  The calculated mass† response vs. time for the enzyme injection 
is shown in Fig. 7.11.   
 
Fig. 7.11.  Mass response vs. time for injection of α-chymotrypsin (4 μM in Tris buffer) 
over a SAM of 5.11 at a flow rate of 100 μL min-1 
                                                 
† Calculated using the Sauerbrey equation, as described in chapter 1, section 1.7.3 
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It can be seen from this plot that the apparent mass increases during injection of enzyme 
over the surface, then decreases to a level close to the original surface mass when the 
injection ceases.  These results show that very little, if any, enzyme has attached to the 
surface (<10 ng cm-2).  Therefore, the SAM of alcohol 5.11 blocks enzyme attachment to 
the surface, as expected.   
 
QCM study of α-chymotrypsin binding to mixed SAMs of 5.16 and 5.11 
 
 In further experiments, mixed SAMs of 5.16 and 5.11 were formed on two QCM crystals 
(as described above, χ5.16 = 0.05 and 0.1).  QCM analysis was then carried out by injection 
of a solution of α-chymotrypsin over both crystals simultaneously.  The mass response vs. 
time is shown in Fig. 7.12.  Here, a significant increase in mass is observed on injection of 
enzyme, and the mass decreases somewhat when buffer flow is returned.  The observed 
relative mass increases are approximately proportional to the amount of inhibitor 5.16 
present in the SAM (i.e. the mass increase at the SAM containing 10% 5.16 is 
approximately twice that of the SAM containing 5% 5.16).  This suggests that enzyme has 
attached to the surface-attached inhibitors.  The mass increase appears to be largely stable 
over the timescale of this experiment.   
Fig. 7.12.  Mass response vs. time for injection of α-chymotrypsin (4 μM) over mixed 
SAMs of 5.16 and 5.11 at a flow rate of 100 μL min-1. 
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While enzyme attachment to the surface-bound inhibitor was achieved, the observed stable 
attachment may arise from denaturation of enzymes and binding of the hydrophobic core 
residues to the surface, as discussed in chapter 1, section 1.4.3.  In this study, enzyme 
attachment via inhibitor-active site interactions is required for successful photoswitching. 
 
Using the QCM instrument, attached enzyme could not be easily removed for repeated use 
of a surface in photoswitching studies.  In addition, the long equilibration time required to 
obtain a stable baseline (2.5 h) would be problematic in photoswitching experiments.  
Consequently, SPR studies were carried out to address these problems. 
 
7.5 SPR studies of enzyme binding and photoswitching at a surface 
 
Attachment of photoswitch inhibitor 4.4 to a SPR chip 
 
Gold surfaces are commercially available for SPR that contain a carboxylic acid 
containing dextran polymer layer which allows attachment of molecules and blocks non-
specific enzyme binding.  Consequently, these surfaces were appropriate for use in this 
study, but a different attachment method was required to that used to modify the QCM 
crystals (described earlier).  To link alkyne 4.4 to an SPR chip by azide-alkyne 
cycloaddition, a surface containing azide groups was required.  A carboxylic-acid 
containing SPR chip was reacted with azide 7.1 (Fig. 7.13) to generate such a surface.   
 
 
 
Fig. 7.13.  Azide 7.1 for generation of an azide terminated SPR chip. 
 
This reaction was carried out in an SPR instrument, by activation of the carboxylic acid 
terminated surface using EDCI/NHS, then coupling of 7.1 to the activated surface.†  The 
SPR response increased by 147 RU (resonance units) after injection of 7.1.  While this 
SPR response is not quantifiable without calibration, this increase represents a significant 
quantity of 7.1 attached to the surface, by comparison with the increase observed on 
attachment of NHS to the surface (109 RU).   
                                                 
† Full details of SPR procedures and surface modification are given in the experimental chapter, section 9.7. 
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The azide modified surface was removed from the instrument and reacted with alkyne 4.4.  
150 μL of reaction solution (4.4, CuBr, 2,6-lutidine, 2,2’-bipyridine and sodium ascorbate 
in 1:1 DMF/H2O) was pipetted onto the surface and left for 1 h at room temperature, then 
rinsed off by washing sequentially with 1:1 DMF/H2O, H2O, 0.1 M EDTA, 1:1 DMF/H2O, 
then H2O.  This procedure is adapted from a reported method used to attach alkynes to an 
azide polymer.9  The chip was then replaced in the instrument and an SPR sensorgram was 
obtained while flowing Tris buffer for several hours to allow equilibration of the system.   
 
SPR analysis of α-chymotrypsin binding to surface-attached 4.4 
 
After equilibration, α-Chymotrypsin solutions (0, 2.0, 6.0 or 18 μM in Tris buffer, 150 μL) 
were sequentially injected over the surface for 5 min each, at a flow rate of 30 μL min-1.  
After each injection, buffer was run for 5 min to monitor dissociation of enzyme from the 
surface, then the surface was regenerated to remove attached enzyme for the next injection.  
Regeneration was carried out as per the recommended approach for SPR10 by the injection 
of guanidine hydrochloride (6 M, 5 μL) followed by acetic acid (1 M, 10 μL) then Tris 
buffer for 5 min, all at a flow rate of 5 μL min-1.  The SPR curves (response vs. time) for 5 
min enzyme injection and 5 min buffer are shown in Fig. 7.14.  The response of a control 
surface not containing inhibitor 4.4 (formed as above except omitting injection of 7.1) was 
subtracted from these curves.  
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Fig. 7.14.  SPR response for 5 min injection of α-chymotrypsin (0-18 μM in Tris buffer) 
beginning at time = 70 s at 30 μL min-1 flow rate over a surface containing attached 4.4. 
 
An increase in response (proportional to an increase in mass) is observed on injection of 
enzyme over the surface, suggesting the attachment of enzyme to the surface.  The 
response slowly decreases after enzyme injection ceases, suggesting that enzyme slowly 
desorbs from the surface, and thus that the attachment is at least partially reversible. 
 
Calculation of the KD affinity constant for enzyme binding to the surface-bound inhibitor  
from this data was attempted using a curve-fitting model.  However, a good fit could not 
be obtained by simultaneous modelling of all three concentration curves.  Individual 
modelling of each curve gave calculated kA, kD and KD, values† shown in Table 7.3. 
 
 
 
 
                                                 
†  KD is the equilibrium dissociation constant, determined from the equation KD = kD/kA, where kD is the 
kinetic dissociation constant and kA is the kinetic association constant. 
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Table 7.3.  Apparent kA, kD, and KD constants for binding of α-chymotrypsin to a surface 
containing inhibitor 4.4, calculated by individual curve fitting to SPR data. 
Enzyme concentration 
(μM) 
kA (M-1 s-1) kD (s-1) KD (μM) 
2.0 3260 ± 70 3.24 × 10-4 ± 4 × 10-6 0.099 ± 0.003 
6.0 1400 ± 20 3.25 × 10-4 ± 2 × 10-6 0.233 ± 0.005 
18 590 ± 4 3.19 × 10-4 ± 2 × 10-6 0.541 ± 0.007 
 
The apparent affinity constant KD increases with increasing enzyme concentration, 
corresponding to apparently weaker binding at higher enzyme concentrations.  This is 
surprising, since a constant KD value should be obtained.  The apparent kinetic dissociation 
rate constant (kD) is almost constant at all enzyme concentrations, but the apparent kinetic 
association rate constant (kA) decreases with increasing enzyme concentration.  This shows 
that the rate of association of α-chymotrypsin with surface-bound 4.4 is decreased at high 
enzyme concentrations.  This trend of a decrease in the apparent association constant with 
increasing enzyme concentration was also observed in solution-phase studies of the 
binding of trifluoromethylketones to α-chymotrypsin.11  The decrease in kA was attributed 
to an equilibrium between the active ketone inhibitor and an inactive hydrated form, as 
shown in the equation: 
 
Ih Ik
E
E-I
H2O  
 
where Ih represents hydrated inhibitor, Ik represents ketone inhibitor, E represents  
α-chymotrypsin and E-I represents the enzyme-inhibitor complex.  In aqueous solutions, 
the hydrated form Ih is known to be present in an approximately 4500-fold excess.11 At a 
high concentration of enzyme, the concentration of ketone will be significantly decreased 
by reaction with the enzyme and it was proposed that a relatively slow rate of hydrate to 
ketone dehydration would lead to a decrease in the actual concentration of ketone, 
dependent on the enzyme concentration.  This would lead to a decrease in the apparent kA 
as the enzyme concentration increases, and thus an increase in the apparent KD.  It seems 
likely that the surface-attached trifluoromethylketone in the present study is exhibiting the 
same behaviour. 
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Photoregulated binding of α-chymotrypsin to surface-attached 4.4 
 
To achieve photoswitching of the surface bound inhibitor, enzyme binding was measured 
before and after irradiation of the surface with a UV lamp, as described in chapter 6 for 
solution-phase irradiations.  The SPR chip, after regeneration, was removed from the 
instrument and irradiated with UV light for 5 min, then replaced in the instrument and 
injection of enzyme (0, 2.0, 6.0 or 18 μM) was repeated as previously.  The surface was 
regenerated, removed from the instrument, irradiated with visible light for 5 min, then 
enzyme injection was repeated.  The SPR curves for the 2.0 μM enzyme injections before 
and after each irradiation are shown in Fig. 7.16, and representative data (maximum 
response at time = 370 s, apparent kA, kD, and KD) for all enzyme concentrations is given in 
tables 7.4-7.6. 
 
Fig. 7.16.  Reversible photoregulation of α-chymotrypsin binding (2.0 μM) to surface 
attached inhibitor 4.4. 
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Table 7.4.  Maximum SPR response (RU) for binding of α-chymotrypsin binding to 
surface attached inhibitor 4.4, before and after UV/vis irradiations. 
Enzyme 
concentration 
(μM) 
Maximum SPR 
response before 
irradiation (RU) 
Maximum SPR 
response after UV 
irradiation (RU) 
Maximum SPR 
response after visible 
irradiation (RU) 
2.0 690 1200 720 
6.0 1100 1700 1200 
18 1600 2100 1700 
 
Table 7.5.  Apparent kA, kD, and KD constants for binding of α-chymotrypsin to a surface 
containing inhibitor 4.4 after UV irradiation, calculated by individual curve fitting to SPR 
data. 
Enzyme concentration 
(μM) 
kA (M-1 s-1) kD (s-1) KD (μM) 
2.0 4220 ± 70 5.02 × 10-4 ± 1 × 10-6 0.119 ± 0.002 
6.0 1890 ± 20 4.82 × 10-4 ± 1 × 10-6 0.255 ± 0.003 
18 748 ± 6 4.43 × 10-4 ± 1 × 10-6 0.593 ± 0.006 
 
Table 7.6.  Apparent kA, kD, and KD constants for binding of α-chymotrypsin to a surface 
containing inhibitor 4.4 after visible irradiation, calculated by individual curve fitting to 
SPR data. 
Enzyme concentration 
(μM) 
kA (M-1s-1) kD (s-1) KD (μM) 
2.0 3060 ± 50 3.31 × 10-4 ± 1 × 10-6 0.108 ± 0.002 
6.0 1330 ± 10 3.22 × 10-4 ± 1 × 10-6 0.242 ± 0.003 
18 533 ± 3 2.98 × 10-4 ± 1 × 10-6 0.559 ± 0.004 
 
After UV irradiation, a greater amount of enzyme attaches to the surface (see Table 7.4) 
and the apparent association and dissociation rate constants kA and kD are increased (see 
tables 7.3 and 7.5), as compared to the surface before irradiation.  However, only a small 
increase in the apparent KD affinity constant is observed after irradiation.  After visible 
irradiation, the binding response is restored to close to that of the surface before UV 
irradiation (see tables 7.4 and 7.6).   
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The lack of a large change of the KD affinity constants after irradiation contrasts with the 
solution-phase photoswitching studies (see chapter 6), where the E- and Z-enriched PSS of 
4.4 exhibit a > 3.6 fold difference in IC50 affinity constants.  This difference is attributed to 
the fact that solution phase studies yield an overall affinity value for binding of both E- 
and Z-4.4, since the affinity constant is calculated from the total activity and total 
concentration of both E and Z isomers.  Conversely, the observed SPR response is likely to 
be predominantly due to binding of α-chymotrypsin to the more potent Z isomer of 4.4, 
since the activity of the less potent E-isomer is unlikely to significantly alter the shape of 
the SPR curve, and the concentrations of surface-attached E- and Z-4.4 are not involved in 
the affinity calculations.  UV irradiation of the surface then gives an increase in the 
amount of Z-4.4 at the surface, and thus more enzyme is able to bind to the surface (at a 
given enzyme concentration) with a similar thermodynamic dissociation constant.  Visible 
irradiation restores surface-attached Z-4.4 to E-4.4, resulting in a reduction to the original 
enzyme binding capacity.   The small increase in the apparent KD on UV irradiation 
represents slightly weaker binding, despite a larger amount of enzyme attachment to the 
surface.  This is consistent with the greater apparent KD values observed on injection of 
higher enzyme concentrations over the surface, and is also attributed to the ketone-hydrate 
equilibrium. 
 
7.6 Summary 
 
SAMs of disulfides 5.9 and 5.11 were formed on a gold plug electrode and gold film 
surfaces and characterised with contact angle measurements and electrochemistry.  
Surfaces were obtained that blocked electron transfer, and gave lower contact angles than 
unmodified surfaces.  SAMs of photoswitch inhibitor 5.16 and diluent 5.11 were formed 
on gold electrodes and gold coated QCM crystals, and characterised using the same 
techniques.  The two disulfides were found to bind to the surface in proportions equal to 
those in the deposition solution.  SAMs of 5.11 on QCM crystals exhibited lower contact 
angles than SAMs of 5.11 on evaporated gold substrates, but were less blocking to electron 
transfer.  α-Chymotrypsin attachment to mixed SAMs of 5.16 and 5.11 was studied by 
QCM.  Enzyme attachment was observed, but was largely irreversible.  Photoregulated 
binding of α-chymotrypsin to surface attached inhibitor 4.4 was studied by SPR.  Enzyme 
attachment to the surfaces was observed, but a single KD affinity constant could not be 
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obtained as the apparent affinity decreased as enzyme concentration was increased.  This 
decrease is attributed to the ketone-hydrate equilibrium of the trifluoromethylketone 
inhibitor.  UV/vis irradiation reversibly modified the amount and kinetic rates of enzyme 
binding to the surface, presumably due to photoisomerisation of surface-attached inhibitor 
4.4. 
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Conclusions and future work 
 
Reversible photoswitching of α-chymotrypsin binding to a surface attached inhibitor was 
achieved, as shown schematically in Fig. 8.1.   
 
 
Fig. 8.1.  Schematic of photoswitching showing surface attached inhibitor 4.4 with  
α-chymotrypsin bound to the Z isomer. 
 
A range of azobenzene-containing photoswitch inhibitors of α-chymotrypsin with boronic 
acid, trifluoromethylketone and α-ketoester enzyme binding groups were designed and 
synthesised (chapters 2 and 4).  Photoisomerisation studies and enzyme assays of these 
inhibitors (chapter 6) found that the trifluoromethylketones and α-ketoesters were effective 
photoswitch inhibitors, with a best result of a reversible > 5.3 fold increase in activity 
obtained on UV/vis irradiation.  The most promising photoswitch for surface attachment, 
trifluoromethylketone 4.4, was attached to a gold surface in a two step process involving 
amide bonding and ‘click chemistry’ azide-alkyne cycloaddition.  Photoregulated binding 
of α-chymotrypsin to this surface was studied by SPR (chapter 7).  A reversible change in 
the rate and amount of enzyme binding to this surface was detected on UV/visible 
irradiation of the surface.   
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These results represent a preliminary example of photoregulated surface binding of a 
protease.  A modular inhibitor design was developed with an azobenzene photoswitch core 
containing attached groups for surface attachment and enzyme binding.  The system 
presented here uses a peptidomimetic trifluoromethylketone group specific for  
α-chymotrypsin as enzyme binding group.  Future work will investigate extension of this 
approach to target other proteases using enzyme binding groups specific to these enzymes. 
 
The photoswitching achieved here is not complete.  In particular, the azobenzene group 
does not completely isomerise to either the E or Z isomer on irradiation.  Consequently, a 
maximum of approximately 5 fold change in activity is possible with azobenzene 
inhibitors of this type.  Furthermore, it appears that the less active E isomer of the 
inhibitors also binds to the enzyme to some extent.  Future work will investigate 
improvement of photoswitching using a photoswitch group that gives more complete 
photoisomerisation, or by use of multiple azobenzene groups in a single inhibitor molecule.   
 
In addition, the kinetic dissociation rate for enzyme from surface-attached inhibitor 4.4 is 
very slow, most likely due to the tight binding mode of the trifluoromethylketone group 
with α-chymotrypsin.  Consequently, a relatively harsh regeneration method (guanidine 
hydrochloride and acetic acid) was required to rapidly remove enzyme from the surface.  
For development of technologies such as reversible biosensors, surfaces are required that 
rapidly dissociate enzyme under mild conditions.  Future work will investigate obtaining 
faster kinetic dissociation using alternative enzyme binding groups, preferably those 
lacking an electrophilic warhead as investigated in chapter 3.  
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Experimental 
 
9.1 General Methods and Experimental Procedures 
 
NMR data reporting for azobenzene derivatives 
 
The azobenzenes reported in this work were synthesised as predominantly the E isomer 
(<5% Z), unless specified otherwise, and NMR data is reported for the E isomer only.  
NMR data for the Z isomer are reported for selected cases where the amount of Z isomer 
was enriched. 
 
Elemental Analysis 
 
Elemental analyses were performed for carbon, nitrogen and hydrogen at the University of 
Otago microanalytical laboratory. 
 
Concentrating of solvents 
 
Bulk removal of solvent and volatiles was carried out under reduced pressure using a 
Büchi rotary evaporator (low vacuum pump).  More rigorous drying was achieved under 
high vacuum (oil pump) for at least 30 min. 
 
Column Chromatography 
 
Column chromatography was performed on silica 60 gel, using either N2 pressure or 
gravity to elute solvents from the column.  All solvents were distilled before use. 
 
High Performance Liquid Chromatography 
 
Analytical HPLC was performed on a Dionex liquid chromtograph controlled by 
Chromeleon software, with a Prodigy C18 column (250 x 4.6, 5 µm). 
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Infrared Spectroscopy 
 
IR spectra were obtained using a Shimadzu 8201PC series FTIR.  Spectra were run either 
neat or as a nujol mull. 
 
Melting points 
 
All melting points were obtained on an Electrothermal apparatus and are uncorrected. 
Melting points are not reported for diastereomeric or ketone/hydrate mixtures. 
 
Mass Spectrometry 
 
Electrospray ionisation (ES) mass spectroscopy was performed on a Micromass LCT TOF 
Mass Spectrometer operating with a probe voltage of 3.2 kV at 150 °C and a source 
temperature of 80 °C. 
 
Nuclear Magnetic Resonance 
 
1H NMR spectra were obtained on either a Varian UNITY 300 or INOVA 500 
spectrometer operating at 300 and 500 MHz, respectively.  19F NMR were obtained on the 
Varian UNITY 300 spectrometer operating at 282 MHz. 13C NMR were obtained on either 
the Varian UNITY 300 or the INOVA 500 spectrometer operating at 75 and 126 MHz, 
respectively.  All spectra were obtained at 23 °C with a delay (D1) of at least 1 s. 1H and 
19F NMR experiments had an acquisition time (At) of 2 s, 13C NMR experiments had an 
acquisition time of 1-2 s. All two-dimensional NMR experiments, which include COSY, 
HSQC, and HMBC were run on the INOVA 500 spectrometer.  
 
Chemical shifts are reported in parts per million (ppm) on the δ scale and were referenced 
to the appropriate residual solvent peaks: CDCl3 referenced to (CH3)4Si at δH 0.00 ppm 
(1H) and (CDCl3) at δC 77.16 ppm (13C); methanol-d4 referenced to CHD2OD at δH 3.31 
ppm (1H) and CD3OD at δC 49.00 ppm (13C); acetone-d6 referenced to (CHD2)(CD3)CO at 
δH 2.05 ppm (1H) and (CD3)2CO at δC 29.84 ppm (13C); acetonitrile-d3 referenced to 
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CHD2CN at δH 1.94 ppm (1H) and CD3CN at δC 1.32 ppm; DMSO-d6 referenced to 
(CHD2)(CD3)SO at δH 2.50 ppm (1H) and (CD3)2SO at δC 39.52 ppm (13C); D2O 
referenced to D2O at 4.79 ppm (1H). All 19F NMR spectra were referenced against an 
internal standard (fluorobenzene C6H5F) at δF –113.15 ppm (19F). 
 
Optical Rotary Dispersion 
 
Optical rotation measurements were performed on a Perkin Elmer polarimeter Model 341 
with a 1.00 dm pathlength. Measurements were taken at 20 ºC, at a wavelength of 589 nm. 
[α]D values are given in º mL g-1 dm-1 and the sample concentration given in units of 10 
mg mL-1. 
 
Ultraviolet Spectroscopy 
 
UV/Visible spectroscopy was performed on a GBC UV/Vis 918 spectrometer running the 
default GBC Scientific v 2.01 software package. 
 
Thin Layer Chromatography 
 
Analytical TLC was performed on plastic-backed Merck-Kieselgel KG60F254 or Polygram 
Sil G/UV254 plates. Traces were visualised with UV light and/or a suitable dip, typically 
basic potassium permanganate (general use), ninhydrin (amines), or ammonium 
molybdate-ceric sulphate dip (azobenzenes, sulfur compounds). 
 
Reagents and solvents 
 
Purchased reagents (primarily from Aldrich, Sigma, Fluka and Acros) were used as 
supplied.  All other reagents and solvents were purified according to well established 
procedures.1 Triethylamine, dichloromethane, pyridine and toluene were distilled from 
calcium hydride powder immediately prior to use. Ether and THF were distilled from 
sodium benzophenone ketyl immediately prior to use. Anhydrous methanol was distilled 
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from magnesium ethoxide or magnesium methoxide respectively and stored under argon 
over 4 Å molecular sieves.  
 
9.2 Experimental for work described in chapter 2 
 
(E)-4-phenylazobenzoic acid 2.15:2   
 
 
 
 
A solution of nitrosobenzene 2.13 (730 mg, 6.8 mmol) and 4-aminobenzoic acid 2.14 (940 
mg, 1 eq) in AcOH (5.0 mL) was stirred for 20 h then filtered to collect an orange 
precipitate, which was washed with AcOH (2 × 5.0 mL) then concentrated.  The crude 
product was recrystallised from EtOH to give 2.15 (820 mg, 53%) as an orange solid:  
mp 247-248 ºC (lit 248.5-249.5)2 
1H NMR (300 MHz, (CD3)2SO) δ 7.59-7.66 (3H, m), 7.91-8.00 (4H, m), 8.15 (2H, d, J = 
8.6 Hz). 
 
(E)-4-(Phenylazo)-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) 
benzamide 2.1:  
 
 
 
 
To a mixture of carboxylic acid 2.15 (200 mg, 0.88 mmol), amine 2.16 (190 mg, 1 eq) and 
HATU (370 mg, 1.1 eq) was added DMF (5.0 mL) then DIEA (340 μL, 2.2 eq). The 
mixture was stirred for 16 h then diluted with EtOAc (50 mL), washed with water (50 mL 
× 2), dried over MgSO4 and concentrated. The crude product was purified by flash 
chromatography, eluting with DCM followed by 1:9 EtOAc/DCM then 1:4 EtOAc/DCM 
to give 2.1 (200 mg, 53%) as an orange solid:  
mp: 162–164 ºC 
Elemental analysis: Calcd. for C25H26BN3O3: C 70.27, H 6.13, N 9.83%, found: C, 70.19; 
H, 6.04; N, 9.93. 
N
N
OH
O
N
N
N
H
O
B
O
O
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1H NMR (300 MHz, CDCl3) δ 1.32 (12H, s, (CMe2)2), 7.37 (1H, t, J = 7.8), 7.50 (3H, m), 
7.60 (1H, d, J = 7.2), 7.87–8.04 (8H, m), 8.23 (1H, s). 
13C NMR (75 MHz, CDCl3) δ 24.9, 84.0, 123.1, 123.1, 123.3, 126.2, 128.0, 128.7, 129.2, 
131.0, 131.7, 136.5, 137.3, 152.5, 154.3, 164. 
HRMS(ES): Calcd. 428.2145 for C25H27BN3O3 (MH+), found 428.2162. 
 
(S,E)-4-Methyl-2-(4-(phenylazo)-benzoylamino)-pentanoic acid methyl ester 2.17:3, 4  
 
 
 
 
 
To a solution of carboxylic acid 2.15 (200 mg, 0.88 mmol), H-Leu-OMe.HCl (160 mg, 1 
eq), and HATU (370 mg, 1.1 eq) in DMF (3.0 mL) was added DIEA (510 μL, 3.3 eq).  
The resultant solution was stirred for 16 h then diluted with EtOAc (50 mL), washed with 
H2O (50 mL × 2), HCl (50 mL), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 
and concentrated.  The crude material was purified by flash chromatography, eluting with 
1:19 EtOAc/DCM to give 2.17 (290 mg, 93%) as an orange solid: 
mp: 88-90 ºC 
[α]D20: +1.5 º (c = 0.65, MeOH) 
1H NMR (500 MHz, CDCl3) δ 0.96-1.03 (6H, m, CHMe2), 1.65-1.82 (3H, m, CH2CHMe2 
and CH2CHMe2), 3.78 (3H, s, OMe), 4.89 (1H, m, NHCH), 6.79 (1H, d, J = 8.2 Hz, NH), 
7.47-7.55 (3H, m), 7.92-7.95 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 22.1, 23.0, 25.1 (CH2CHMe2), 41.9 (CH2CHMe2), 51.4 
(NHCH), 52.6 (OMe), 123.0, 123.2, 128.2, 129.3, 131.7, 135.7, 152.6, 154.4, 166.5, 173.8. 
HRMS (ES): Calcd. for C20H24N3O3 (MH+) 354.1818, found 354.1802. 
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(S,E)-3-Methyl-2-(4-(phenylazo)-benzoylamino)-butyric acid methyl ester 2.18:  
 
 
 
 
To a solution of 2.15 (200 mg, 0.88 mmol), H-Val-OMe.HCl (150 mg, 1 eq), and HATU 
(370 mg, 1.1 eq) in DMF (3.0 mL) was added DIEA (510 μL, 380 mg, 3.3 eq).  The 
resulting solution was stirred for 16 h then diluted with EtOAc (50 mL), washed with H2O 
(50 mL), HCl (1.0 M, 50 mL), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 
and concentrated.  The crude material was purified by flash chromatography, eluting with 
1:19 EtOAc/DCM to give 2.18 (270 mg, 89%) as an orange solid: 
mp: 139-141 ºC 
[α]D20: +17.8 º (c = 0.40, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.01-1.06 (6H, m, CHMe2), 2.31 (1H, m, CHMe2), 3.80 (3H, 
s, OMe), 4.82 (1H, dd, J = 8.5, 4.9 Hz, CHNH), 6.69 (1H, d, J = 8.5 Hz, NH), 7.49-7.57 
(3H, m), 7.94-8.00 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 18.2, 19.2, 31.8, 52.5, 57.7, 123.1, 123.2, 128.2, 129.3, 
131.7, 135.9, 152.6, 154.5, 166.7, 172.7. 
HRMS(ES): Calcd. 340.1661 for C19H22N3O3 (MH+), found 340.1677. 
  
(E)-(4-(Phenylazo)-benzoylamino)-acetic acid methyl ester 2.19:  
 
 
 
 
To a solution of 2.15 (200 mg, 0.88 mmol), H-Gly-OMe.HCl (120 mg, 1 eq) HATU (370 
mg, 1.1 eq) in DMF (3.0 mL) was added DIEA (510 μL, 380 mg, 3.3 eq).  The resulting 
solution was stirred for 16 h then diluted with EtOAc (50 mL), washed with H2O (50 mL), 
HCl (1.0 M, 50 mL), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and 
concentrated.  The crude material was purified by flash chromatography, eluting with 1:4 
EtOAc/DCM to give 2.19 (250 mg, 96%) as an orange solid: 
mp: 123-124 ºC 
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1H NMR (500 MHz, CDCl3) δ 3.83 (3H, s, Me), 4.29 (2H, d, J = 5.0 Hz, CH2), 6.73 (1H, s, 
NH), 7.49-7.57 (3H, m), 7.93-8.01 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 41.9, 52.7, 123.1, 123.2, 128.2, 129.3, 131.8, 135.4, 152.6, 
154.6, 166.9, 170.6. 
HRMS(ES): Calcd. 298.1192 for C16H16N3O3 (MH+), found 298.1186. 
 
(S,E)-2-(4-(Phenylazo)-benzoylamino)-propionic acid methyl ester 2.20:  
 
 
 
 
To a solution of 2.15 (200 mg, 0.88 mmol), H-Ala-OMe.HCl (130 mg, 1 eq), HATU (370 
mg, 1.1 eq) in DMF (3.0 mL) was added DIEA (510μL, 380 mg, 3.3 eq).  The resulting 
solution was stirred for 16 h, then diluted with EtOAc (50 mL), washed with H2O (50 mL), 
HCl (1.0 M, 50 mL), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and 
concentrated.  The crude material was purified by flash chromatography, eluting with a 
gradient from 1:19 to 1:4 EtOAc/DCM to give 2.20 (230 mg, 85%) as an orange solid: 
mp: 144-147 ºC 
[α]D20: +19.3 º (c = 0.60, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.56 (3H, d, J = 7.2 Hz, CHMe), 3.82 (3H, s, OMe), 4.84 
(1H,  p, J = 7.2 Hz, CHMe), 6.80 (1H, d, J = 7.0 Hz, NH), 7.49-7.57 (3H, m), 7.93-8.00 
(6H, m). 
13C NMR (75 MHz, CDCl3) δ 18.8, 48.7, 52.8, 123.1, 123.2, 128.2, 129.3, 131.7, 135.7, 
152.6, 154.5, 166.2, 173.8. 
HRMS(ES): Calcd. 312.1348 for C17H18N3O3 (MH+), found 312.1344. 
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(S,E)-4-Methyl-2-(4-(phenylazo)-benzoylamino)-pentanoic acid 2.21:3, 4 
 
 
 
 
 
A solution of ester 2.17 (150 mg, 0.42 mmol) in THF (10 mL) was cooled to 0 ºC, then 
LiOH (0.25 M in 2:1 THF/H2O, 2.7 mL) was added.  The resultant mixture was stirred for 
2 h, then diluted with 1:1 DCM/H2O (50 mL).  The aqueous layer was separated, washed 
with DCM (50 mL), acidified with 10% HCl (50 mL), then extracted with DCM (50 mL × 
2).  The final organic extracts were combined  and concentrated to give 2.21 (140 mg, 
97%) as an orange solid: 
mp: 122-124 ºC (lit. 115-115.5 ºC)3 
[α]D20: +5.8 º (c = 0.50, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.01-1.04 (6H, m, CHMe2), 1.72-1.92 (3H, m CH2CHMe2 
and CH2CHMe2), 4.88 (1H, m, NHCH), 6.58 (1H, d, J = 7.9 Hz, NH), 7.48-7.56 (3H, m), 
7.92-7.99 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 22.0, 23.0, 25.2 (CH2CHMe2), 41.3 (CH2CHMe2), 51.6 
(NHCH), 123.0, 123.2, 128.4, 129.2, 131.7, 135.3, 152.6, 154.5, 167.5, 177.0. 
HRMS (ES): Calcd. for C19H22N3O3 (MH+) 340.1661, found 340.1670. 
 
(S,E)-3-Methyl-2-(4-(phenylazo)-benzoylamino)-butyric acid 2.22: 
 
 
 
 
A solution of ester 2.18 (260 mg, 0.75 mmol) in THF (10 mL) was cooled to 0ºC and 
LiOH (0.25 M in 2:1 THF/H2O, 4.5 mL) was added.  The resulting mixture was stirred for 
2 h, then diluted with DCM (50 mL) and H2O (50 mL) and the layers were separated.  The 
organic layer was concentrated to return starting material 2.18 (77 mg, 30%). The aqueous 
layer was acidified with HCl (1.0 M) and extracted with DCM (50 mL).  The organic 
extract was washed with brine (50 mL), dried over MgSO4 and concentrated to give 2.22 
(150 mg, 63%) as an orange solid: 
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mp: 159-162 ºC 
[α]D20: +30.0 º (c = 0.65, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.05-1.12 (6H, m), 2.40 (1H, m, CHMe2), 4.85 (1H, dd, J = 
8.2, 4.9 Hz, CHNH), 6.71 (1H, d, J = 8.2 Hz, NH), 7.49-7.56 (3H, m), 7.93-8.00 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 18.0, 19.2, 31.5, 57.8, 123.1, 123.3, 128.3, 129.3, 131.8, 
135.5, 152.6, 154.6, 167.5, 175.9. 
 HRMS(ES): Calcd. 326.1505 for C18H20N3O3 (MH+), found 326.1520. 
 
(E)-(4-(Phenylazo)-benzoylamino)-acetic acid 2.23:  
 
 
 
 
A solution of ester 2.19 (240 mg, 0.81 mmol) in THF (10 mL) was cooled to 0ºC and 
LiOH (0.25 M in 2:1 THF/H2O, 5.0 mL) was added.  The resulting mixture was stirred for 
2 h then diluted with DCM (50 mL) and H2O (50 mL) and the layers were separated.  The 
aqueous layer was acidified with HCl (1.0 M) and extracted with DCM (50 mL).  The final 
organic extract was washed with brine (50 mL), dried over MgSO4 and concentrated to 
give 2.23 (190 mg, 83%) as an orange solid: 
mp: 224-227 ºC 
1H NMR (500 MHz, (CD3)2CO) δ 4.19 (2H, d, J = 5.9 Hz, CH2), 7.57-7.65 (3H, m), 7.96-
8.03 (4H, m), 8.14 (2H, d, J = 8.6 Hz), 8.25 (1H, s). 
13C NMR (75 MHz, (CD3)2SO) δ 41.4, 122.5, 122.8, 128.6, 129.6, 132.1, 136.0, 151.9, 
153.4, 165.8, 171.3. 
HRMS (ES): Calcd. 284.1035 for C15H14N3O3 (MH+), found 284.1031. 
 
 (S,E)-2-(4-(Phenylazo)-benzoylamino)-propionic acid 2.24: 
 
 
 
 
A solution of ester 2.20 (220 mg, 0.71 mmol) in THF (10 mL) was cooled to 0ºC and 
LiOH (0.25 M in 2:1 THF/H2O, 4.2 mL) was added.  The resulting mixture was stirred for 
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2 h, then diluted with DCM (50 mL) and H2O (50 mL) and the layers were separated.  The 
aqueous layer was acidified with HCl (1.0 M) and extracted with DCM (50 mL).  The final 
organic extract was washed with brine (50 mL), dried over MgSO4 and concentrated to 
give 2.24 (210 mg, qu) as an orange solid: 
mp: 213-215 ºC 
[α]D20: +35.4 º (c = 0.65, MeOH) 
1H NMR (500 MHz, (CD3)2CO) δ 1.54 (3H, d, J = 7.3 Hz, Me), 4.71 (1H,  p, J = 7.3 Hz, 
CHMe), 7.57-7.64 (3H, m), 7.95-8.01 (4H, m), 8.07 (1H, d, J = 6.6 Hz, NH), 8.14 (2H, d, J 
= 8.7 Hz). 
13C NMR (75 MHz, CD3OD) δ 17.5, 123.7, 124.0, 129.7, 130.3, 132.9, 137.3, 153.9, 155.6, 
169.2, 176.1. 
HRMS(ES): Calcd. 298.1192 for C16H16N3O3 (MH+), found 298.1196. 
 
(S,E)-N-(4-Methyl-1-oxo-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl 
amino)pentan-2-yl)-4-(phenylazo)-benzamide  2.2:  
 
 
 
 
 
A solution of carboxylic acid 2.21 (170 mg, 0.49 mmol), amine 2.16 (110 mg, 1 eq), EDCI 
(130 mg, 1 eq) and HOBt (92 mg, 1 eq) in DCM (5.0 mL) was stirred for 16 h then washed 
with water (50 mL), brine (50 mL), and filtered to give 2.2 (110 mg, 43%) as an orange 
solid:  
mp: 225–227 ºC 
[α]D20: +1.0º (c = 0.60, DMSO) 
1H NMR (300 MHz, (CD3)2SO) δ 1.05 (6H, t, J = 6.8, CHMe2), 1.38 (12H, s, (CMe2)2) 
1.72 (1H, m), 1.80–2.00 (2H, m), 4.77 (1H, m, COCH), 7.42 (2H, m), 7.71 (3H, m), 7.92 
(1H, d, J = 6.6), 8.05 (5H, m), 8.25 (2H, d, J = 8.4 Hz), 8.92 (1H, d, J = 7.2), 10.30 (1H, s). 
13C NMR (75 MHz, (CD3)2SO) δ 21.6 (CHMe2), 23.2 (CHMe2), 24.8 (2C, (CMe2)2 and 
CHMe2), 41 (obscured by solvent peak, CH2), 53.2 (COCH), 83.8 (CMe2)2), 122.4, 122.9, 
125.6, 128.5, 129.1, 129.4, 129.7, 132,2, 136.3, 138.8, 152.0, 153.5, 165.9, 171.5. 
HRMS (ES): Calcd. 541.2986 for C31H38BN4O4 (MH+), found 541.2958. 
N
N
N
H
O H
N
O
B O
O
Chapter Nine: Experimental 
 
177
 
(E)-N-((S)-2-Methyl-1-(3-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-phenyl 
carbamoyl)-propyl)-4-(phenylazo)-benzamide 2.3:  
 
 
 
 
A solution of carboxylic acid 2.22 (100 mg, 0.31 mmol), aminophenylboronic acid 2.16 
(68 mg, 1 eq), EDCI (65 mg, 1.1 eq) and HOBt (46 mg, 1.1 eq) in DCM (10 mL) was 
stirred for 16 h, diluted with DCM (50 mL), washed with H2O (50 mL × 2), brine (50 mL), 
dried over MgSO4 and concentrated.  The crude product was purified by flash 
chromatography, eluting with 1:9 EtOAc/DCM to give 2.3 (52 mg, 32%) as an orange 
solid. 
mp: 215-220 ºC 
[α]D20: +1.2 º (c = 0.33, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.09 (6H, d, J = 6.1 Hz, CHMe2), 1.29 (12H, s, (CMe2)2), 
2.34 (1H, m), 4.92 (1H, t, J = 7.5 Hz), 7.31 (1H, t, J = 7.5 Hz), 7.47-7.59 (5H, m), 7.79 
(1H, d, J = 7.5 Hz), 7.90-8.08 (7H, m), 9.19 (1H, s). 
13C NMR (75 MHz, CDCl3) δ 18.9, 19.6, 25.0, 31.9, 60.0, 84.0, 123.1, 123.2, 123.3, 126.3, 
128.5, 128.6, 129.3, 131.0, 131.7, 135.7, 137.4, 152.6, 154.5, 167.3, 170.2. 
HRMS (ES): Calcd. 527.2830 for C30H36BN4O4 (MH+), found 527.2839. 
 
(E)-4-(Phenylazo)-N-((3-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-phenyl 
carbamoyl)-methyl)-benzamide 2.4:  
 
 
 
 
A solution of carboxylic acid 2.23 (100 mg, 0.35 mmol), aminophenylboronic acid 2.16 
(72 mg, 1 eq), EDCI (75 mg, 1.1 eq) and HOBt (53 mg, 1.1 eq) in DCM (10 mL) was 
stirred for 16 h, diluted with DCM (50 mL), washed with H2O (50 mL × 2), brine (50 mL), 
dried over MgSO4 and concentrated.  The crude product was purified by flash 
chromatography, eluting with 1:4 EtOAc/DCM to give 2.4 (70 mg, 41%) as an orange 
solid: 
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mp: 255-257 ºC 
1H NMR (300 MHz, (CD3)2SO) δ 1.28 (12H, s, (CMe2)2), 4.09 (2H, d, J = 5.6 Hz, CH2), 
7.29-7.38 (2H, m), 7.57-7.68 (3H, m), 7.75 (1H, d, J = 7.2 Hz), 7.91-8.02 (5H, m), 8.13 
(2H, d, J = 8.3 Hz), 9.05 (1H, t, J = 5.6 Hz, NHCH2), 10.10 (1H, s, NHCOCH2). 
13C NMR (300 MHz, (CD3)2SO) δ 24.7, 43.4, 83.7, 122.2, 122.5, 122.8, 125.3, 128.4, 
128.7, 129.3, 129.6, 132.1, 136.2, 138.5, 152.0, 153.4, 166.0, 167.8. 
HRMS (ES): Calcd. 485.2360 for C27H30BN4O4 (MH+), found 485.2375. 
 
(E)-4-(Phenylazo)-N-((S)-1-(3-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-phenyl 
carbamoyl)-ethyl)-benzamide 2.5:   
 
 
 
 
A solution of carboxylic acid 2.24 (100 mg, 0.34 mmol), aminophenylboronic acid 2.16 
(74 mg, 1 eq), EDCI (71 mg, 1.1 eq) and HOBt (50 mg, 1.1 eq) in DCM (7.0 mL) was 
stirred for 16 h, diluted with DCM (50 mL), washed with H2O (50 mL × 2), brine (50 mL), 
dried over MgSO4 and concentrated.  The crude product was purified by flash 
chromatography, eluting with a gradient from DCM to 15:85 EtOAc/DCM to give 2.5 (70 
mg, 41%) as an orange solid: 
mp: 211-213 ºC 
[α]D20: +4.4 º (c = 0.50, EtOAc) 
1H NMR (300 MHz, (CD3)2SO) δ 1.28 (12H, s, (CMe2)2), 1.47 (3H, d, J = 7.1 Hz, CHMe), 
4.61 (1H,  p, J = 7.1 Hz, CHMe), 7.33 (2H, m), 7.58-7.66 (3H, m), 7.77 (1H, d, J = 7.1 Hz), 
7.91-8.01 (5H, m), 8.15 (1H, d, J = 8.4 Hz), 8.85 (1H, d, J = 6.8 Hz), 10.10 (1H, s). 
13C NMR (75 MHz, (CD3)2SO) δ 18.6, 24.8, 50.1, 83.9, 123.0, 123.1, 126.0, 128.3, 128.5, 
129.1, 130.9, 131.6, 135.2, 137.3, 152.5, 154.4, 166.8, 170.6. 
HRMS (ES): Calcd. 499.2517 for C28H32BN4O4 (MH+), found 499.2495. 
 
 
 
 
 
N
N
N
H
O H
N
O
B O
O
Chapter Nine: Experimental 
 
179
 
(S,E)-Methyl-4-methyl-2-(4-(phenylazo)phenylsulfonamido)pentanoate 2.26:  
 
 
 
 
 
A mixture of 4-(phenylazo)benzenesulfonyl chloride 2.255 (supplied by Nathan 
Alexander6, 770 mg, 2.8 mmol) and H-LeuOMe.HCl (500 mg, 1 eq) was dissolved in 
DCM (15 mL) then DIEA (1.4 mL, 3 eq) was added. The reaction mixture was refluxed 
for 2 h then cooled, diluted with EtOAc (100 mL), washed with water (100 mL) then brine 
(100 mL), dried over MgSO4 and concentrated. The crude product was purified by flash 
chromatography, eluting with DCM then 1:9 EtOAc/DCM to obtain 2.26 (980 mg, 91%) 
as an orange solid:  
mp: 131–134 ºC 
[α]D20: +19.0 º (c = 1.0, MeOH) 
1H NMR (300 MHz, CDCl3) δ 0.91 (6H, m, CHMe2), 1.53 (2H, t, J = 7.1, CH2), 1.81 (1H, 
m, CHMe2), 3.45 (3H, s, OMe), 4.03 (1H, m, COCH), 5.39 (1H, d, J = 9.6, NH), 7.54 (3H, 
m), 7.93–8.01 (6H, m). 
13C NMR (126 MHz, CDCl3) δ 21.3, 22.7, 24.3, 42.2, 52.3, 54.4, 123.1, 123.2, 128.3, 
129.2, 132.1, 141.1, 152.3, 154.6, 172.5. 
HRMS(ES): Calcd. 390.1488 for C19H24N3O4S (MH+), found 390.1485. 
 
 (S)-4-Methyl-2-(4-(phenylazo)phenylsulfonamido)pentanoic acid 2.27:  
 
 
 
 
 
To a solution of ester 2.26 (500 mg, 1.3 mmol) in THF (20 mL) was added a solution of 
LiOH (8.0 mL; 0.25 M in 2:1 THF/water).  The reaction mixture was stirred for 16 h then 
diluted with water (100 mL), washed with DCM (100 mL), then acidified to pH 3 with 
HCl (1.0 M) and extracted with DCM (100 mL). The organic layer was dried over MgSO4 
and concentrated. The crude material was purified by silica column chromatography, 
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eluting with 1:1 EtOAc–DCM to give recovered starting material 2.26 (114 mg, 23%) and 
2.27 (300 mg, 63%) as an orange solid:  
mp: 128–130 ºC 
[α]D20: +31.6 º (c = 0.45, MeOH) 
1H NMR (300 MHz, CDCl3) δ 0.83 (6H, m, CHMe2), 1.48 (2H, m, CH2), 1.74 (1H, m, 
CHMe2), 3.97 (1H, m, COCH), 5.18 (1H, d, J = 9.9, NH), 5.35–5.90 (1H, br s, OH), 7.54 
(3H, m), 7.96 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 21.1, 22.7, 24.3, 41.9, 54.1, 123.2, 123.3, 128.3, 129.3, 
132.2, 141.0, 152.3, 154.8, 176.6. 
HRMS(ES): Calcd. 376.1331 for C18H22N3O4S (MH+), found 376.1345. 
 
(S,E)-4-Methyl-2-(4-(phenylazo)phenylsulfonamido)-N-(3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)pentanamide 2.6:  
 
 
 
 
 
A mixture of amine 2.16 (50 mg, 0.23 mmol), carboxylic acid 2.27 (100 mg, 1 eq) and 
HATU (95 mg, 1.1 eq) was dissolved in DMF (5.0 mL) and DIEA (87 μL, 2.2 eq) was 
added. The reaction mixture was stirred overnight then diluted with EtOAc (50 mL), 
washed with water (50 mL), brine (50 mL), dried over MgSO4 and concentrated. The 
crude material was purified by flash chromatography, eluting with 1:19 EtOAc/DCM to 
give 2.6 (43 mg, 28%) as an orange solid:  
mp: 75–80 ºC 
[α]D20: -17.1 º (c = 0.90, MeOH) 
1H NMR (500 MHz, CDCl3) δ 0.75 (3H, d, J = 5, CHMe2), 0.87 (3H, d, J = 5.5, CHMe2), 
1.31 (12H, m, (CMe2)2), 1.54 (1H, t, J = 9), 1.65 (2H, m), 3.88 (1H, m, COCH), 5.45 (1H, 
m, NH), 7.24 (1H, t, J = 7.8), 7.49–7.54 (4H, m), 7.60 (1H, s), 7.64 (1H, d, J = 7), 7.86 
(1H, s), 7.90–7.96 (4H, m), 8.03 (2H, d, J = 7.5). 
13C NMR (75 MHz, CDCl3) δ 21.4 (CHMe2), 22.9 (CHMe2), 24.4 (CHMe2), 24.8 
((CMe2)2), 42.2 (CH2), 56.4 (COCH), 83.9 (CMe2)2), 123.1, 123.3, 123.4, 125.9, 128.4, 
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128.5, 129.2, 131.1, 132.1, 136.4, 140.5, 152.3, 154.8, 169.2. 
HRMS (ES): Calcd. 577.2656 for C30H38BN4O5S (MH+), found 577.2665. 
 
2-Benzyl-4,4,5,5-tetramethyl-(1,3,2)dioxaborolane 2.30:7  
 
 
 
 
Mg turnings (8.0 g, 0.33 mol) were stirred under a nitrogen atmosphere for 16 h, then ether 
(100 mL) was added and the mixture was cooled to 0ºC and stirred for 1 h. Benzyl 
chloride 2.28 (35 mL, 38 g, 0.30 mol) was added and the mixture was warmed to r.t. to 
initiate the Grignard reaction.  After the reaction subsided, ether (100 mL) was added.  The 
Grignard mixture and a solution of trimethyl borate (34 mL, 31 g, 0.30 mol) in ether (150 
mL) were then added alternately to cooled (-60 ºC) ether (150 mL), maintaining the 
temperature below -30ºC.  The resulting mixture was then stirred for 16 h, warming to r.t., 
then was cooled to 0 ºC and H2SO4 (40% aqueous, 75 mL) was added slowly, maintaining 
the temperature below 15 ºC.  The mixture was stirred overnight, warming to r.t., then the 
layers were separated, and the aqueous layer was extracted with ether (70 mL × 4).  The 
organic extracts were combined and the ether solvent was removed by distillation at 60 ºC.  
The distilland residue was collected to obtain benzylboronic acid 2.29 (56 g) as a pale 
yellow oil, which was used subsequently without further purification.  A solution of the 
crude benzylboronic acid (30 g, < 0.22 mol) and pinacol (26 g, 0.22 mol) in ether (100 
mL) was stirred for 16 h, washed with H2O (100 mL × 3), dried over MgSO4 and 
concentrated.  The crude product was purified by flash chromatography, eluting with a 
gradient of pet ether to 1:19 EtOAc/pet ether to obtain 2.30 (20 g, 63% over 2 steps) as a 
colourless oil: 
1H NMR (500 MHz, CDCl3) δ 1.23 (12H, s, (CMe2)2), 2.29 (2H, s, CH2), 7.12 (1H, t, J = 
7.2 Hz), 7.18 (1H, d, J = 7.2 Hz), 7.24 (2H, m). 
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2-(1-Chloro-2-phenyl-ethyl)-4,4,5,5-tetramethyl-(1,3,2)dioxaborolane 2.31:7 
 
 
 
 
 
A solution of diisopropylamine (7.7 mL, 5.6 g, 55 mmol) and THF (1.0 mL) was cooled to 
0ºC and n-butyllithium (1.6 M in THF, 32 mL, 51 mmol) was added to form LDA in situ.  
A solution of boronate ester 2.30 (10 g, 46 mmol) in DME (80 mL) and DCM (4.7 mL) 
was cooled to -78ºC and the LDA solution was added slowly.  The resulting solution was 
stirred for  4 d, warming to r.t., then diluted with DCM (100 mL), filtered and concentrated.  
The residue was then dissolved in pet ether (100 mL), filtered and concentrated to obtain 
2.31 (12 g) as a brown oil, which was used subsequently without further purification: 
selected peaks from 1H NMR (500 MHz, CDCl3) δ 1.22 (12H, m, (CMe2)2), 3.09 (1H, dd, 
J = 13.7, 8.3 Hz), 3.17 (1H, dd, J = 13.7, 8.1 Hz), 3.59 (1H, t, J = 8.2 Hz), 7.20-7.31 (5H, 
m). 
 
2-(1-(1,1,1,3,3,3-Hexamethyl-disilazan-2-yl)-2-phenyl-ethyl)-4,4,5,5-tetramethyl-
(1,3,2)dioxaborolane 2.32:7 
 
 
 
 
A solution of HMDS (9.0 mL, 6.9 g, 43 mmol) in THF (60 mL) was cooled to -78 ºC and 
n-BuLi (1.6 M in THF, 27 mL, 43 mmol) was added.  The solution was then warmed to r.t., 
then cooled to -78ºC and a solution of crude 2.31 (10 g, < 38 mmol) in THF (15 mL) was 
added.  The resulting mixture was stirred overnight, warming to r.t., then concentrated to 
give 2.32 (16 g) as a brown oil which was used subsequently without further purification: 
selected peaks from 1H NMR (500 MHz, CDCl3) δ 0.05 (18H, s, N(SiMe3)2), 1.21 (12H, s, 
(CMe2)2), 2.61 (1H, dd, J = 13.1, 8.2 Hz), 2.73 (1H, dd, J = 8.2, 6.4 Hz), 2.99 (1H, dd, J = 
13.1, 6.4 Hz), 7.12-7.26 (5H, m, Ph). 
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2-Phenyl-1-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-ethylamine trifluoroacetate 
2.33:7   
 
 
 
 
A solution of crude 2.32 (16 g) in ether (100 mL) was cooled to 0ºC and TFA (8.7 mL) 
was added slowly.  The resulting mixture was stirred 10 min then concentrated, dissolved 
in pet ether, filtered and concentrated.  The crude product was recrystallised twice from 
EtOAc to give 2.33 (2.7 g, 19% over 3 steps) as a white solid:  
mp 174-181 ºC (lit.7 109-112 ºC)  
1H NMR (500 MHz, CDCl3) δ 1.20-1.28 (12H, m, (CMe2)2), 3.16-3.33 (3H, m), 4.67 (1H, 
s), 7.22-7.40 (5H, m, Ph), 7.97 (2H, s). 
 
(E)-N-(2-Phenyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-ethyl)-4-(phenylazo) 
benzamide 2.7: 
 
 
 
 
 
To a solution of carboxylic acid 2.15 (190 mg, 0.84 mmol) in THF (5.0 mL) was added 
isobutylchloroformate (110 μL, 1 eq) then NMM (180 μL, 2 eq). The reaction mixture was 
stirred for 10 min, then a solution of amine 2.33 (300 mg, 1 eq) in THF (5.0 mL) was 
added. The resulting mixture was stirred for 16 h, then diluted with EtOAc (50 mL), 
washed with water (50 mL) then brine (50 mL) and concentrated. The crude material was 
purified by flash chromatography, eluting with 3:7 EtOAc/DCM to give 2.7 (190 mg, 
51%) as an orange solid:  
mp: 205–206 ºC 
Elemental analysis: Calcd. for C27H30BN3O3: C 71.22, H 6.64, N 9.23%, found: C, 71.13; 
H, 6.55; N, 9.31. 
1H NMR (500 MHz, CDCl3) δ 1.31 (6H, s, (CMe2)2), 1.32 (6H, s, (CMe2)2), 2.83 (1H, dd, 
J = 11.8 and 14.3, CHCH2), 3.08 (1H, dd, J = 4.3 and 14.3, CHCH2), 3.15 (1H, m, 
TFA.H2N B
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CHCH2), 6.96 (1H, s, NH), 7.27 (3H), 7.36 (2H, t, J = 7.8), 7.53 (3H), 7.87 (2H, d, J = 8.5), 
7.94 (4H). 
13C NMR (126 MHz, CDCl3) δ 25.0, 25.3, 37.3 (CHCH2), 46.3 (CHCH2), 81.0, 122.9, 
123.2, 126.3, 128.7, 128.9, 129.0, 129.2, 131.9, 140.8, 152.4, 155.2, 170.4. 
HRMS (ES): Calcd. 456.2458 for C27H31BN3O3 (MH+), found 456.2451. 
 
(E)-(N-((S)-3-Methyl-1-((S)-2-phenyl-1-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-
ethylcarbamoyl)-butyl)-4-phenylazo-benzamide 2.8  
and (E)-(N-((S)-3-Methyl-1-((R)-2-phenyl-1-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-
2-yl)-ethylcarbamoyl)-butyl)-4-phenylazo-benzamide 2.9:  
 
A solution of carboxylic acid 2.21 (100 mg, 0.29 mmol) in THF (4.0 mL) was cooled to 0 
ºC, then isobutylchloroformate (40 μL, 1 eq) and NMM (65 μL, 2 eq) were added. The 
reaction mixture was stirred for 10 min then a solution of amine 2.33 (110 mg, 1 eq) in 
THF (4.0 mL) was added. The mixture was stirred for 16 h, diluted with EtOAc (50 mL), 
washed with water (50 mL) then brine (50 mL), dried over MgSO4 and concentrated. The 
crude material was purified by silica column chromatography on deactivated silica 
(containing 35% water w/w), eluting with 3:7 EtOAc/DCM to give a mixture of 2.8 and 
2.9 (130 mg, 76%) as an orange solid. The mixture of diastereomers was further purified 
three times by column chromatography to give 2.8 (5.0 mg, 3%, 86% de) as an orange 
solid:  
1H NMR (500 MHz, CD3OD) δ 0.96 (3H, d, J = 6, CHMe2), 0.99 (3H, d, J = 6.5, CHMe2), 
1.10 (6H, s, (CMe2)2), 1.15 (6H, s, (CMe2)2), 1.68 (1H, m), 1.78 (1H, m), 1.87 (1H, m), 
2.62 (1H, dd, J = 8.5, 12), 2.84 (2H, m), 4.92 (1H, dd, J = 5, 10.5), 7.17 (1H,m), 7.26 (4H, 
m), 7.55 (4H, m), 7.94–8.04 (6H, m). 
HRMS(ES): Calcd. 569.3299 for C33H42BN4O4 (MH+), found 569.3279. 
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and 2.9 (8.0 mg, 5%, 86% de) as an orange solid:  
1H NMR (500 MHz, CD3OD) δ 0.98 (3H, d, J = 6.5, CHMe2), 1.00 (3H, d, J = 5, CHMe2), 
1.14 (12H, m, (CMe2)2), 1.68–1.87 (3H, m), 2.60 (1H, dd, J = 9.3, 12.8), 2.80–2.88 (2H, 
m), 4.89 (1H, m, COCH), 7.12– 7.23 (5H, m), 7.55 (3H,m), 7.94–8.03 (6H, m). 
HRMS(ES): Calcd. 569.3299 for C33H42BN4O4 (MH+), found 569.3307. 
 
(4-Nitro-benzyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 2.35:3, 8  
 
 
 
 
A solution of 4-nitrobenzylamine hydrochloride 2.34 (1.3 g, 8.5 mmol) and  
9-fluorenylmethyl chloroformate (2.4 g, 1.1 eq) in DCM (50 mL) was cooled to 0 ºC then 
DIEA was added (1.6 mL, 1.2 g, 1.1 eq).  The resulting solution was stirred for 18 h then 
concentrated.  The crude product was recrystallised from DCM to give 2.35 (1.7 g, 52%) 
as a white solid:  
mp: 141-144 ºC (lit.3 155-156 ºC) 
1H NMR (500 MHz, CDCl3) δ 4.23 (1H, t, J = 6.5 Hz), 4.46 (2H, d, J = 5.9 Hz), 4.54 (2H, 
d, J = 6.6 Hz), 5.16 (1H, s), 7.29-7.47 (6H, m), 7.60 (2H, d, J = 7.2 Hz), 7.78 (2H, d, J = 
7.2 Hz), 8.18 (2H, d, J = 8.1 Hz). 
13C NMR (300 MHz, CDCl3) δ 44.2, 47.3, 66.6, 120.0, 123.8, 124.9, 127.0, 127.7, 127.8, 
141.3, 143.6, 146.0, 147.2, 156.4. 
HRMS(ES): Calcd. 375.1345 for C22H19N2O4 (MH+), found 175.1353. 
 
(4-Amino-benzyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 2.36:3, 8  
 
 
 
 
To a solution of 2.35 (1.7 g, 4.4 mmol) in EtOAc (120 mL) was added PtO2 (50 mg).  The 
reaction vessel was evacuated then filled with H2 gas.  The mixture was stirred under H2 
for 16 h, then filtered through Celite-545 filter aid and concentrated.  The crude product 
NO2
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was purified by flash chromatography, eluting with a gradient from DCM to 1:9 
EtOAc/DCM to give 2.36 (1.3 g, 86%) as a white solid: 
mp: 144-146ºC decomp. (lit.3 147-147.5) 
1H NMR (300 MHz, CDCl3) δ 3.67 (2H, br s, NH2), 4.17-4.31 (3H, m), 4.43 (2H, d, J = 
6.5 Hz), 4.98 (1H, s), 6.64 (2H, d, J = 8.0 Hz), 7.07 (2H, d, J = 8.0 Hz), 7.24-7.45 (4H, m), 
7.59 (2H, d, J = 7.4 Hz), 7.76 (2H, d, J = 7.4 Hz). 
 
(E)-Ethyl 4-((4-((((9H-fluoren-9-yl)methoxy)carbonylamino)methyl)-phenyl)diazenyl)  
benzoate 2.39:  
 
 
 
 
 
A mixture of ethyl 4-aminobenzoate 2.37 (2.0 g, 12 mmol) and MoO5·H2O·HMPA (0.45 g, 
0.1 eq) was dissolved in DCM (20 mL) and a solution of H2O2 (6.0 mL; 30% in water) was 
added.  The reaction mixture was stirred for 16 h then quenched by addition of excess 
MgSO4, filtered and concentrated. The crude material was purified by flash 
chromatography, eluting with 1:9 EtOAc/DCM to obtain ethyl 4-nitrosobenzoate 2.38 as a 
yellow solid.  To this compound was added the aniline 2.36 (1.2 g, 3.49 mmol) then AcOH 
(25 mL).  The resulting mixture was heated to 100 ºC for 1 h, then cooled and filtered to 
collect an orange precipitate.  The filtrate was diluted with DCM (100 mL), washed with 
sat. NaHCO3 (100 mL × 3) then dried over MgSO4 and concentrated.  This crude material 
was combined with the precipitate and purified by silica column chromatography, eluting 
with 1:19 EtOAc/DCM to give 2.39 (1.3 g, 22% over 2 steps) as an orange solid:  
mp: 191–194 ºC 
1H NMR (300 MHz, CDCl3) δ 1.43 (3H, t, J = 7, Me), 4.24 (1H, t, J = 6.3, CH2CH), 4.40–
4.53 (6H, m), 5.17 (1H, NH), 7.26–7.42 (6H, m), 7.61 (2H, d, J = 6.9), 7.77 (2H, d, J = 
7.2), 7.93 (4H, m), 8.20 (2H, d, J = 8.7). 
13C NMR (75 MHz, CDCl3) δ 14.3 (Me), 44.7, 47.3 (CH2CH), 61.3, 66.7, 120.0, 122.6, 
123.5, 125.0, 127.1, 128.1, 130.6, 132.2, 141.4, 142.3, 143.8, 151.9, 155.0, 156.5, 166.1. 
HRMS(ES): Calcd. for C31H28N3O4 (MH+) 506.2080, found 506.2120. 
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(E)-Ethyl 4-((4-((2-(tert-butoxycarbonylamino)acetamido)methyl)-phenyl)diazenyl)  
benzoate 2.41:  
 
 
 
 
 
To a solution of 2.39 (900 mg, 1.78 mmol) in DMF (12 mL) was added piperidine (3.0 
mL). The reaction mixture was stirred for 15 min then diluted with EtOAc (100 mL), 
washed with water (100 mL) then brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give amine 2.40 as an orange solid which was not purified further. 
To this compound was added Boc-Gly-OH (310 mg, 1 eq), HATU (680 mg, 1 eq) then 
DMF (10 mL) and DIEA (620 μL, 2 eq). The reaction mixture was stirred for 16 h, diluted 
with EtOAc (100 mL) and washed with water (100 mL) brine (100 mL), dried over 
MgSO4, filtered and concentrated. The crude material was purified by silica column 
chromatography, eluting with 1:1 EtOAc/DCM to give 2.41 (690 mg, 88% over 2 steps) as 
an orange solid:  
mp: 136–139 ºC 
1H NMR (500 MHz, CDCl3) δ 1.41–1.47 (12H, CMe3 and CH2Me), 3.87 (2H, d, J = 5.5), 
4.42 (2H, q, J = 5.4), 4.57 (2H, d, J = 6.0), 5.13 (1H, br, NH), 6.56 (1H, br,NH), 7.44 (2H, 
d, J = 8.0), 7.92 (2H, d, J = 8.0), 7.94 (2H, d, J = 8.5), 8.19 (2H, d, J = 8.5). 
13C NMR (75 MHz, CDCl3) δ 14.3, 28.2, 42.9, 44.5, 61.2, 80.4, 122.6, 123.4, 128.2, 130.5, 
132.1, 141.8, 151.8, 154.9, 156.2, 166.0, 169.6. 
HRMS(ES): Calcd. for C23H29N4O5 (MH+) 441.2138, found 441.2108. 
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(E)-4-((4-((2-(tert-Butoxycarbonylamino)acetamido)methyl)phenyl)-diazenyl)benzoic 
acid 2.42:  
 
 
 
 
 
To a solution of 2.41 (68 mg, 0.15 mmol) in THF (5.0 mL) was added a solution of LiOH 
(1.0 mL; 0.25 M in 2:1 THF/water). The reaction mixture was heated to 50 ºC and stirred 
for 16 h then concentrated. The crude material was purified by flash chromatography, 
eluting with 1:99 AcOH/EtOAc to give 2.42 (55 mg, 87%) as an orange solid:  
mp > 360 ºC 
1H NMR (500 MHz, CD3OD) δ 1.45 (9H, s, CMe3), 3.76 (2H, s), 4.49 (2H, s), 7.47 (2H, d, 
J = 8), 7.87 (4H, m), 8.08 (2H, d, J = 8). 
13C NMR (75 MHz, CD3OD) δ 29.0 (CMe3), 43.9, 45.1, 81.1 (CMe3), 123.4, 124.3, 129.5, 
131.5, 141.8, 144.0, 153.5, 155.3, 158.8, 173.1, 174.7. 
HRMS(ES): Calcd. for C21H25N4O5 (MH+) 413.1825, found 413.1805. 
 
(E)-tert-Butyl-2-oxo-2-(4-((4-(2-phenyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)ethylcarbamoyl)phenyl)diazenyl)benzylamino)-ethylcarbamate 2.10:  
 
 
 
 
 
 
A solution of 2.42 (30 mg, 0.07 mmol) in DMF (3.0 mL) was cooled to 0ºC and 
isobutylchloroformate (10 μL, 1 eq) and NMM (16 μL, 2 eq) were added. The reaction 
mixture was stirred for 10 min then a solution of amine 2.33 (26 mg, 1 eq) in DMF (2.0 
mL) was added. The resulting mixture was stirred for 16 h, warming from 0 ºC to r.t., then 
diluted with EtOAc (50 mL), washed with water (50 mL × 2), brine (50 mL), dried over 
MgSO4, filtered and concentrated. The crude material was purified by silica column 
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chromatography on deactivated silica (containing 35% water w/w), eluting with EtOAc to 
give 2.10 (28 mg, 60%) as an orange solid:  
mp: 188–191 ºC 
1H NMR (500 MHz, CDCl3) δ 1.31 (12H, m, (CMe2)2), 1.45 (9H, s, CMe3), 2.83 (1H, dd, J 
= 12,14.1, CHCH2), 3.08 (1H, dd, J = 14.1, 3.80, CHCH2), 3.16 (1H, m, CHCH2), 3.86 
(2H, d, J = 6), 4.55 (2H, d, J = 5.5), 5.18 (1H, s, NH), 6.65 (1H, s, NH), 7.13 (1H, s, NH), 
7.28 (3H, m), 7.37 (2H, t, J = 7.8), 7.41 (2H, d, J = 8), 7.88 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 25.0 (CMe2)2), 25.1 (CMe2)2), 28.2 (CMe3), 37.4 (CHCH2), 
42.7, 44.2, 46.8 (CHCH2), 80.1 (CMe2), 80.6 (CMe2)2), 122.7, 123.3, 126.0, 127.8, 128.4, 
129.0, 129.2, 140.7, 142.1, 151.4, 154.8, 156.2, 169.9, 170.5, 207.0. 
HRMS (ES): Calcd. 642.3463 for C35N45BN5O6 (MH+), found 642.3488. 
 
(E)-4-((4-((2-Aminoacetamido)methyl)phenyl)diazenyl)-N-(2-phenyl-1-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-ethyl)benzamide 2.11:   
 
 
 
 
 
 
To a solution of 2.10 (17 mg, 0.03 mmol) in DCM (4.0 mL) was added TFA (1.0 mL). The 
reaction mixture was stirred for 30 min then concentrated.  The crude material was purified 
by flash chromatography, eluting with 1:3 EtOH/DCM to give 2.11 (14 mg, 82%) as an 
orange solid:  
mp 157–160 ºC 
1H NMR (500 MHz, CD3OD) δ 1.15 (12H, m, (CMe2)2), 2.73 (1H, dd, J = 9.1,13.8), 2.96 
(1H, dd, J = 6.4, 13.8), 2.99 (1H, dd, J = 6.4, 9.1), 3.72 (2H, s), 4.49 (2H, s), 7.16 (1H, m), 
7.27 (4H, m), 7.47 (2H, d, J = 8.1), 7.89 (2H, d, J = 8.1), 7.96 (2H, d, J = 8.1), 8.09 (2H, d, 
J = 8.1). 
HRMS(ES): Calcd. 542.2938 for C30H37BN5O6 (M – TFA + H+), found 542.2965. 
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1-acetamido-2-phenyl-ethylboronic acid 2.12:9, 10  
 
 
 
 
A solution of crude 2.32 (1.5 g, < 3.8 mmol) in THF (10 mL) was cooled to -78 ºC and 
AcOH (0.3 mL) and Ac2O (1.4 mL, 3.9 eq) were added dropwise.  The resulting mixture 
was stirred overnight, warming to r.t., then concentrated.  The residue was dissolved in 
EtOAc, washed with H2O (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  
The crude product was purified by flash chromatography, eluting with 1:19 EtOH/DCM to 
obtain boronate ester 2.43 (480 mg) as a yellow solid.  A solution of 2.43 (100 mg, 0.35 
mmol) in DCM (4.0 mL) was cooled to -78 ºC and BCl3 (1.0 M in DCM, 1.5 mL, 1.5 
mmol) was added.  The resulting solution was stirred 1 h, warmed to r.t., stirred 1.5 h and 
concentrated.  The residue was dissolved in MeOH (100 mL) and distilled to remove 
B(OH)3.  The distilland residue was concentrated, then ether (3.0 mL) and H2O (4.0 mL) 
were added.  The layers were separated and the aqueous layer was washed with ether (3.0 
mL × 2) and lyophilized to obtain 2.12 (17 mg, 11% over 4 steps) as a white solid: 
1H NMR (500 MHz, D2O) δ 2.09 (3H, s, Me), 2.55 (1H, dd, J = 13.8, 11.0 Hz), 2.82 (1H, 
dd, J = 11.0, 5.0 Hz), 2.88 (1H, dd, J = 13.6, 4.9 Hz), 7.27-7.34 (3H, m), 7.39 (2H, t, J = 
7.6 Hz). 
 
9.3 Experimental for work described in chapter 3 
 
((S)-1-Benzylcarbamoyl-2-phenyl-ethyl)-carbamic acid tert-butyl ester 3.7:11, 12   
 
 
 
 
 
To a solution of Boc-Phe-OH 3.6 (900 mg, 3.4 mmol), benzylamine (360 mg, 1 eq) and 
HATU (1.3 g, 1 eq) in DMF (10 mL) was added DIEA (1.2 mL, 0.89 g, 2 eq) and the 
resulting mixture was stirred for 17 h, then diluted with EtOAc (50 mL), washed with H2O 
(50 mL × 2), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  
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The crude material was purified by recrystallisation from EtOH to give 3.7 (500 mg, 41%) 
as a white solid:  
mp: 132-133 ºC (lit.11 131-132 ºC) 
[α]D20: +0.9 º (c = 0.65, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.39 (9H, s, CMe3), 3.08 (2H, m), 4.35 (3H, d, J = 5.4 Hz), 
5.07 (1H, s), 6.11 (1H, s), 7.04-7.31 (10H, m, 2Ph). 
HRMS (ES): Calcd. for C21H27N2O3 (MH+) 355.2022, found 355.2033. 
 
(S)-2-Amino-N-benzyl-3-phenyl-propionamide 3.8:12, 13  
 
 
 
 
To a solution of 3.7 (350 mg, 0.98 mmol) in DCM (4.0 mL) was added TFA (1.0 mL) and 
the resulting mixture was stirred for 1 h then concentrated.  The residue was dissolved in 
H2O (10 mL), washed with DCM (10 mL), basified by addition of sat. NaHCO3 and 
extracted with DCM (10 mL × 3) to give 3.8 (160 mg, 65%) as a white solid. 
mp: 59-66 ºC 
[α]D20:  +9.7º (c = 0.34, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.34 (2H, br s, NH2), 2.74 (1H, dd, J = 13.6, 9.1 Hz), 3.25 
(1H, dd, J = 13.6, 3.7 Hz), 3.63 (1H, s), 4.41 (2H, m), 7.16-7.33 (10H, m, 2Ph), 7.63 (1H, 
s). 
HRMS (ES): Calcd. for C16H19N2O (MH+) 255.1497, found 255.1504. 
 
(R)-2-Acetylamino-4-methyl-pentanoic acid ((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-
amide 3.3: 
 
 
 
 
 
To a solution of 3.8 (50 mg, 0.20 mmol), Ac-D-Leu-OH (34 mg, 1 eq) and HATU (82 mg, 
1.1 eq) in DMF (2.0 mL) was added DIEA (76 μL, 56 mg, 2.2 eq) and the resulting 
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mixture was stirred for 16 h, then diluted with EtOAc (50 mL), washed with HCl (1.0 M, 
50 mL), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The 
crude material was purified by flash chromatography, eluting with DCM to remove leading 
impurities, then EtOAc to give 3.3 (59 mg, 72%) as a white solid: 
mp 194-197 ºC 
[α]D20: -22.7 º (c = 0.30, MeOH) 
1H NMR (300 MHz, (CD3)2SO) δ 0.69 (3H, d, J = 6.1 Hz, CHMeMe), 0.75 (3H, d, J = 6.0 
Hz, CHMeMe), 1.02-1.21 (3H, m), 1.75 (3H, s, OMe), 2.75 (1H, dd, J = 13.7, 11.1 Hz), 
3.14 (1H, dd, J = 13.6, 3.9 Hz), 4.12 (1H, q, J = 7.4 Hz), 4.30 (2H, dd, J = 5.8, 3.0 Hz), 
4.42-4.51 (1H, m), 7.14-7.33 (10H, m, 2Ph), 8.04 (1H, d, J = 6.8 Hz), 8.41-8.51 (2H, m). 
13C NMR (75 MHz, (CD3)2SO) δ 22.3, 22.3, 22.5, 23.9, 37.2, 40.5, 42.2, 51.8, 54.5, 126.2, 
126.8, 127.2, 128.0, 128.3, 129.2, 138.2, 139.2, 169.8, 171.0, 172.4. 
HRMS (ES): Calcd. for C24H32N3O3 (MH+) 410.2444, found 410.2454. 
 
((R)-1-((S)-1-Benzylcarbamoyl-2-phenyl-ethylcarbamoyl)-3-methyl-butyl)-carbamic 
acid tert-butyl ester 3.9:14 
 
 
 
 
 
To a solution of amine 3.8 (50 mg, 0.20 mmol), Boc-D-Leu-OH (45 mg, 1 eq) and HATU 
(82 mg, 1.1 eq) in DMF (3.0 mL) was added DIEA (75 μL, 56 mg, 2.2 eq) and the 
resulting mixture was stirred for 16 h, then diluted with EtOAc (50 mL), washed with H2O 
(50 mL), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The 
crude material was purified by flash chromatography, eluting with 1:4 EtOAc/DCM to 
give 3.9 (70 mg, 76%) as a white solid: 
mp: 129-133ºC (lit.14 179-181ºC) 
[α]D20: -18.2 º (c = 0.55, MeOH) 
1H NMR (500 MHz, CDCl3) δ  0.81-0.88 (6H, m, CHMe2), 1.33 (11H, m), 1.54 (1H, dt, J 
= 13.5, 6.8 Hz), 3.12-3.22 (2H, m), 3.81 (1H, m), 4.27 (1H, dd, J = 14.8, 5.4 Hz), 4.50 (1H, 
dd, J = 14.8, 6.2 Hz), 4.74-4.84 (2H, m), 6.22 (1H, d, J = 7.4 Hz), 7.01 (1H, s), 7.14-7.30 
(10H, m, 2Ph). 
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(R)-2-amino-N-((S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl)-4-
methylpentanamide 3.10:   
 
 
 
 
 
To a solution of 3.9 (55 mg, 0.12 mmol) in DCM (0.8 mL) was added TFA (0.2 mL) and 
the resulting mixture was stirred for 1 h then concentrated.  The residue was dissolved in 
H2O (10 mL), washed with DCM (10 mL), basified by addition of sat NaHCO3 and 
extracted with DCM (10 mL × 3) to give 3.10 (37 mg, 85%) as a white solid: 
mp: 130-132 ºC 
[α]D20: -20.9 º (c = 0.44, MeOH) 
1H NMR (500 MHz, CDCl3) δ 0.84-0.90 (6H, m, CHMe2), 1.23 (1H, m), 1.50-1.64 (2H, 
m), 1.79 (2H, br s, NH2), 3.07 (1H, dd, J = 13.8, 7.6 Hz), 3.17 (1H, dd, J = 13.8, 7.6 Hz), 
3.34 (1H, dd, J = 9.6, 4.0 Hz), 4.35 (2H, d, J = 5.8 Hz), 4.61 (1H, q, J = 7.6 Hz), 6.55 (1H, 
s), 7.11 (2H, m), 7.19-7.29 (8H, m), 7.84 (1H, d, J = 7.1 Hz). 
13C NMR (75 MHz, CDCl3) δ 21.4, 23.5, 24.9, 38.0, 43.5, 44.0, 53.5, 54.5, 127.0, 127.5, 
127.6, 128.7, 128.7, 129.4, 137.0, 138.0, 171.0, 176.2. 
HRMS (ES): Calcd. for C22H30N3O2 (MH+) 368.2338, found 368.2328. 
 
tert-Butyl 2-((R)-1-((S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-ylamino)-4-methyl- 
1-oxo pentan-2-ylamino)-2-oxoethylcarbamate 3.4:   
 
 
 
 
 
To a solution of 3.10 (100 mg, 0.27 mmol), Boc-Gly-OH (48 mg, 1 eq) and HATU (120 
mg, 1.1 eq) in DMF (8.0 mL) was added DIEA (110 μL, 78 mg, 2.2 eq) and the resulting 
mixture was stirred for 16 h, then diluted with EtOAc (50 mL), washed with sat. NaHCO3 
(50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The crude material was 
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purified by flash chromatography, eluting with 2:3 EtOAc/DCM, then by recrystallisation 
from EtOAc/pet ether to give 3.4 (78 mg, 55%) as white solid: 
 mp: 174-176 ºC 
[α]D20: -5.9 º (c = 0.32, MeOH) 
1H NMR (500 MHz, (CD3)2SO) δ 0.72 (6H, dd, J = 16.5, 5.7 Hz, CH(CH3)2), 1.12-1.18 
(3H, m, NHCHCH2CH and NHCHCH2CH), 1.36 (9H, s, C(CH3)3), 2.74 (1H, dd, J = 13.5, 
10.9 Hz, CHCHHPh), 3.10 (1H, dd, J = 13.5, 4.1 Hz, CHCHHPh), 3.51 (2H, d, J = 5.8 Hz), 
4.16-4.34 (3H, m), 4.48 (1H, m), 6.90 (1H, t, J = 6.0 Hz), 7.15-7.26 (8H, m), 7.30 (2H, t, J 
= 7.4 Hz), 7.81 (1H, d, J = 7.3 Hz), 8.42-8.49 (2H, m). 
13C NMR (126 MHz, (CD3)2CO) δ 22.2, 22.7, 23.8, 28.2, 37.4, 40.9, 42.2, 43.1, 51.4, 54.4, 
78.1, 126.2, 126.8, 127.3, 128.1, 128.3, 129.3, 138.1, 139.2, 155.8, 169.4, 171.0, 171.9. 
HRMS (ES): Calcd. for C29H41N4O5 (MH+) 525.3077, found 525.3072  
 
(E)-(4-Phenylazo-benzyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 3.11:3  
 
 
 
 
A solution of the aniline 2.36 (1.6 g, 4.7 mmol) and nitrosobenzene 2.13 (600 mg, 1.2 eq) 
in AcOH (50 mL) was stirred for 2 days, then diluted with DCM (100 mL) and H2O (100 
mL).  The mixture was neutralised by addition of solid NaCO3, the layers were separated 
and the aqueous layer was back extracted with DCM. The combined organic layers were 
concentrated.  The crude product was purified by flash chromatography, eluting with DCM 
to give 3.11 (1.5 g, 71%) as an orange solid: 
mp: 166-168 ºC (lit.3 164.5-165.5 ºC) 
1H NMR (500 MHz, CDCl3) δ 4.24 (1H, t, J = 6.7 Hz), 4.46 (2H, d, J = 6.0 Hz), 4.51 (2H, 
d, J = 6.7 Hz), 5.13 (1H, t, J = 5.4 Hz), 7.32 (2H, t, J = 7.2 Hz), 7.37-7.44 (4H, m), 7.45-
7.55 (3H, m), 7.61 (2H, d, J = 7.6 Hz), 7.77 (2H, d, J = 7.4 Hz), 7.87-7.94 (4H, m). 
HRMS(ES): Calcd. for C28H24N3O2 (MH+) 434.1869, found 434.1854. 
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(E)-4-Phenylazo-benzylamine 3.12:3, 15  
 
 
 
To a solution of 3.11 (100 mg, 0.23 mmol) in DMF (4.0 mL) was added piperidine (1.0 
mL).  The solution was stirred for 15 min then diluted with EtOAc (50 mL), washed with 
H2O (50 mL × 3) then HCl (1.0 M, 50 mL).  An orange precipitate formed which was 
collected, washed with H2O (5.0 mL) and EtOAc (5.0 mL), then stirred in a mixture of 1:1 
EtOAc/sat. NaHCO3 for 10 min.  The organic layer was collected, washed with brine, 
dried and concentrated to give 3.12 as an orange solid (37 mg, 76%): 
1H NMR (500 MHz, CDCl3) δ 1.50 (2H, s), 3.92 (2H, s), 7.40-7.52 (5H, m), 7.87-7.93 (4H, 
m). 
 
(S)-2-((R)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-phenyl-
propionic acid ethyl ester 3.14:  
 
 
 
 
 
To a solution of Boc-D-Leu-OH 3.13 (500 mg, 2.1 mmol), H-Phe-OEt (470 mg, 1 eq), and 
HATU (900 mg, 1.2 eq) in DMF (8.0 mL) was added DIEA (1.3 mL, 3.6 eq) and the 
resulting mixture was stirred 16 h, diluted with EtOAc (50 mL), washed with H2O (50 mL 
× 2), brine (50 mL), dried over MgSO4 and concentrated.  The crude material was purified 
by flash chromatography, eluting with 1:9 EtOAc/DCM to give 3.14 (760 mg, 92%) as a 
white solid: 
mp: 75-82ºC 
[α]D20: +16.0 º (c = 0.75, MeOH) 
1H NMR (500 MHz, CDCl3) δ 0.89 (6H, d, J = 6.2 Hz, CHMe2), 1.23 (3H, t, J = 7.15 Hz, 
OCH2Me), 1.43 (9H, s, CMe3), 1.53-1.64 (2H, m), 3.06-3.16 (2H, m), 4.07-4.20 (3H, m) 
4.77-4.86-4.77 (2H, m), 6.56 (1H, m), 7.12 (2H, m), 7.21-7.30 (3H, m). 
13C NMR (75 MHz, CDCl3) δ 14.2, 22.0, 23.0, 14.8, 28.4, 38.1, 41.4, 53.2, 61.6, 80.2, 
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127.2, 128.6, 129.4, 135.9, 155.7, 155.7, 171.4, 172.3. 
HRMS(ES): Calcd. for C22H35N2O5 (MH+) 407.2546, found 407.2528. 
 
(E)-((R)-3-Methyl-1-((S)-2-phenyl-1-(4-phenylazo-benzylcarbamoyl)-
ethylcarbamoyl)-butyl)-carbamic acid tert-butyl ester 3.16: 
 
 
 
 
 
A solution of 3.14 (150 mg, 0.37 mmol) in THF (4.0 mL) was cooled to 0ºC and LiOH 
(0.25 M in 2:1 THF/H2O, 2.2 mL) was added.  The resulting mixture was stirred for 2 h, 
then diluted with DCM (50 mL) and H2O (50 mL) and the layers were separated.  The 
aqueous layer was acidified to pH 4 with HCl (1.0 M) and extracted with DCM (50 mL).  
The final organic extract was washed with brine (50 mL), dried over MgSO4 and 
concentrated to give 3.1516 (60 mg, 43%) as a white solid.  To a solution of 3.15 (60 mg, 
0.16 mmol), 3.12 (34 mg, 1 eq) and HATU (67 mg, 1.1 eq) in DMF (3.0 mL) was added 
DIEA (61 μL, 45 mg, 2.2 eq) and the resulting mixture was stirred for 16 h then diluted 
with EtOAc (50 mL), washed with H2O (50 mL × 2), sat NaHCO3 (50 mL), brine (50 mL), 
dried over MgSO4 and concentrated.  The crude material was purified by flash 
chromatography, eluting with 1:4 EtOAc/DCM to give 3.16 (65 mg, 72%) as an orange 
solid: 
mp: 124-127 ºC 
[α]D20: -42.1º (c = 1.4, DCM) 
1H NMR (500 MHz, CDCl3) δ  0.82-0.87 (6H, m, CHMe2), 1.29-1.34 (11H, m), 1.56 (1H, 
m), 3.14-3.27 (2H, m), 3.78 (1H, m), 4.35 (1H, dd, J = 15.3, 5.2 Hz), 4.61 (1H, dd, J = 
15.3, 6.3 Hz), 4.82 (2H, m), 6.14 (1H, d, J = 8.8 Hz), 7.12-7.36 (8H, m), 7.45-7.54 (3H, m), 
7.84 (2H, d, J = 8.3 Hz), 7.91 (2H, d, J = 7.1 Hz). 
13C NMR (75 MHz, CDCl3) δ 22.4, 22.7, 24.6, 28.3, 37.7, 40.9, 43.1, 54.0, 54.3, 80.4, 
122.9, 123.1, 127.1, 128.1, 128.8, 129.1, 129.4, 131.0, 136.6, 141.4, 151.8, 152.7, 156.1, 
170.9, 173.0. 
HRMS (ES): Calcd. for C33H42N5O4 (MH+) 572.3237, found 572.3265. 
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(R)-2-amino-4-methyl-N-((S)-1-oxo-3-phenyl-1-((E)-4-(phenylazo)benzylamino) 
propan-2-yl)pentanamide trifluoroacetate 3.5:   
 
 
 
 
 
To a solution of 3.16 (65 mg, 0.11 mmol) in DCM (0.8 mL) was added TFA (0.2 mL) and 
the resulting mixture was stirred for 1 h, then diluted with DCM (50 mL), washed with 
HCl (1.0 M, 50 mL), sat NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and 
concentrated.  The crude product was purified by recrystallisation from EtOAc/pet ether to 
give 3.5 (48 mg, 89%) as an orange solid: 
mp: 161-164 ºC 
[α]D20: -8.3º (c = 0.29, MeOH) 
1H NMR (500 MHz, CDCl3) δ  0.82-0.90 (6H, m, CHMe2), 1.17-1.42 (3H, m), 1.49-1.67 
(2H, m), 3.09 (1H, dd, J = 13.7, 7.5 Hz, CHCHHPh), 3.18 (1H, dd, J = 13.7, 7.5 Hz, 
CHCHHPh), 3.28 (1H, dd, J = 9.2, 4.0 Hz), 4.42 (2H, m), 4.70 (1H, q, J = 7.5 Hz, 
CHCH2Ph), 6.91 (1H, t, J = 5.8 Hz), 7.20-7.29 (7H, m), 7.44-7.53 (3H, m), 7.79-7.85 (3H, 
m), 7.88-7.91 (2H, m). 
13C NMR (75 MHz, CDCl3) δ 21.3, 23.5, 24.9, 37.9, 43.1, 44.0, 53.5, 54.5, 122.9, 123.2, 
127.0, 128.2, 128.7, 129.2, 129.4, 131.1, 136.9, 141.1, 151.9, 152.7, 171.1, 176.4. 
HRMS (ES): Calcd. for C28H34N5O2 (MH+) 472.2713, found 472.2690. 
 
9.4 Experimental for work described in chapter 4 
 
((S)-1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester 4.11:17, 18  
 
 
 
 
A solution of Cbz-Phe-OMe 4.10 (1.0 g, 3.2 mmol) in toluene (15 mL) was cooled to -78 
ºC, then DIBAL (20% in toluene, 4.5 mL, 1.7 eq) was added, and the resulting mixture 
was stirred for 2.5 h at -78 ºC.  Cold anhydrous MeOH (-50 ºC, 10 mL) was added and the 
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mixture was stirred for a further 20 min at -78 ºC then warmed to r.t. and HCl (1.0 M, 10 
mL) was added.  The mixture was stirred for 20 min, diluted with EtOAc (50 mL), washed 
with HCl (1.0 M, 50 mL × 3), sat NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and 
concentrated to give 4.11 (810 mg) which was used subsequently without further 
purification: 
mp: 69-74 ºC (lit.18 78.5-80 ºC) 
[α]D20: -51.2 (c = 1.0, MeOH) 
1H NMR (500 MHz, CDCl3) δ 3.14 (2H, d, J = 6.4 Hz, CHCH2), 4.51 (1H, m, CHCH2), 
5.11 (2H, s, OCH2), 5.31 (1H, d, J = 5.5 Hz, NH), 7.16-7.40 (10H, m), 9.63 (1H, s, CHO). 
 
((S)-1-Benzyl-2-cyano-2-hydroxy-ethyl)-carbamic acid benzyl ester 4.12:17, 19  
 
 
 
 
A solution of 4.11 (720 mg, 2.5 mmol) in EtOAc (4.0 mL) was cooled to 0 ºC and a 
solution of NaHSO3 (300 mg, 1.1 eq) in H2O (2.0 mL) was added.  The resulting mixture 
was stirred for 30 min at 0 ºC then 20 h at 4 ºC.  EtOAc (40 mL) and a solution of KCN 
(180 mg, 1.1 eq) in H2O (3.0 mL) were added and the mixture was stirred vigorously at r.t. 
for 4.5 h then the layers were separated.  The organic layer was washed with H2O (50 mL 
× 2), brine (50 mL), dried over MgSO4 and concentrated.  The crude material was purified 
by flash chromatography, eluting with 1:9 EtOAc/DCM to give 4.12 (620 mg, 79 %) as a 
white solid: 
1H NMR (500 MHz, (CD3)2SO) δ 2.61 (0.4H, dd, J = 10.9, 13.0 Hz), 2.71 (0.6H, dd, J = 
11.2, 13.8 Hz), 2.99 (1H, m), 3.90 (1H, m, CHNH), 4.41 (0.4H, m), 4.61 (0.6H, m), 4.96 
(2H, s, OCH2), 6.81 (0.6H, d, J = 5.7 Hz), 6.86 (0.4H, d, J = 7.2), 7.17-7.34 (10H, m), 7.54 
(0.4H, d, J = 9.4), 7.68 (0.6H, d, J = 8.6). 
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(2R,3S)-3-Benzyloxycarbonylamino-2-hydroxy-4-phenyl-butyric acid methyl ester 
4.13 and (2S,3S)-3-Benzyloxycarbonylamino-2-hydroxy-4-phenyl-butyric acid methyl 
ester 4.14:17, 20  
 
  
 
 
 
An HCl saturated mixture of ether (7.5 mL) and dry MeOH (2.5 mL) was cooled to 0 ºC 
and 4.12 (200 mg, 0.64 mmol) was added.  The resulting mixture was stirred for 24 h at  
4 ºC, then cold H2O (0 ºC, 2.5 mL) was added slowly.  The mixture was stirred at 4 ºC for 
48 h, then concentrated.  The crude material was purified by flash chromatography, eluting 
with 2:3 EtOAc/pet ether to give 4.13 (73 mg, 33%):  
mp: 95-96 ºC (lit.20 94-95 ºC) 
[α]D20: -76.4 º (c = 1.0, MeOH)  
1H NMR (500 MHz, CDCl3) δ 2.87-2.99 (2H, m, CHCH2), 3.11 (1H, d, J = 3.5 Hz), 3.71 
(3H, s, OMe), 4.08 (1H, s), 4.33 (1H, m, CHNH), 5.02-5.08 (3H, m), 7.19-7.38 (10H, m). 
 
then 4.14 (42 mg, 19%):  
mp: 119-120 ºC (lit.20 121-122 ºC) 
[α]D20: -158.0 º (c = 1.0, MeOH) 
1H NMR (500 MHz, CDCl3) δ 2.81 (2H, m, CHCH2), 3.19 (1H, s), 3.57 (3H, s, OMe), 
4.32-4.43 (2H, m), 5.03-5.12 (3H, m), 7.17-7.37 (10H, m). 
 
(2R,3S)-3-Amino-2-hydroxy-4-phenyl-butyric acid methyl ester 4.9:21  
 
 
 
 
To a solution of 4.13 (40 mg, 0.064 mmol) in EtOAc (5 mL) was added Pd/C (5.0 mg).  
The resulting mixture was evacuated then stirred for 16 hours under a H2 atmosphere, 
filtered through celite-545 filter aid and concentrated to obtain 4.9 (25 mg, qu) as a pale 
yellow gel which was used in subsequent reactions without further purification:  
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Selected peaks from 1H NMR (500 MHz, CDCl3) δ 2.75 (1H, dd, J = 8.3, 13.2 Hz), 2.93 
(1H, dd, J = 6.5, 13.2 Hz), 3.39 (1H, s), 3.78 (3H, s, OMe), 4.09 (1H, s), 7.18-7.36 (5H, m). 
HRMS (ES): Calcd. for C11H16NO3 (MH+) 210.1130, found 210.1122. 
 
(2R,3S,E)-methyl 3-(4-((4-((2-(tert-butoxycarbonylamino)acetamido)methyl)phenyl) 
diazenyl) benzamido)-2-hydroxy-4-phenylbutanoate 4.15:  
 
 
 
 
 
 
To a solution of 2.42 (20 mg, 0.048 mmol), 4.9 (10 mg, 1 eq), EDCI (10 mg, 1.1 eq) and 
HOBt (7.0 mg, 1.1 eq) in DMF (2.0 mL) was added DIEA (18 μL, 2.2 eq) and the 
resulting mixture was stirred for 16 h, diluted with EtOAc (50 mL), washed with H2O (50 
mL × 2), brine (50 mL), dried over MgSO4 and concentrated.  The crude product was 
purified by column chromatography, eluting with EtOAc to give 4.15 (20 mg, 69%) as an 
orange gel:  
[α]D = -73.9 º (c = 1.0, MeOH) 
1H NMR (500 MHz, CDCl3) δ  1.43 (9H, s, CMe3), 3.04-3.14 (2H, m), 3.73 (3H, s, OMe), 
3.88 (2H, s), 4.27 (1H, d, J = 1.9 Hz), 4.45 (2H, m), 4.85 (1H, m), 5.62 (1H, s), 7.00 (1H, d, 
J = 9.2 Hz), 7.18-7.37 (8H, m), 7.73-7.76 (5H, m). 
13C NMR (126 MHz, CDCl3) δ 28.3, 37.8, 42.9, 52.8, 53.7, 70.5, 80.4, 122.8, 123.3, 126.8, 
127.9, 128.0, 128.6, 129.4, 135.8, 137.3, 141.5, 151.6, 154.0, 166.8, 170.1, 174.1. 
HRMS (ES): Calcd. for C32H38N5O7 (MH+) 604.2771, found 604.2792. 
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(S,E)-methyl-3-(4-((4-((2-(tert-butoxycarbonylamino)acetamido)methyl)phenyl) 
diazenyl)benzamido)-2-oxo-4-phenylbutanoate 4.5:   
 
 
 
 
 
 
A solution of alcohol 4.15 (13 mg, 0.022 mmol) and Dess-Martin periodinane (19 mg, 2 
eq) in DCM (1.0 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with 
Na2S2O3 (0.25 M in sat. NaHCO3, 50 mL × 2), sat. NaHCO3 (50 mL × 2), brine (50 mL), 
dried over MgSO4 and concentrated.  The crude material was purified by column 
chromatography, eluting with EtOAc to give 4.5 (11 mg, 83%) as an orange gel:  
[α]D = -85.6 º (c = 1.0, MeOH) 
1H NMR (300 MHz, (CDCl3) δ 1.43 (9H, s, CMe3), 3.23 (1H, dd, J = 14.1, 6.8 Hz, 
CHCHH), 3.40 (1H, dd, J = 14.3, 6.0 Hz, CHCHH), 3.83-3.93 (5H, m), 4.51 (2H, d, J = 
5.9 Hz), 5.37 (1H, s), 5.62 (1H, q, J = 6.7 Hz, CHCH2), 6.88-6.98 (2H, m), 7.18 (2H, d, J = 
6.4 Hz), 7.25-7.39 (5H, m), 7.76-7.89 (6H, m). 
13C NMR (75 MHz, (CDCl3) δ 28.3, 36.7, 42.9, 44.5, 53.3, 57.1, 80.4, 122.9, 123.4, 127.4, 
128.1, 128.1, 128.8, 129.4, 134.7, 135.1, 141.8, 151.7, 154.4, 156.2, 160.7, 166.5, 169.8, 
191.5. 
HRMS (ES): Calcd. for C32H36N5O7 (MH+) 602.2614, found 602.2632. 
 
(E)-((4-[4-(1-Benzyl-3,3,3-trifluoro-2-hydroxy-propylcarbamoyl)-phenylazo)-benzyl 
carbamoyl)-methyl)-carbamic acid tert-butyl ester 4.16:  
 
 
 
 
 
 
To a solution of carboxylic acid 2.42 (20 mg, 0.049 mmol), amine 4.822 (supplied by 
Nathan Alexander6, 11 mg, 1 eq), EDCI (10 mg, 1 eq) and HOAt (7.0 mg, 1 eq) in DMF 
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(3.0 mL) was added DIEA (9.0 μL, 6.7 mg, 1 eq) and the resulting mixture was stirred for 
16 h, diluted with EtOAc (50 mL), washed with H2O (50 mL × 2), brine (50 mL), dried 
over MgSO4 and concentrated.  The crude product was purified by flash chromatography, 
eluting with 3:2 EtOAc/DCM to give 4.16 (15 mg, 50%) as an orange solid:  
1H NMR (500 MHz, (CD3)2CO) δ 1.42 (9H, s, C(CH3)3), 3.17 (2H, m, CHCH2), 3.84 (2H, 
d, J = 5.7 Hz), 4.23 (1H, m), 4.53 (2H, d, J = 6.0 Hz), 4.72 (1H, m), 6.35-6.40 (2H, m), 
7.21 (1H, t, J = 7.4 Hz, CHCHCHCHCH), 7.30 (2H, t, J = 7.4 Hz, CHCHCHCHCH), 7.37 
(2H, d, J = 7.4 Hz, CHCHCHCHCH), 7.50 (2H, d, J = 8.0 Hz), 7.83-7.96 (6H, m), 7.98 
(2H, d, J = 8.5 Hz). 
13C NMR (126 MHz, (CD3)2CO) δ 28.5, 37.9, 43.0, 44.8, 52.2, 70.5 (q, J = 29.5 Hz), 79.4, 
123.3, 123.8, 127.4, 128.9, 129.2, 129.3, 130.2, 137.4, 138.9, 144.5, 152.3, 154.9, 156.9, 
167.3, 170.7. 
19F NMR  (282 MHz, CD3OD) δ -74.69 (d, J = 7.3 Hz), -75.97 (d, J = 7.4 Hz). 
HRMS (ES): Calcd. for C31H35F3N5O5 (M - CF3COO)+ 614.2590, found 614.2602.  
 
(E)-((4-(4-(1-Benzyl-3,3,3-trifluoro-2-oxo-propylcarbamoyl)-phenylazo)-benzyl 
carbamoyl)-methyl)-carbamic acid tert-butyl ester 4.1: 
 
 
 
 
 
 
A solution of 4.16 (7.0 mg, 0.011 mmol) and Dess-Martin periodinane23 (20 mg, 7 eq) in 
DCM (0.5 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with Na2S2O3 
(0.25 M in sat. NaHCO3, 50 mL), sat. NaHCO3 (50 mL × 2), brine (50 mL), dried over 
MgSO4 and concentrated.  The crude material was purified by column chromatography, 
eluting with 4:1 EtOAc/DCM to give 4.1 (3.0 mg, 44%, predominantly hydrate isomer 
with traces of ketone) as an orange solid:  
1H NMR (500 MHz, (CD3)2CO) δ 1.42 (9H, s, C(CH3)3), 3.25 (1H, m, CHCHH), 3.39 (1H, 
m, CHCHH), 3.81 (2H, d, J = 5.2 Hz), 4.42 (1H, m, CHCH2), 4.53 (2H, d, J = 5.5 Hz), 
6.32 (1H, s), 6.80 (1H, s), 7.13-7.38 (6H, m), 7.51 (2H, d, J = 7.8 Hz), 7.80-7.92 (7H, m), 
8.22 (1H, d, J = 8.0 Hz). 
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selected peaks from 13C NMR (75 MHz, (CD3)2CO) δ 28.5, 33.7, 43.0, 44.8, 58.6, 79.4, 
95.4 (q, J = 29.9Hz), 123.3, 123.8, 127.2, 129.0, 129.2, 129.5, 130.1, 136.7, 139.5, 144.8, 
152.3, 155.1, 169.7, 170.6. 
HRMS (ES): Calcd. for C32H37F3N5O6 (M + CH3OH)+ 644.2696, found 644.2717.  
 
(E)-Azobenzene-4,4ʹ-dicarboxylic acid 4.20:24  
 
 
 
 
 
A mixture of 4-nitrobenzoic acid 4.19 (13 g, 78 mmol), NaOH (50 g) and H2O (230 mL) 
was warmed to 50 ºC and a solution of glucose (100 g, 7.2 eq) in H2O (150 mL) was added.  
The resulting mixture was stirred vigorously in air for 16 hours, then acidified by addition 
of HCl (1.0 M) and filtered to collect a brown precipitate.  The crude material was 
recrystallised from a solution of K2CO3, then acidified by HCl (1.0 M) and filtered to 
obtain 4.20 (7.0 g, 33%) as an orange solid:  
mp > 360 ºC 
1H NMR (300 MHz, D2O) δ 8.01 (4H, d, J = 8.4 Hz), 7.88 (4H, d, J = 8.4 Hz). 
 
(E)-Azobenzene-4,4ʹ-diacid chloride 4.21:24, 25 
 
 
 
 
 
A solution of 4.20 (1.0 g, 3.7 mmol) in 1,2-dichloroethane (15 mL) was cooled to 0 ºC, 
and PCl5 (2.0 g, 2.6 eq) was added.  The resulting mixture was refluxed for 2 h, cooled and 
filtered to collect a red precipitate.  The crude material was purified by flash 
chromatography, eluting with 1:1 DCM/pet ether to obtain 4.21 (540 mg, 47%) as a red 
solid:  
mp: 161-163 ºC (lit.24 164 ºC)  
1H NMR (500 MHz, CDCl3) δ 8.31 (4H, d, J = 8.8 Hz), 8.07 (4H, d, J = 8.8 Hz). 
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2-(2-(2-(2-Prop-2-ynyloxy-ethoxy)-ethoxy)-ethoxy)-ethanol 4.23:26   
 
 
 
A solution of tetraethylene glycol 4.22 (8.2 g, 42 mmol) in THF (10 mL) was cooled to  
0 ºC and NaH (60 % in mineral oil, 340 mg, 1 eq) was added.  The resulting mixture was 
stirred for 20 min, then propargyl bromide (80% in toluene, 1.3 g, 8.7 mmol) was added 
slowly, and the mixture was stirred overnight, warming to r.t., then concentrated.  The 
crude material was purified by flash chromatography, eluting with 1:9 MeOH/EtOAc to 
give 4.23 (1.1 g, 54%) as a yellow oil: 
1H NMR (500 MHz, CDCl3) δ 2.07-2.26 (1H, br s, OH), 2.43 (1H, t, J = 2.4 Hz, CH), 
3.60-3.75 (16H, m), 4.21 (2H, d, J = 2.4 Hz, CHCCH2). 
13C NMR (75 MHz, CDCl3) δ 58.5, 61.9, 69.2, 70.5, 70.5, 70.7, 70.7, 70.8, 73.7, 74.7, 79.7. 
 
(E)-4-(4-Chlorocarbonyl-phenylazo)-benzoic acid 2-(2-(2-(2-prop-2-ynyloxy-ethoxy)- 
ethoxy)-ethoxy)-ethyl ester 4.24: 
 
 
 
 
 
A solution of 4.23 (100 mg, 0.43 mmol) in THF (5.0 mL) was cooled to 0 ºC and TEA (1.0 
mL) then a solution of 4.21 (260 mg, 2 eq) in THF (13 mL) were added.  The solution was 
stirred for 2 h, at which point TLC showed that the acid chloride had been consumed.  The 
mixture was diluted with EtOAc (50 mL) and filtered to obtain an orange precipitate and 
an orange filtrate.  The ester 4.24 was not detected in either sample by 1H NMR. 
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(E)-4-(4-(1-Benzyl-3,3,3-trifluoro-2-hydroxy-propylcarbamoyl)-phenylazo)-benzoyl 
chloride 4.25:  
 
 
 
 
 
 
To a solution of amine 4.822 (supplied by Nathan Alexander6, 35 mg, 0.16 mmol) in DCM 
(5.0 mL) was added DIEA (29 μL, 22 mg, 1 eq) then a solution of 4.21 (100 mg, 2 eq) in 
DCM (5.0 mL) was added.  The resulting mixture was stirred overnight, then washed with 
HCl (1.0 M, 20 mL), brine (20 mL), dried over MgSO4 and concentrated.  The crude 
product was purified by flash chromatography, eluting with 1:19 EtOAc/DCM to give 4.25 
(30 mg, 38%) as a red-orange solid:  
mp: 168-170 ºC 
1H NMR (500 MHz, CDCl3) δ 3.10 (1H, dd, J = 13.8, 7.8 Hz, CHH), 3.33 (1H, dd, J = 
13.8, 7.8 Hz, CHH), 4.11 (1H, m), 4.41 (1H, dq, J = 7.8, 2.2 Hz, CHCH2), 4.77 (1H, d, J = 
7.1 Hz), 6.62 (1H, d, J = 7.8 Hz, NH), 7.25-7.37 (5H, m), 7.83 (2H, d, J = 8.3 Hz), 7.98-
8.04 (4H, m), 8.29 (2H, d, J = 8.4 Hz). 
13C NMR (75 MHz, (CD3)2CO) δ 37.9, 52.1, 70.4 (q, J = 28.5 Hz, CHCF3), 123.9, 124.1, 
127.4, 129.3, 129.4, 130.2, 133.5, 135.5, 138.7, 138.9, 154.7, 157.0, 167.0, 168.1. 
HRMS (ES): Calcd. for C25H23F3N3O4 (M – Cl + OCH3 + H+) 486.1641, found 486.1661.  
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(E)-4-(4-(1-Benzyl-3,3,3-trifluoro-2-hydroxy-propylcarbamoyl)-phenylazo)-benzoic 
acid 2-(2-(2-(2-prop-2-ynyloxy-ethoxy)-ethoxy)-ethoxy)-ethyl ester 4.26: 
 
 
 
 
 
 
To a solution of 4.25 (20 mg, 0.042 mmol) and 4.23 (10 mg, 1 eq) in DCM (3.0 mL) was 
added DIEA (8.0 μL, 1 eq) and the resultant mixture was stirred for 16 h.  TLC showed 
only returned starting materials. 
 
(R)-2-tert-Butoxycarbonylamino-propionic acid 2-(2-(2-(2-prop-2-ynyloxy-ethoxy)- 
ethoxy)-ethoxy)-ethyl ester 4.27:  
 
 
 
A solution of 4.23 (100 mg, 0.43 mmol), Boc-Ala-OH (82 mg, 1 eq), EDCI (83 mg, 1 eq) 
and DMAP (7.0 mg, 1 eq) in DCM (3.0 mL) was stirred for 16 h, diluted with EtOAc (50 
mL), washed with H2O (50 mL × 2), brine (50 mL), dried over MgSO4 and concentrated.  
The crude product was purified by flash chromatography, eluting with 1:1 EtOAc/DCM to 
give 4.27 (160 mg, 94%) as a colourless oil: 
[α]D20: -127.0 º (c = 0.63, MeOH) 
1H NMR (500 MHz, CDCl3) δ 1.39 (3H, d, J = 7.2 Hz, CHMe), 1.45 (9H, s, C(CH3)3), 
2.43 (1H, t, J = 2.4 Hz, CHCCH2), 3.64-3.72 (14H, m), 4.21 (2H, d, J = 2.4 Hz, CHCCH2), 
4.25-4.37 (3H, m), 5.05-5.12 (1H, br s, NH). 
13C NMR (75 MHz, CDCl3) δ 18.1, 28.0, 48.9, 58.0, 64.0, 68.6, 68.7, 70.0, 70.2, 74.6, 79.3, 
154.9, 173.0. 
HRMS (ES): Calcd. for C19H33NNaO8 (MNa+) 426.2104, found 426.2090.  
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(R)-2-Amino-propionic acid 2-(2-(2-(2-prop-2-ynyloxy-ethoxy)-ethoxy)-ethoxy)-ethyl 
ester trifluoroacetate 4.28:  
 
 
 
To a solution of 4.27 (150 mg, 0.37 mmol) in DCM (0.8 mL) was added TFA (0.2 mL) 
and the resulting mixture was stirred for 30 min then concentrated to give 4.28 (210 mg) as 
a pale yellow oil which was used subsequently without further purification: 
Selected peaks from 1H NMR (500 MHz, CDCl3) δ 1.61 (3H, d, J = 7.1 Hz, Me), 2.51 (1H, 
t, J = 2.0 Hz, CHCCH2), 3.63-3.77 (14H, m), 4.15-4.28 (3H, m), 4.34 (1H, m), 4.51 (1H, 
m). 
Selected peaks from 13C NMR (75 MHz, CDCl3) δ 15.9, 49.4, 58.4, 65.0, 68.6, 68.8, 69.9, 
70.0, 70.1, 70.1, 70.2, 75.4, 79.0, 169.8. 
HRMS (ES): Calcd. for C14H26NO6 (MH+) 304.1760, found 304.1745.  
 
(R,E)-2-(4-(4-Chlorocarbonyl-phenylazo)-benzoylamino)-propionic acid 2-(2-(2-(2- 
prop-2-ynyloxy-ethoxy)-ethoxy)-ethoxy)-ethyl ester 4.29: 
 
 
 
 
 
To a solution of 4.28 (68 mg, 0.16 mmol) in DCM (5.0 mL) was added DIEA (120 μL,  
4 eq) then a solution of 4.21 (100 mg, 2 eq) in DCM (5.0 mL).  The resultant mixture was 
stirred for 16 h then filtered to obtain an orange precipitate and an orange filtrate.  MS 
showed the presence of 4.29 in the filtrate, but only traces of azobenzene products could be 
identified in this sample by TLC and NMR. 
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(R,E)-2-(4-(4-(1-Benzyl-3,3,3-trifluoro-2-hydroxy-propylcarbamoyl)-phenylazo)-
benzoylamino)-propionic acid 2-(2-(2-(2-prop-2-ynyloxy-ethoxy)-ethoxy)-ethoxy)- 
ethyl ester 4.30: 
 
 
 
 
 
 
To a solution of acid chloride 4.25 (14 mg, 0.030 mmol) and alcohol 4.28 (16 mg, 1.3 eq) 
in DCM (2.0 mL) was added DIEA (21 μL, 16 mg, 4 eq) and the resulting mixture was 
stirred for 16 h, diluted with EtOAc (50 mL), washed with HCl (1.0 M, 50 mL), sat. 
NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The crude product 
was purified by flash chromatography, eluting with EtOAc to give 4.30 (16 mg, 70% over 
two steps) as a colourless oil: 
1H NMR (500 MHz, CDCl3) δ 1.62 (3H, d, J = 7.2 Hz, Me), 2.43 (1H, t, J = 2.4 Hz, 
CHCCH2O), 3.12 (1H, m, CHCHH), 3.23 (1H, dd, J = 13.3, 7.0 Hz, CHCHH), 3.62-3.70 
(12H, m), 3.76 (2H, t, J = 4.7 Hz), 4.08 (1H, s), 4.17 (2H, d, J = 2.1 Hz, CHCCH2O), 4.38 
(2H, dd, J = 8.1, 3.9 Hz), 4.65 (1H, m), 4.82 (1H,  p, J = 7.1 Hz, CHCH3), 5.71 (1H, s), 
7.26 (1H, t, J = 7.2 Hz), 7.30-7.37 (4H, m), 7.48-7.70 (10H, m). 
13C NMR (75 MHz, CDCl3) δ 17.7, 37.6, 49.0, 51.1, 58.3, 64.5, 68.8, 69.0, 70.2, 70.4, 70.5, 
70.5, 74.8, 79.5, 122.6, 126.9, 127.8, 128.0, 128.7, 129.4, 135.8, 136.4, 137.0, 153.2, 153.3, 
167.7, 168.0, 172.7. 
HRMS (ES): Calcd. for C38H44F3N4O9 (MH+) 757.3060, found 757.3094.  
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(R,E)-2-(4-(4-(1-Benzyl-3,3,3-trifluoro-2-oxo-propylcarbamoyl)-phenylazo)-
benzoylamino)-propionic acid 2-(2-(2-(2-prop-2-ynyloxy-ethoxy)-ethoxy)-ethoxy)- 
ethyl ester 4.2:  
 
 
 
 
 
 
A solution of alcohol 4.30 (31 mg, 0.041 mmol) and Dess-Martin periodinane (38 mg, 3.7 
eq) in DCM (3.0 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with 
Na2S2O3 (0.25 M in sat. NaHCO3, 50 mL × 2), sat. NaHCO3 (50 mL × 2), brine (50 mL), 
dried over MgSO4 and concentrated.  The crude material was purified by flash 
chromatography, eluting with EtOAc to give 4.2 (32 mg, qu, a 2:3 mixture of 
ketone/hydrate), as an orange gel: 
[α]D20: +21.1º (c = 0.29, MeOH) 
1H NMR (500 MHz, (CD3)2CO) δ 1.54 (3H, d, J = 7.3 Hz, Me), 2.92 (1H, t, J = 2.4 Hz, 
CHCCH2O), 3.27 (1H, m, CHCHH), 3.40 (1H, m, CHCHH), 3.53-3.64 (12H, m), 3.68-
3.72 (2H, m, CH2CH2OCO), 4.17 (2H, d, J = 2.4 Hz, CHCCH2O) 4.24 (1H, m, 
CH2CHHOCO), 4.31 (1H, m, CH2CHHOCO), 4.47 (0.6H, t, J = 8.8 Hz, CHCH2 (hydrate 
isomer)), 4.71 (1H, p, J = 7.3 Hz, CHMe), 5.26 (0.4H, dt, J = 9.3, 6.0 Hz), 6.79 (0.4H, s), 
7.12 (0.4H, s), 7.19 (1H, t, J = 7.4 Hz), 7.23-7.39 (4H, m), 7.89 (2H, m), 7.94-8.01 (4H, m), 
8.10 (2H, m), 8.18-8.25 (1.6H, m, NHCHCH2(hydrate isomer) and NHCHMe), 8.69 (0.4H, 
d, J = 6.7 Hz). 
HRMS (ES): Calcd. for C38H44F3N4O10 (MH3O+) 773.3010, found 773.3019.  
 
4-Nitroso-benzoic acid methyl ester 4.35:27 
 
 
 
To a solution of 4-methyl aminobenzoate 4.34 (1.0 g, 6.6 mmol) in DCM (20 mL) was 
added Oxone (8.2 g, 2 eq) in H2O (80 mL) and the resulting mixture was stirred vigorously 
for 30 min, then the layers were separated.  The organic layer was washed with H2O (50 
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mL), brine (50 mL), dried over MgSO4 and concentrated.  The crude product was purified 
by flash chromatography, eluting with DCM to give 4.35 (680 mg, 62%) as an green solid:  
mp 123-124 ºC 
1H NMR (300 MHz, CDCl3) δ 3.99 (3H, s, Me), 7.94 (2H, d, J = 8.7 Hz), 8.31 (2H, d, J = 
8.7 Hz). 
 
(E)-4-(4-Bromo-phenylazo)-benzoic acid methyl ester 4.37:27  
 
 
 
 
 
Method A: 
A mixture of bromoaniline 4.36 (170 mg, 1.0 mmol), nitrosobenzene 4.35 (200 mg, 1.2 eq) 
and AcOH (7.0 mL) stirred for 16 h at 40 ºC, then further bromoaniline 4.36 (90 mg, 0.5 
eq) was added.  The mixture was stirred for a further 4 h at 40 ºC then cooled and 
concentrated.  The crude material was purified by flash chromatography, eluting with 4:1 
DCM/pet. ether to give 4.37 (99 mg, 30%) as an orange solid: 
mp 136 ºC (decomp) 
1H NMR (300 MHz, CDCl3) δ 3.96 (3H, s, Me), 7.67 (2H, d, J = 8.8 Hz), 7.83 (2H, d, J = 
8.8 Hz), 7.95 (2H, d, J = 8.8 Hz), 8.19 (2H, d, J = 8.8 Hz). 
 
Method B: 
A mixture of nitrosobenzene 4.38 (200 mg, 1.1 mmol), 4-methyl aminobenzoate 4.34 (180 
mg, 1.1 eq) and AcOH (5.0 mL) was stirred for 16 h then filtered to collect an orange 
precipitate.  The precipitate was purified by flash chromatography, eluting with 4:1 
DCM/pet ether to obtain 4.37 (180 mg, 52%) as an orange solid. 
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1-Bromo-4-nitroso-benzene 4.38:27  
 
 
 
To a solution of bromoaniline 4.36 (5.0 g, 29 mmol) in DCM (90 mL) was added Oxone 
(36 g, 2 eq) in H2O (360 mL) and the resulting mixture was stirred vigorously for 3 h 10 
min, then the layers were separated.  The organic layer was washed with HCl (1.0 M, 50 
mL), sat. NaHCO3 (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The 
crude product was purified by flash chromatography, eluting with 1:9 EtOAc/pet ether to 
give 4.38 (5.3 g, 98%) as an green solid: 
1H NMR (500 MHz, CDCl3) δ 7.76-7.81 (4H, m). 
 
(E)-4-(4-(3-Hydroxy-3-methyl-but-1-ynyl)-phenylazo)-benzoic acid methyl ester 4.39:   
 
 
 
 
 
 
To a solution of 4.37 (3.0 g, 9.4 mmol), 2-methyl-3-butyn-2-ol (930 mg, 1.2 eq), PPh3 (28 
mg, 0.12 eq) and CuI (7.0 mg, 0.0039 eq) in TEA (50 mL) was added PdCl2(PPh3)2 (8.0 
mg, 0.012 eq).  The resulting mixture was refluxed for 1 h, then cooled and concentrated.  
The crude product was purified by flash chromatography, eluting with 1:9 EtOAc/DCM to 
give 4.39 (2.8 g, 93%) as an orange solid:  
mp 198-201 ºC 
1H NMR (500 MHz, CDCl3) δ 1.65 (6H, s), 3.96 (3H, s), 7.57 (2H, d, J = 8.4 Hz), 7.90 
(2H, d, J = 8.4 Hz), 7.95 (2H, d, J = 8.5 Hz), 8.19 (2H, d, J = 8.5 Hz). 
13C NMR (75 MHz, CDCl3) δ 31.6, 52.5, 65.8, 81.9, 96.8, 122.9, 123.2, 126.3, 130.8, 
132.1, 132.7, 151.8, 155.2, 166.6. 
HRMS (ES): Calcd. for C19H19N2O3 (MH+) 323.1396, found 323.1396.  
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(E)-4-(4-Ethynyl-phenylazo)-benzoic acid 4.40:  
 
 
 
 
 
A solution of NaOH (150 mg) in butanol (8.0 mL) was heated to reflux and ester 4.39 (20 
mg, 0.062 mmol) was added.  The resulting mixture was refluxed for 15 min, then cooled 
and filtered to collect an orange precipitate which was washed with DCM (50 mL) then 
dissolved in MeOH (20 mL), acidified with HCl (1.0 M) and filtered to collect 4.40 (11 mg, 
71%) as a pale orange solid:  
mp 210 ºC (decomp) 
1H NMR (500 MHz, (CD3)2SO) δ 4.50 (1H, s, CHCC6H4), 7.72 (2H, d, J = 8.6 Hz), 7.94 
(2H, d, J = 8.6 Hz), 7.99 (2H, d, J = 8.6 Hz), 8.15 (1H, d, J = 8.6 Hz). 
13C NMR (75 MHz, (CD3)2SO) δ 83.0, 83.9, 122.7, 123.1, 125.3, 130.7, 133.0, 133.1, 
151.4, 154.2, 166.7. 
HRMS (ES): Calcd. for C15H11N2O2 (MH+) 251.0821, found 251.0819.  
 
(E)-N-(1-Benzyl-3,3,3-trifluoro-2-hydroxy-propyl)-4-(4-ethynyl-phenylazo)-
benzamide 4.41: 
 
 
 
 
 
To a solution of carboxylic acid 4.40 (150 mg, 0.60 mmol), amine 4.822 (supplied by 
Nathan Alexander6, 130 mg, 1 eq), EDCI (120 mg, 1 eq) and HOAt (81 mg, 1 eq) in DMF 
(8.0 mL) was added DIEA (210 μL, 160 mg, 2 eq) and the resulting mixture was stirred for 
16 h, diluted with DCM (50 mL), washed with H2O (50 mL), brine (50 mL), dried over 
MgSO4 and concentrated.  The crude product was purified by column chromatography, 
eluting with a gradient from DCM to 1:19 EtOAc/DCM to give 4.41 (150 mg, 56%) as an 
orange solid:  
mp: 173-174 ºC 
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1H NMR (500 MHz, CDCl3) δ 3.10 (1H, dd, J = 13.8, 7.7 Hz, CHH), 3.26 (1H, s, 
CHCC6H4), 3.33 (1H, dd, J = 13.8, 8.0 Hz, CHH), 4.10 (1H, m), 4.36 (1H, dq, J = 7.9, 2.6 
Hz), 4.91 (1H, d, J = 7.3 Hz), 6.59 (1H, d, J = 7.6 Hz), 7.25-7.36 (5H, m, Ph), 7.65 (2H, d, 
J = 8.4 Hz), 7.79 (2H, d, J = 8.4 Hz), 7.94 (2H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.4 Hz). 
13C NMR (75 MHz, (CD3)2CO) δ 37.9, 52.2, 70.4 (q, J = 29.6 Hz, CHCF3), 82.1, 83.6, 
123.5, 123.9, 126.4, 127.4, 129.3, 129.3, 130.2, 133.8, 137.9, 138.9, 152.8, 154.8, 167.2. 
HRMS (ES): Calcd. for C25H21F3N3O2 (MH+) 452.1586, found 452.1571.  
 
(E)-N-(1-Benzyl-3,3,3-trifluoro-2-oxo-propyl)-4-(4-ethynyl-phenylazo)-benzamide 
4.3:  
 
 
 
 
 
 
A solution of alcohol 4.41 (54 mg, 0.12 mmol) and Dess-Martin periodinane (110 mg, 3.7 
eq) in DCM (5.0 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with 
Na2S2O3 (0.25 M in sat. NaHCO3, 50 mL × 2), sat. NaHCO3 (50 mL × 2), brine (50 mL), 
dried over MgSO4 and concentrated.  The crude material was purified by flash 
chromatography, eluting with 1:19 EtOAc/DCM to give 4.3 (49 mg, 91%, a 1:3 mixture of 
ketone/hydrate) as an orange solid:  
mp: 187-189 ºC 
1H NMR (500 MHz, (CD3)2CO) δ 3.25 (1H, m, CHH), 3.38 (1H, m, CHH), 3.92 (1H, s, 
CHCC6H4), 4.40 (0.75H, m, CHCH2 (hydrate isomer)), 5.24 (0.25H, m, CHCH2 (ketone 
isomer)), 6.77 (0.75H, s, OH), 7.12 (0.75H, s, OH), 7.19 (1H, t, J = 7.3 Hz), 7.24-7.38 (4H, 
m), 7.72 (2H, d, J = 8.6 Hz), 7.89-8.04 (6H, m), 8.20 (0.75H, d, J = 8.4 Hz, NH (hydrate 
isomer)), 8.62 (0.25H, d, J = 7.0 Hz, NH (ketone isomer)). 
selected peaks from 13C NMR (75 MHz, (CD3)2CO) δ 33.7, 58.5, 82.1, 83.6, 95.3 (q, J = 
30.1 Hz, CHCF3), 123.5, 123.9, 126.5, 127.2, 129.2, 129.5, 130.1, 133.8, 137.1, 139.5, 
152.8, 154.9, 169.6. 
HRMS (ES): Calcd. for C25H19F3N3O2 (MH+) 450.1429, found 450.1408.  
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(2R,3S,E)-methyl 3-(4-((4-ethynylphenyl)diazenyl)benzamido)-2-hydroxy-4-phenyl 
butanoate 4.42:  
 
 
 
 
 
To a solution of carboxylic acid 4.39 (12 mg, 0.048 mmol), amine 4.9 (10 mg, 1 eq), EDCI 
(10 mg, 1.1 eq) and HOBt (7.0 mg, 1.1 eq) in DMF (2.0 mL) was added DIEA (18 μL, 2.2 
eq) and the resulting mixture was stirred for 16 h, diluted with EtOAc (50 mL), washed 
with H2O (50 mL × 2), brine (50 mL), dried over MgSO4 and concentrated.  The crude 
product was purified by column chromatography, eluting with 1:9 EtOAc/DCM to give 
4.42 (13 mg, 61%) as an orange solid:  
mp: 187-191 ºC 
[α]D = -130.3 º (c = 0.65, MeOH) 
1H NMR (500 MHz, CDCl3) δ  3.02-3.14 (2H, m, CHCH2), 3.26 (1H, s), 3.75 (3H, s, 
OMe), 4.24 (1H, d, J = 1.6 Hz), 4.84 (1H, m, CHNH), 6.65 (1H, d, J = 9.2 Hz, NH), 7.24 
(1H, m), 7.30-7.37 (5H, m), 7.62 (2H, d, J = 8.5 Hz), 7.80 (2H, d, J = 8.5 Hz), 7.85-7.90 
(4H, m). 
13C NMR (126 MHz, CDCl3) δ 37.9, 53.0, 53.4, 70.1, 79.9, 83.1, 123.0, 123.0, 125.3, 
126.8, 128.0, 128.7, 129.4, 133.0, 136.2, 137.1, 151.9, 154.1, 166.5, 174.2. 
HRMS (ES): Calcd. for C26H24N3O4 (MH+) 442.1767, found 442.1769. 
 
(S,E)-methyl 3-(4-((4-ethynylphenyl)diazenyl)benzamido)-2-oxo-4-phenylbutanoate 
4.6:  
 
 
 
 
 
A solution of alcohol 4.42 (11 mg, 0.025 mmol) and Dess-Martin periodinane (21 mg, 2 
eq) in DCM (1.0 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with 
Na2S2O3 (0.25 M in sat. NaHCO3, 50 mL × 2), sat. NaHCO3 (50 mL × 2), brine (50 mL), 
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dried over MgSO4 and concentrated.  The crude material was purified by column 
chromatography, eluting with 1:1 EtOAc/pet ether to give 4.6 (10 mg, 91%) as an orange 
solid:  
mp: 156-161 ºC 
[α]D = -166.4 º (c = 1.0, MeOH) 
1H NMR (300 MHz, (CD3)2CO) δ 3.13 (1H, dd, J = 14.0, 9.3 Hz, CHCHH), 3.40 (1H, dd, 
J = 14.0, 5.2 Hz, CHCHH), 3.83 (3H, s, OMe), 3.92 (1H, s, CHCC6H4), 5.40 (1H, m, 
CHCH2), 7.19-7.41 (5H, m), 7.71 (2H, d, J = 8.5 Hz), 7.89-8.06 (6H, m), 8.39 (1H, d, J = 
6.6 Hz). 
13C NMR (75 MHz, (CD3)2CO) δ 36.1, 53.1, 58.7, 82.1, 83.6, 123.6, 123.9, 126.5, 127.6, 
129.3, 129.5, 130.2, 133.9, 136.9, 138.0, 152.8, 155.0, 162.2, 167.0, 192.5. 
HRMS (ES): Calcd. for C26H22N3O4 (MH+) 440.1610, found 440.1628. 
 
(E)-N-(1-Benzyl-3,3,3-trifluoro-2-hydroxy-propyl)-4-(4-(3-(2-(2-(2-(2-prop-2-ynyloxy-
ethoxy)-ethoxy)-ethoxy)-ethoxy)-prop-1-ynyl)-phenylazo)-benzamide 4.48:  
 
 
 
 
 
 
To a solution of carboxylic acid 4.47 (100 mg, 0.20 mmol), amine 4.822 (supplied by 
Nathan Alexander6, 44 mg, 1 eq), EDCI (43 mg, 1.1 eq) and HOBt (30 mg, 1.1 eq) in 
DMF (5.0 mL) was added DIEA (77 mL, 57 mg, 2.2 eq) and the resulting mixture was 
stirred for 19 h, diluted with EtOAc (50 mL), washed with H2O (50 mL × 4), brine (50 
mL), dried over MgSO4 and concentrated.  The crude product was purified by column 
chromatography, eluting with 2:3 EtOAc/DCM to give 4.48 (110 mg, 80%) as an orange 
gel:   
1H NMR (500 MHz, CDCl3) δ 2.54 (1H, s, OCH2CCH), 3.00-3.20 (2H, m, CHCH2), 3.55-
3.80 (16H, m), 4.18 (1H, t, J = 6.1 Hz), 4.24 (2H, d, J = 2.2 Hz, CHCCH2), 4.52 (2H, s), 
4.75 (1H, m, NHCH), 6.18 (1H, d, J = 7.0 Hz), 7.24-7.43 (5H, m), 7.50 (1H, d, J = 8.3 Hz), 
7.61 (2H, d, J = 8.4 Hz), 7.85-7.95 (6H, m). 
N
N
N
H
O
CF3
OH
O
O
O
O
O
Chapter Nine: Experimental 
 
216
 
13C NMR (126MHz, CDCl3) δ 37.6 (CHCH2), 51.0 (NHCH), 58.2, 59.0, 68.9, 69.2, 70.2, 
70.3, 70.4, 70.4, 70.4, 74.7, 79.5, 85.8, 87.9, 122.9, 123.0, 125.7, 126.9, 128.0, 128.6, 
129.2, 132.4, 135.8, 136.8, 151.5, 154.0, 167.6. 
HRMS (ES) Calcd. for C37H40F3N3NaO7 (MNa+) 718.2716, found 718.2735. 
 
(E)-N-(1-Benzyl-3,3,3-trifluoro-2-oxo-propyl)-4-(4-(3-(2-(2-(2-(2-prop-2-ynyloxy-
ethoxy)-ethoxy)-ethoxy)-ethoxy)-prop-1-ynyl)-phenylazo)-benzamide 4.4:  
 
 
 
 
 
 
A solution of 4.48 (31 mg, 0.045 mmol) and Dess-Martin periodinane (42 mg, 3.7 eq) in 
DCM (2.0 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with Na2S2O3 
(0.25 M in sat. NaHCO3, 50 mL × 2), sat. NaHCO3 (50 mL × 2), brine (50 mL), dried over 
MgSO4 and concentrated.  The crude material was purified by column chromatography, 
eluting with 1:1 EtOAc/DCM to give 4.4 (28 mg, 90%) as an orange gel:  
1H NMR (500 MHz, (CD3)2CO) δ 2.92 (1H, t, J = 2.4 Hz, OCH2CCH), 3.25 (1H, dd, J = 
12.1, 14.0 Hz, CHCH2), 3.40 (1H, dd, J = 3.1, 14.0 Hz, CHCH2), 3.55-3.65 (12, m), 3.67 
(2H, m), 3.74 (2H, m), 4.17 (2H, d, J = 2.4 Hz, CHCCH2O), 4.40-4.48 (3H, m), 6.80 (1H, 
s), 7.14 (1H, s), 7.19 (1H, t, J = 7.4 Hz), 7.27 (2H, t, J = 7.4 Hz), 7.34 (2H, d, J = 7.4 Hz), 
7.67 (2H, d, J = 8.6), 7.88-7.94 (6H, m), 8.20 (1H, d, J = 8.1 Hz). 
13C NMR (126MHz, (CD3)2CO) δ 33.7 (CHCH2), 58.5, 58.5, 59.3, 69.7, 70.0, 70.9, 71.1, 
71.2, 71.2, 75.7, 80.9, 85.8, 89.8, 95.3 (q, J = 29.8, CCF3), 123.4, 123.9, 127.0, 127.2, 
129.2, 129.5, 130.1, 133.5, 137.0, 139.5, 152.6, 155.0, 169.6. 
HMRS (ES) Calcd. for C37H40F3N3NaO8 (M + H2O + Na+) 734.2665, found 734.2652. 
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(2R,3S,E)-methyl 3-(4-((4-(4,7,10,13,16-pentaoxanonadeca-1,18-diynyl)phenyl)  
diazenyl)benzamido)-2-hydroxy-4-phenylbutanoate 4.49:  
 
 
 
 
 
 
 
To a solution of 4.47 (24 mg, 0.048 mmol), 4.9 (10 mg, 1 eq), EDCI (10 mg, 1.1 eq) and 
HOBt (7.0 mg, 1.1 eq) in DMF (2.0 mL) was added DIEA (18 μL, 2.2 eq) and the 
resulting mixture was stirred for 16 h, diluted with EtOAc (50 mL), washed with H2O (50 
mL × 2), brine (50 mL), dried over MgSO4 and concentrated.  The crude product was 
purified by column chromatography, eluting with 1:1 EtOAc/DCM to give 4.49 (19 mg, 
58%) as an orange gel:  
[α]D = -58.2 º (c = 0.5, MeOH) 
1H NMR (500 MHz, CDCl3) δ 2.43 (1H, t, J = 2.4 Hz, CHCCH2O), 3.01-3.14 (m, 2H, 
CHCH2), 3.63-3.81 (19H, m), 4.20 (2H, d, J = 2.4 Hz, CHCCH2O), 4.23 (1H, d, J = 1.2 Hz, 
CHOH), 4.47 (2H, s), 4.83 (1H, m, CHCH2), 6.64 (1H, m, NH), 7.25 (1H, m), 7.30-7.37 
(4H, m), 7.58 (2H, d, J = 8.3 Hz), 7.82 (2H, d, J = 8.5 Hz), 7.86-7.92 (4H, m). 
13C NMR (126 MHz, CDCl3) δ 37.9, 53.0, 53.4, 58.3, 59.1, 69.0, 69.3, 70.1, 70.3, 70.4, 
70.5, 70.5, 70.5, 70.6, 74.5, 79.6, 85.8, 88.0, 122.9, 123.0, 125.8, 126.8, 128.0, 128.6, 
129.4, 132.5, 136.1, 137.1, 151.7, 154.1, 166.4, 174.1. 
HRMS (ES): Calcd. for C38H43N3NaO9 (MNa+) 708.2897, found 708.2913. 
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(S,E)-methyl 3-(4-((4-(4,7,10,13,16-pentaoxanonadeca-1,18-diynyl)phenyl)diazenyl) 
benzamido)-2-oxo-4-phenylbutanoate 4.7:  
 
 
 
 
 
 
A solution of 4.49 (21 mg, 0.031 mmol) and Dess-Martin periodinane (26 mg, 2 eq) in 
DCM (1.0 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with Na2S2O3 
(0.25 M in sat. NaHCO3, 50 mL × 2), sat. NaHCO3 (50 mL × 2), brine (50 mL), dried over 
MgSO4 and concentrated.  The crude material was purified by column chromatography, 
eluting with 1:1 EtOAc/DCM to give 4.7 (11 mg, 51%) as an orange gel:  
[α]D = -2.2 º (c = 1.0, MeOH) 
1H NMR (300 MHz, CDCl3) δ 2.43 (1H, t, J = 2.4 Hz, CHCCH2O), 3.24 (1H, dd, J = 14.1, 
6.6 Hz, CHCHH), 3.40 (1H, dd, J = 14.1, 6.1 Hz, CHCHH), 3.64-3.82 (16H, m), 3.90 (3H, 
s, OMe), 4.20 (2H, d, J = 2.4 Hz, CHCCH2O), 4.47 (2H, s), 5.64 (1H, q, J = 6.5 Hz, 
CHCH2), 6.73 (1H, d, J = 6.9 Hz, NH), 7.17 (2H, m), 7.24-7.36 (3H, m), 7.59 (2H, d, J = 
8.5 Hz), 7.81-8.00 (6H, m). 
13C NMR (75 MHz, CDCl3) δ 36.8, 53.3, 57.0, 58.4, 59.2, 69.1, 69.3, 70.3, 70.4, 70.5, 70.5, 
70.6, 70.6, 74.5, 79.6, 85.8, 88.0, 123.1, 123.1, 126.0, 127.5, 128.1, 128.8, 129.4, 132.6, 
134.9, 135.0, 151.7, 154.4, 160.6, 166.3, 191.4. 
HRMS (ES): Calcd. for C38H43N3NaO10 (M + H2O + Na+) 738.3003, found 738.3010. 
 
9.5 Experimental for work described in chapter 5 
 
Methanesulfonic acid 2-(2-(2-hydroxy-ethoxy)-ethoxy)-ethyl ester 5.20:28, 29    
 
 
 
A solution of MsCl (650 mg, 6.0 mmol) in DCM (2.0 mL) was added dropwise to a 
solution of triethylene glycol 5.19 (750 mg, 5.0 mmol) and Ag2O (1.3 g, 5.5 mmol) in 
DCM (10 mL).  The resultant mixture was stirred for 68 h, filtered through Celite-545 and 
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concentrated.  The crude material was purified by flash chromatography, eluting with 1:9 
MeOH/EtOAc to give 5.20 (740 mg, 65%) as a pale yellow oil: 
1H NMR (500 MHz, CDCl3) δ  3.07 (3H, s, Me), 3.60 (2H, m), 3.68 (4H, s), 3.73 (2H, m), 
3.78 (2H, m), 4.38 (2H, m). 
HRMS (ES): Calcd. for C7H17O6S (MH+) 229.0746, found 229.0744. 
 
2-(2-(2-Azido-ethoxy)-ethoxy)-ethanol 5.21:28, 30 
 
 
A mixture of 5.20 (400 mg, 1.8 mmol), NaN3 (170 mg, 1.5 eq) and DMF (2.0 mL) was 
stirred for 2.5 h at 110 ºC, then cooled and concentrated.  The crude material was purified 
by flash chromatography to give 5.21 (310 mg, qu) as a colourless oil: 
1H NMR (500 MHz, CDCl3) δ  3.40 (2H, t, J = 4.9 Hz), 3.61 (2H, m), 3.65-3.70 (6H, m), 
3.73 (2H, m). 
 
5-(1,2)Dithiolan-3-yl-pentanoic acid 2-(2-(2-azido-ethoxy)-ethoxy)-ethyl ester 5.4:   
 
 
 
To a solution of 5.21 (100 mg, 0.57 mmol), lipoic acid 5.1 (120 mg, 1 eq) and HATU (220 
mg, 1 eq) in DMF (5.0 mL) was added DIEA (200 μL, 2 eq).  The resultant solution was 
stirred for 16 h then diluted with EtOAc (50 mL), washed with brine (50 mL × 2), dried 
over MgSO4 and concentrated.  The crude material was purified by flash chromatography, 
eluting with 1:19 EtOAc/DCM to give 5.4 (79 mg, 38%) as a yellow oil: 
1H NMR (500 MHz, CDCl3) δ  1.47 (2H, m), 1.68 (4H, m), 1.91 (1H, m), 2.35 (2H, t, J = 
7.4 Hz), 2.46 (1H, m), 3.14 (2H, m), 3.39 (2H, t, J = 4.8 Hz), 3.57 (1H, m), 3.65-3.73 (8H, 
m), 4.23 (2H, m). 
13C NMR (75 MHz, CDCl3) δ 24.3, 28.4, 33.6, 34.3, 38.2, 39.9, 50.4, 56.0, 63.1, 68.9, 69.8, 
70.3, 70.4, 173.0 (COO). 
HRMS (ES): Calcd. for C14H25N3NaO4S2 (MNa+) 386.1184, found 386.1166. 
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Methanesulfonic acid 2-(2-(2-(2-(2-(2-hydroxy-ethoxy)-ethoxy)-ethoxy)-ethoxy)- 
ethoxy)-ethyl ester 5.23:29  
 
 
 
A solution of hexaethylene glycol 5.22 (11 g, 39 mmol) in THF was cooled to 0 ºC then 
NaH (60% in mineral oil, 520 mg, 13 mmol) was added. The mixture was stirred for 30 
min, then MsCl (1.0 mL, 1.5 g, 13 mmol) was added dropwise.  The resulting mixture was 
stirred for 16 h, warming to r.t., then concentrated.  The crude material was purified by 
flash chromatography, eluting with 1:9 MeOH/EtOAc to give 5.23 (2.1 g, 45%) as a 
colourless oil: 
1H NMR (300 MHz, (CDCl3) δ 2.84 (1H, t, J = 6.1 Hz, OH), 3.10 (3H, s), 3.58-3.80 (22H, 
m), 4.39 (2H, m). 
 
2-(2-(2-(2-(2-(2-Azido-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethanol 5.24:31 
 
 
A mixture of 5.23 (1.0 g, 2.8 mmol), NaN3 (270 mg, 1.5 eq) and DMF (3.0 mL) was 
stirred for 2 h 30 min at 110 ºC, cooled then concentrated.  The crude product was purified 
by flash chromatography, eluting with 1:9 MeOH/EtOAc to give 5.24 (690 mg, 81%) as a 
yellow oil: 
1H NMR (500 MHz, (CDCl3) δ 2.87 (1 H, t, J = 6.2 Hz, OH), 3.39 (2H, t, J = 5.1 Hz), 3.61 
(2H, m), 3.64-3.69 (18H, m), 3.73 (2H, m). 
 
5-(1,2)Dithiolan-3-yl-pentanoic acid 2-(2-(2-(2-(2-(2-azido-ethoxy)-ethoxy)-ethoxy)- 
ethoxy)-ethoxy)-ethyl ester 5.5:  
 
 
 
A solution of alcohol 5.24 (150 mg, 0.48 mmol), lipoic acid 5.1 (100 mg, 1 eq), EDCI (100 
mg, 1.1 eq) and DMAP (20 mg, 0.34 eq) in DCM (5.0 mL) was stirred for 16 h, diluted 
with DCM (50 mL), washed with H2O (50 mL), brine (50 mL), dried over MgSO4 and 
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concentrated.  The crude product was purified by flash chromatography, eluting with 
EtOAc to give 5.5 (180 mg, 77%) as a yellow oil: 
1H NMR (500 MHz, (CDCl3) δ 1.47 (2H, m), 1.68 (4H, m), 1.91 (1H, m), 2.35 (2H, t, J = 
7.4 Hz), 2.46 (1H, m), 3.12 (1H, m), 3.19 (1H, m), 3.39 (2H, t, J = 5.0 Hz), 3.57 (1H, m), 
3.64-3.72 (20H, m), 4.23 (2H, m). 
13C NMR (75 MHz, CDCl3) δ 24.2, 28.3, 33.5, 34.2, 38.1, 39.8, 50.2, 55.9, 63.0, 68.7, 69.6, 
70.1, 70.1, 70.2, 70.2, 70.2, 70.2, 172.9. 
HRMS (ES): Calcd. for C20H37N3NaO7S2 (MNa+) 518.1971, found 518.1983. 
FTIR: 1734 (C=O), 2105 (N3) cm-1 
 
5-(1,2)Dithiolan-3-yl-pentanoic acid 2-(2-hydroxy-ethoxy)-ethyl ester 5.6:  
 
 
 
To a solution of EDCI (92 mg, 0.48 mmol), diethylene glycol (510 mg, 10 eq) and DMAP 
(20 mg, 0.34 eq) in DCM (5.0 mL) was added a solution of lipoic acid 5.1 (100 mg, 1 eq) 
in DCM (1.0 mL).  The resulting mixture was stirred for 16 h then concentrated.  The 
crude product was purified by flash chromatography, eluting with 1:19 MeOH/DCM to 
give 5.6 (110 mg, 78%) as a yellow oil: 
1H NMR (500 MHz, CDCl3) δ 1.48 (2H, m), 1.60-1.76 (4H, m), 1.91 (1H, m), 2.05 (1H, s, 
OH), 2.36 (2H, t, J = 7.5 Hz), 2.46 (1H, m), 3.12 (1H, m), 3.18 (1H, m), 3.53-3.65 (3H, m), 
3.68-3.77 (4H, m), 4.25 (2H, t, J = 4.8 Hz). 
13C NMR (75 MHz, (CD3)2CO) δ 24.6, 28.7, 34.0, 34.6, 38.5, 40.3, 56.4, 61.7, 63.4, 69.2, 
72.4, 173.6. 
HRMS (ES): Calcd. for C12H23O4S2 (MH+) 295.1038, found 295.1043. 
 
11-Acetylsulfanyl-undecanoic acid 5.25:29, 32 
 
 
 
A solution of 11-mercaptoundecanoic acid 5.2 (1.0 g, 4.6 mmol) in DCM (12 mL) and 
AcOH (12 mL) was cooled to 0 ºC, AcCl (7.0 mL) was added and the resulting solution 
was stirred for 5 min, warmed to r.t. and stirred for 2 h, then washed with cold HCl (0 ºC, 
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0.1 M, 50 mL × 2), brine (50 mL) and concentrated.  The crude product was purified by 
flash chromatography, eluting with 1:4 EtOAc/pet ether to give 5.25 (760 mg, 63%) as a 
white solid:  
mp: 47-52 ºC (lit.32 49-50 ºC) 
1H NMR (500 MHz, CDCl3) δ 1.24-1.39 (12H, m), 1.52-1.67 (4H, m), 2.31-2.37 (5H, m), 
2.86 (2H, t, J = 7.4 Hz). 
HRMS (ES): Calcd. for C13H25O3S (MH+) 261.1524, found 261.1519. 
 
(2-(2-(2-Hydroxy-ethoxy)-ethoxy)-ethoxy)-acetic acid tert-butyl ester 5.27:33 
 
 
 
A solution of triethylene glycol 5.19 (10 g, 68 mmol) in THF (20 mL) was cooled to 0 ºC, 
NaH (60% in mineral oil, 540 mg, 14 mmol) was added and the resulting mixture was 
stirred for 30 min.  tert-Butyl bromoacetate 5.26 (2.7 g, 14 mmol) was added dropwise 
over 10 min, the mixture was stirred for 16 h, warming to r.t., then concentrated.  The 
crude product was purified by flash chromatography, eluting with EtOAc to give 5.27  
(1.4 g, 38%) as a colourless oil: 
1H NMR (500 MHz, CDCl3) δ 1.48 (9H, s, C(Me)3), 3.62 (2H, m), 3.66-3.77 (10H, m), 
4.03 (2H, s, COCH2). 
HRMS (ES): Calcd. for C12H24NaO6 (MNa+) 287.1471, found 287.1463. 
 
11-Acetylsulfanyl-undecanoic acid 2-(2-(2-tert-butoxycarbonylmethoxy-ethoxy)- 
ethoxy)-ethyl ester 5.28:  
 
 
 
A solution of alcohol 5.27 (150 mg, 0.58 mmol), carboxylic acid 5.25 (150 mg, 1 eq), 
EDCI (110 mg, 1 eq) and DMAP (14 mg, 0.2 eq) in DCM (5.0 mL) was stirred for 16 h, 
diluted with EtOAc (50 mL), washed with brine (50 mL × 2), dried over MgSO4 and 
concentrated.  The crude material was purified by flash chromatography, eluting with a 
gradient of 1:19 to 1:9 EtOAc/DCM to give 5.28 (180 mg, 63%) as a colourless oil: 
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1H NMR (500 MHz, CDCl3) δ 1.23-1.38 (12H, m), 1.48 (9H, s), 1.52-1.65 (4H, m), 2.30-
2.35 (5H, m), 2.86 (2H, t, J = 7.3 Hz), 3.66-3.73 (10H, m), 4.02 (2H, s), 4.22 (2H, t, J = 4.9 
Hz). 
13C NMR (75 MHz, CDCl3) δ 25.0, 28.2, 28.9, 29.2, 29.2, 29.2, 29.3, 29.4, 29.5, 29.6, 30.7, 
34.3, 63.5, 69.1, 69.3, 70.6, 70.7, 70.7, 70.8, 81.6, 169.7, 173.9, 196.1. 
HRMS (ES): Calcd. for C25H46NaO8S (MH+) 529.2811, found 529.2835. 
 
11-Acetylsulfanyl-undecanoic acid 2-(2-(2-carboxymethoxy-ethoxy)-ethoxy)-ethyl 
ester 5.7:  
 
 
To a solution of 5.28 (50 mg, 0.099 mmol) in DCM (4.0 mL) was added TFA (1.0 mL). 
The reaction mixture was stirred for 1 h then concentrated.  The crude material was 
purified by flash chromatography, eluting with 30:70:1 EtOAc/DCM/AcOH to give 5.7 
(33 mg, 74%) as a colourless oil:  
1H NMR (500 MHz, CDCl3) δ 1.24-1.38 (12H, m), 1.52-1.65 (4H, m), 2.31-2.35 (5H, m), 
2.86 (2H, t, J = 7.4 Hz), 3.65-3.73 (8H, m), 3.74-3.78 (2H, m), 4.18 (2H, s), 4.24 (2H, t, J 
= 4.8 Hz). 
13C NMR (75 MHz, CDCl3) δ 25.0, 28.9, 29.2, 29.2, 29.3, 29.3, 29.5, 29.5, 29.6, 30.8, 34.3, 
63.4, 68.9, 69.4, 70.4, 70.5, 70.8, 71.5, 172.6, 174.0, 196.3. 
HRMS (ES): Calcd. for C21H39O8S (MH+) 451.2365, found 451.2383. 
 
11-Acetylsulfanyl-undecanoic acid 2-(2-(2-(2-(2-(2-azido-ethoxy)-ethoxy)-ethoxy)- 
ethoxy)-ethoxy)-ethyl ester 5.8:  
 
 
 
A solution of alcohol 5.24 (200 mg, 0.65 mmol), carboxylic acid 5.25 (170 mg, 1 eq), 
EDCI (130 mg, 1 eq) and DMAP (27 mg, 0.34 eq) in DCM (5.0 mL) was stirred for 16 h, 
diluted with DCM (50 mL), washed with H2O (50 mL), brine (50 mL), dried over MgSO4 
and concentrated.  The crude product was purified by flash chromatography, eluting with 
1:9 EtOAc/pet ether to give 5.8 (100 mg, 29%) as a yellow oil: 
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1H NMR (500 MHz, (CDCl3) δ 1.24-1.38 (12H, m), 1.52-1.65 (4H, m), 2.30-2.34 (5H, m), 
2.86 (2H, t, J = 7.3 Hz), 3.39 (2H, t, J = 5.0 Hz), 3.63-3.71 (20H, m), 4.22 (2H, t, J = 4.9 
Hz). 
13C NMR (75 MHz, (CDCl3) δ 25.0, 28.9, 29.2, 29.2, 29.2, 29.3, 29.4, 29.5, 29.6, 30.7, 
34.3, 50.8, 63.4, 69.3, 70.1, 70.6, 70.7, 70.7, 70.8, 70.8, 173.9, 196.1. 
HRMS (ES): Calcd. for C25H48N3O8S (MH+) 550.3162, found 550.3175. 
FTIR: 1689 (C=O), 1734 (C=O), 2106 (N3) cm-1 
 
11-(10-(2-(2-(2-(2-(2-(2-Azido-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethoxy)-
ethoxycarbonyl)-decyldisulfanyl)-undecanoic acid 2-(2-(2-(2-2-(2-azido-ethoxy)- 
ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethyl ester 5.9:  
 
 
 
A solution of 5.8 (25 mg, 0.045 mmol) and hydrazine acetate (8.0 mg, 2 eq) in DMF (1.0 
mL) was stirred for 2 d, diluted with DCM (50 mL), washed with H2O (50 mL × 2) and 
concentrated.  The crude material was purified by flash chromatography, eluting with 1:9 
MeOH/EtOAc to give 5.9 (23 mg, qu) as a colourless oil: 
1H NMR (500 MHz, (CDCl3) δ 1.24-1.41 (12H, m), 1.58-1.70 (4H, m), 2.32 (2H, t, J = 7.6 
Hz), 2.68 (2H, t, J = 7.3 Hz), 3.39 (2H, t, J = 5.0 Hz), 3.63-3.72 (20H, m), 4.22 (2H, t, J = 
4.9 Hz). 
13C NMR (75 MHz, (CDCl3) δ 24.8, 28.4, 29.1, 29.1, 29.2, 29.3, 29.4, 34.1, 39.1, 50.6, 
63.3, 69.1, 70.0, 70.5, 70.5, 70.6, 70.6, 70.6, 173.7. 
HRMS (ES): Calcd. for C46H88N6NaO14S2 (MNa+) 1035.5698, found 1035.5697. 
FTIR: 1734 (C=O), 2106 (N3) cm-1 
 
11-Acetylsulfanyl-undecanoic acid 2-(2-hydroxy-ethoxy)-ethyl ester 5.10:  
 
 
 
To a solution of diethylene glycol (410 mg, 10 eq), EDCI (74 mg, 1 eq) and DMAP (10 
mg, 0.2 eq) in DCM (4.0 mL) was added a solution of 5.25 (100 mg, 0.38 mmol) in DCM 
(1.0 mL) and the resulting solution was stirred for 16 h, diluted with EtOAc (50 mL) 
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washed with brine (50 mL × 2), dried over MgSO4 and concentrated.  The crude product 
was purified by flash chromatography, eluting with 1:4 EtOAc/DCM to give 5.10 (100 mg, 
76%) as a white solid:  
mp: 24-26 ºC 
1H NMR (500 MHz, (CDCl3) δ 1.23-1.38 (12H, m), 1.52-1.66 (4H, m), 2.31-2.36 (5H, m), 
2.86 (2H, t, J = 7.4 Hz), 3.61 (2H, t, J = 4.5 Hz), 3.71 (2H, t, J = 4.8 Hz), 3.74 (2H, t, J = 
4.5 Hz), 4.25 (2H, t, J = 4.8 Hz). 
13C NMR (75 MHz, CDCl3) δ 25.0, 28.8, 29.1, 29.1, 29.2, 29.3, 29.4, 29.4, 29.5, 30.7, 34.3, 
61.8, 63.3, 69.2, 72.4, 173.9, 196.1. 
HRMS (ES): Calcd. for C17H33O5S (MH+) 349.2048, found 349.2048. 
 
11-(10-(2-(2-Hydroxy-ethoxy)-ethoxycarbonyl)-decyldisulfanyl)-undecanoic acid 2-(2-
hydroxy-ethoxy)-ethyl ester 5.11: 
 
 
 
A solution of 5.10 (15 mg, 0.043 mmol) and hydrazine acetate (5.0 mg, 1 eq) in DMF (1.0 
mL) was stirred for 2 d, diluted with DCM (50 mL), washed with H2O (50 mL × 2) and 
concentrated.  The crude material was purified by flash chromatography, eluting with 
EtOAc to give 5.11 (7.0 mg, 53%) as a white solid:  
mp: 54-56 ºC 
1H NMR (500 MHz, (CDCl3) δ 1.23-1.42 (12H, m), 1.64 (4H, m), 2.23-2.40 (3H, m), 2.68 
(2H, t, J = 7.4 Hz), 3.61 (2H, t, J = 4.6 Hz), 3.71 (2H, t, J = 4.7 Hz), 3.74 (2H, t, J = 4.6 
Hz), 4.25 (2H, t, J = 4.7 Hz). 
13C NMR (75 MHz, CDCl3) δ 25.0, 28.6, 29.2, 29.3, 29.3, 29.5, 29.5, 34.3, 39.2, 61.8, 63.3, 
69.3, 72.4, 173.9. 
HRMS (ES): Calcd. for C30H59O8S2 (MH+) 611.3651, found 611.3645. 
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(E)-4-(4-((2,2,2-Trifluoro-acetylamino)-methyl)-phenylazo)-benzoic acid ethyl ester 
5.29:  
 
 
 
 
 
To a solution of 2.41 (12 mg, 0.027 mmol) in DCM (4.0 mL) was added TFA (1.0 mL). 
The reaction mixture was stirred for 1 h then concentrated to give 5.29 (12 mg, 98%) as an 
orange solid:  
mp: 206-210 ºC 
1H NMR (500 MHz, (CD3OD)) δ 1.41 (3H, t, J = 7.2 Hz, CH2Me), 3.77 (2H, s), 4.40 (2H, 
q, J = 7.2 Hz, CH2Me), 4.54 (2H, s), 7.52 (2H, d, J = 8.3Hz), 7.3 (2H, d, J = 8.3Hz), 7.96 
(2H, d, J = 8.3Hz), 8.18 (2H, d, J = 8.3Hz). 
13C NMR (75 MHz, (CD3OD)) δ 14.6 (CH2Me), 41.5, 43.8, 62.5 (CH2Me), 123.7, 124.4, 
129.5, 131.6, 133.5, 143.7, 153.2, 167.3. 
HRMS (ES): Calcd. for C18H21N4O3 (MH+) 341.1614, found 341.1609. 
 
4-(4-((5-(1,2)Dithiolan-3-yl-pentanoylamino)-methyl)-phenylazo)-benzoic acid ethyl 
ester 5.12:  
 
 
 
 
To a solution of 5.29 (12 mg, 0.026 mmol), lipoic acid 5.1 (6.0 mg, 1 eq), EDCI (6.0 mg, 1 
eq) and HOBt (4.0 mg, 1 eq) in DMF (2.0 mL) was added DIEA (10 μL, 7.4 mg, 2 eq) and 
the resulting mixture was stirred for 16 h, diluted with EtOAc (50 mL), washed with H2O 
(50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The crude material was 
purified by column chromatography, eluting with 1:19 MeOH/DCM to give 5.12 (5.0 mg, 
36%) as an orange solid: 
mp: 163-167 ºC 
1H NMR (500 MHz, CDCl3) δ 1.36-1.52 (5H, m), 1.57-1.73 (4H, m), 1.87 (1H, m), 2.26 
(2H, t), 2.42 (1H, m), 3.05-3.19 (2H, m), 3.53 (1H, m), 4.00 (2H, d, J = 5.2 Hz), 4.42 (2H, 
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q, J = 7.1 Hz, CH2Me), 4.53 (2H, d, J = 5.9 Hz), 6.40 (1H, s), 6.81 (1H, s), 7.42 (2H, d, J = 
8.3 Hz), 7.88-7.97 (4H, m), 8.19 (2H, d, J = 7.9 Hz). 
13C NMR (75 MHz, CDCl3) δ 14.5, 25.4, 29.0, 34.7, 36.1, 38.6, 40.4, 43.3, 43.6, 56.5, 61.4, 
122.8, 123.6, 128.5, 130.7, 132.4, 141.7, 152.0, 155.1, 166.2, 169.2, 173.7. 
HRMS (ES): Calcd. for C26H33N4O4S2 (MH+) 529.1943, found 529.1924. 
 
(E)-4-(4-((2-(2-(2-(2-(2-(11-Acetylsulfanyl-undecanoyloxy)-ethoxy)-ethoxy)-ethoxy)-
acetylamino)-acetylamino)-methyl)-phenylazo)-benzoic acid ethyl ester 5.13: 
 
To a solution of amine 5.29 (10 mg, 0.022 mmol), carboxylic acid 5.7 (10 mg, 1 eq), EDCI 
(5.0 mg, 1 eq) and HOBt (3.0 mg, 1 eq) in DCM (2.0 mL) was added DIEA (12 μL, 8.9 
mg, 3 eq) and the resulting mixture was stirred for 16 h, diluted with EtOAc (50 mL), 
washed with brine (50 mL × 2) and concentrated.  The crude material was purified by 
column chromatography, eluting with 1:19 MeOH/DCM to give 5.13 (9.0 mg, 53%) as an 
orange gel: 
1H NMR (500 MHz, CDCl3) δ 1.21-1.37 (12H, m), 1.43 (3H, t, J = 7.0 Hz), 1.50-1.63 (4H, 
m), 2.27-2.33 (5H, m), 2.85 (2H, t, J = 7.3 Hz), 3.61-3.71 (10H, m), 4.02-4.07 (4H, m), 
4.21 (2H, t, J = 4.8 Hz), 4.42 (2H, q, J = 7.1 Hz), 4.53 (2H, d, J = 5.9 Hz), 6.99 (1H, t, J = 
5.7 Hz), 7.43 (2H, d, J = 8.2 Hz), 7.80 (1H, t, J = 5.8 Hz), 7.88-7.95 (4H, m), 8.19 (2H, d, J 
= 8.3 Hz). 
13C NMR (75 MHz, CDCl3) δ 14.4, 25.0, 28.9, 29.2, 29.2, 29.2, 29.3, 29.5, 29.5, 29.6, 30.8, 
34.3, 43.2, 61.4, 63.3, 69.3, 70.2, 70.4, 70.4, 70.6, 71.2, 122.7, 123.5, 128.5, 130.7, 132.3, 
142.0, 151.9, 155.1, 166.1, 169.2, 171.3, 173.9, 196.2. 
HRMS (ES): Calcd. for C39H57N4O10S (MH+) 773.3795, found 773.3820. 
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(E)-4-(4-((2-Amino-acetylamino)-methyl)-phenylazo)-N-(1-benzyl-3,3,3-trifluoro-2-
hydroxy-propyl)-benzamide trifluoroacetate 5.30: 
 
 
 
 
 
 
To a solution of 4.16 (10 mg, 0.016 mmol) in DCM (4.0 mL) was added TFA (1.0 mL). 
The reaction mixture was stirred for 80 min then concentrated.  The crude material was 
purified by column chromatography, eluting with 1:3 EtOH–DCM to give 5.30 (6.0 mg, 
60%), as an orange solid:  
mp: 109–112 ºC 
1H NMR (500 MHz, CD3OD) δ 3.06 (2H, d, J = 7.8 Hz), 3.76 (2H, s), 4.05 (1H, m, 
CHCH2), 4.54 (2H, s), 4.73 (1H, t, J = 7.8 Hz, CHCF3), 7.19-7.36 (5H, m), 7.51 (2H, d, J = 
7.3 Hz), 7.83-7.98 (6H, m). 
13C NMR (75 MHz, CD3OD) δ 37.6, 40.4, 42.7, 50.7, 69.0 (q, J = 30.9 Hz), 122.6, 123.1, 
126.7, 128.3, 128.4, 128.5, 129.3, 136.7, 137.9, 142.4, 152.0, 154.4, 166.2, 168.0. 
19F NMR (282 MHz, (CD3OD)) δ -75.98 (d, J = 7.2 Hz, CHCF3), -74.68 (s, COCF3). 
HRMS (ES): Calcd. for C26H27F3N5O3 (M – CF3COOH + H+) 514.2066, found 514.2058. 
 
(E)-11-Acetylsulfanyl-undecanoic acid 2-(2-(2-((((4-[4-(1-benzyl-3,3,3-trifluoro-2- 
hydroxy-propylcarbamoyl)-phenylazo)-benzylcarbamoyl)-methyl)-carbamoyl)-
methoxy)-ethoxy)-ethoxy)-ethyl ester 5.31:  
 
To a solution of amine 5.30 (10 mg, 0.016 mmol), carboxylic acid 5.7 (7.0 mg, 1 eq), 
EDCI (4.0 mg, 1 eq) and HOAt (3.0 mg, 1 eq) in DMF (2.0 mL) was added DIEA (6.0 μL, 
4.5 mg, 2 eq) and the resulting mixture was stirred for 16 h, diluted with EtOAc (50 mL), 
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washed with H2O (50 mL × 2), brine (50 mL), dried over MgSO4 and concentrated.  The 
crude product was purified by column chromatography, eluting with 1:19 MeOH/EtOAc to 
give 5.31 (15 mg, 99%) as an orange gel: 
1H NMR (500 MHz, CDCl3) δ 1.19-1.34 (12H, m), 1.48-1.60 (4H, m), 2.25-2.31 (5H, m), 
2.82 (2H, t, J = 7.3 Hz), 3.06 (1H, dd, J = 13.6, 8.5 Hz), 3.18 (1H, dd, J = 13.5, 7.1 Hz), 
3.58-3.69 (10H, m), 4.00-4.09 (5H, m), 4.16-4.20 (2H, t, J = 4.9 Hz), 4.43 (2H, d, J = 5.5 
Hz), 4.59 (1H, m), 7.18-7.39 (8H, m), 7.69-7.75 (5H, m), 7.84 (1H, m). 
13C NMR (75 MHz, CDCl3) δ 124.9, 28.8, 29.1, 29.2, 29.2, 29.3, 29.4, 29.4, 29.5, 30.7, 
34.2, 37.5, 42.9, 43.1, 51.6, 63.2, 69.2, 70.2, 70.4, 70.5, 71.1, 122.9, 123.4, 127.0, 128.1, 
128.2, 128.8, 129.4, 135.8, 137.2, 141.6, 151.7, 154.1, 167.7, 169.5, 171.5, 174.0, 196.4. 
HRMS (ES): Calcd. for C47H63F3N5O10S (MH+) 946.4248, found 946.4231. 
 
(E)-11-Acetylsulfanyl-undecanoic acid 2-(2-(2-((((4-(4-(1-benzyl-3,3,3-trifluoro-2-oxo- 
propylcarbamoyl)-phenylazo)-benzylcarbamoyl)-methyl)-carbamoyl)-methoxy)-
ethoxy)-ethoxy)-ethyl ester 5.14: 
 
A solution of 5.31 (13 mg, 0.014 mmol) and Dess-Martin periodinane (22 mg, 3.7 eq) in 
DCM (1.0 mL) was stirred for 3 h, diluted with EtOAc (50 mL), washed with Na2S2O3 
(0.25 M in sat. NaHCO3, 50 mL), sat. NaHCO3 (50 mL × 2), brine (50 mL), dried over 
MgSO4 and concentrated.  The crude material was purified by column chromatography, 
eluting with 1:19 acetone/EtOAc to give 5.14 (5.0 mg, 38%) as an orange gel: 
1H NMR (500 MHz, ((CD3)2CO) δ 1.25-1.38 (12H, m), 1.50-1.61 (4H, m), 2.27-2.31 (5H, 
m), 3.26 (1H, dd, J = 13.9, 12.1 Hz), 3.38 (1H, dd, J = 14.2, 3.1 Hz), 3.58-3.72 (10H, m), 
3.97-4.01 (4H, m), 4.17 (2H, t, J = 4.8 Hz), 4.40 (1H, m), 4.53 (2H, d, J = 6.0 Hz), 6.79 
(1H, s), 7.14-7.21 (2H, m), 7.27 (2H, t, J = 7.6 Hz), 7.34 (2H, d, J = 7.1 Hz), 7.53 (2H, d, J 
= 8.5 Hz), 7.78-7.85 (2H, m), 7.88-7.92 (6H, m), 8.22 (1H, d, J = 8.2 Hz). 
HRMS (ES): Calcd. for C47H63F3N5O11S (MH3O+) 962.4197, found 962.4221. 
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(E)-11-Acetylsulfanyl-undecanoic acid 2-(2-(2-(2-(2-(2-(4-(4-(4-(1-benzyl-3,3,3- 
trifluoro-2-oxo-propylcarbamoyl)-phenylazo)-phenyl)-(1,2,3)triazol-1-yl)-ethoxy)-
ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethyl ester 5.15:   
 
To a solution of alkyne 4.3 (17 mg, 0.038 mmol) and azide 5.8 (21 mg, 1 eq) in EtOH (9.0 
mL) and H2O (8.0 mL) was added sodium ascorbate (0.45 mg, 0.060 eq) then CuSO4 
(0.070 mg, 0.012 eq) and the resulting mixture was stirred for 16 h, diluted with EtOAc 
(50 mL), washed with H2O (50 mL × 2), brine (50 mL), dried over MgSO4 and 
concentrated.  The crude material was purified by column chromatography, eluting with 
EtOAc to give 5.15 (10 mg, 26%) as an orange gel: 
1H NMR (500 MHz, ((CD3)2CO) δ 1.24-1.38 (12H, m), 1.50-1.62 (4H, m), 2.26-2.31 (5H, 
m), 2.85 (2H, t, J = 7.5 Hz), 3.27 (1H, dd, J = 14.1, 12.1 Hz), 3.40 (1H, dd, J = 14.2, 2.9 
Hz), 3.51-3.68 (18H, m), 3.99 (2H, t, J = 5.1 Hz), 4.15 (2H, t, J = 4.9 Hz ), 4.40 (1H, m), 
4.68 (2H, t, J = 5.1 Hz), 7.16 (1H, s), 7.20 (1 H, t, J = 7.3 Hz), 7.29 (2H, t, J = 7.6 Hz), 
7.35 (2H, d, J = 7.3 Hz), 7.92 (2H, d, J = 8.7 Hz), 7.96 (2H, d, J = 8.7 Hz), 8.05 (2H, d, J = 
8.6 Hz), 8.16 (2H, d, J = 8.6 Hz), 8.21 (1H, d, J = 8.1 Hz), 8.57 (1H, s). 
13C NMR (75 MHz, (CD3)2CO) δ 25.6, 29.4, 29.4, 29.7, 29.8, 30.0, 30.1, 30.1, 30.3, 30.4, 
30.6, 33.7, 33.7, 34.5, 51.0, 58.6, 63.9, 69.7, 70.0, 71.0, 71.1, 71.2, 71.2, 71.2, 71.2, 71.2, 
123.3, 124.5, 127.0, 127.2, 129.2, 129.5, 130.1, 135.9, 136.7, 139.5, 146.7, 152.6, 155.2, 
169.7, 173.7, 195.5. 
HRMS (ES): Calcd. for C50H68F3N6O11S (MNa+) 1017.4619, found 1017.4643. 
 
1-Nitro-4-prop-2-ynyloxy-benzene 5.34:34, 35 
 
 
 
A solution of 4-nitrophenol 5.33 (5.0 g, 0.036 mol), propargyl bromide (5.2 g, 1.2 eq) and 
K2CO3 (6.0 g, 1.2 eq) in DMF (7.0 mL) was stirred for 16 h, diluted with EtOAc (50 mL), 
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washed with H2O (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The crude 
material was purified by recrystallisation twice from 1:4 EtOAc/pet ether to give 5.34 (800 
mg, 13%) as white crystals:  
mp: 108-110 ºC 
1H NMR (500 MHz, CDCl3) δ 2.59 (1H, t, J = 2.5 Hz, CH2CCH), 4.80 (2H, d, J = 2.5 Hz, 
CH2), 7.06 (2H, d, J = 9.3 Hz), 8.23 (2H, d, J = 9.3 Hz). 
13C NMR (75 MHz, CDCl3) δ 56.4, 76.9, 77.2, 115.1, 125.9, 142.2, 162.4. 
HRMS (ES): Calcd. for C9H8NO3 (MH+) 178.0504, found 178.0506. 
 
1-Benzyl-4-(4-nitro-phenoxymethyl)-1H-(1,2,3)triazole 5.35:   
 
 
 
Method A: 
To a solution of 5.32 (130 mg, 1.0 mmol) and 5.34 (180 mg, 1 eq) in tBuOH (1.0 mL) and 
H2O (1.0 mL) was added sodium ascorbate (20 mg,  0.1 eq) then CuSO4 (1.0 M in H2O, 50 
μL, 0.05 eq) and the resulting mixture was stirred for 75 min at 60 ºC, then H2O (10 mL) 
and NH3 (10% in H2O, 1.0 mL) were added.  The mixture was stirred for 5 min at 60 ºC, 
cooled and filtered to obtain a yellow precipitate.  The precipitate was dissolved in DCM 
(20 mL), filtered and concentrated.  The crude material was purified by flash 
chromatography, eluting with a gradient of DCM to 1:9 EtOAc/DCM to give 5.35 (210 mg, 
69%) as a white solid:  
mp: 100-103 ºC 
1H NMR (500 MHz, CDCl3) δ 5.27 (2H, s), 5.55 (2H, s), 7.05 (2H, d, J = 9.2 Hz), 7.28 
(2H, m), 7.36-7.41 (3H, m), 7.59 (1H, s, NCH), 8.17 (2H, d, J = 9.2 Hz). 
13C NMR (75 MHz, CDCl3) δ 54.2, 62.3, 114.8, 123.2, 125.8, 128.0, 128.8, 129.1, 134.3, 
141.6, 142.9, 163.1. 
HRMS (ES): Calcd. for C16H15N4O3 (MH+) 311.1144, found 311.1144. 
 
Method B: 
To a solution of 5.32 (7.0 mg, 0.05 mmol) and 5.34 (9 mg, 1 eq) in tBuOH (0.5 mL) and 
H2O (0.5 mL) was added sodium ascorbate (1 mg,  0.1 eq) then CuSO4 (0.25 M in H2O, 10 
μL, 0.05 eq) and the resulting mixture was stirred for 16 then diluted with DCM (10 mL), 
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washed with H2O (10 mL), filtered and concentrated.  1H NMR of the crude material 
revealed 11% yield of 5.35. 
 
Method C: 
To a solution of 5.32 (7.0 mg, 0.05 mmol) and 5.34 (9 mg, 1 eq) in tBuOH (0.5 mL) and 
H2O (0.5 mL) was added sodium ascorbate (10 mg, 1 eq) then CuSO4 (1.0 M in H2O, 50 
μL, 1 eq) and the resulting mixture was stirred for 16 then diluted with DCM (10 mL), 
washed with H2O (10 mL), filtered and concentrated.  1H NMR of the crude material 
revealed 80% yield of 5.35. 
 
(E)-11-(10-(2-(2-(2-(2-(2-(2-(4-(4-(4-(1-benzyl-3,3,3-trifluoro-2-oxo-propylcarbamoyl)-
phenylazo)-phenyl)-(1,2,3)triazol-1-yl)-ethoxy)-ethoxy)-ethoxy)-ethoxy)-
ethoxycarbonyl)-decyldisulfanyl)undecanoic acid 2-(2-(2-(2-(2-(2-(4-(4-(4-(1-benzyl-
3,3,3-trifluoro-2-oxo-propylcarbamoyl)-phenylazo)-phenyl)-(1,2,3)triazol-1-yl)-
ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethyl ester 5.16:  
To a solution of azide 5.9 (9.0 mg, 0.0089 mmol) and alkyne 4.3 (8.0 mg, 2 eq) in tBuOH 
(0.5 mL) and H2O (0.5 mL) was added sodium ascorbate (4.0 mg, 2.2 eq) then CuSO4  
(1.0 M in H2O, 20 μL, 2.2 eq) and the resulting mixture was stirred for 16 h, diluted with 
EtOAc (50 mL), washed with H2O (50 mL × 2), brine (50 mL), dried over MgSO4 and 
concentrated.  The crude material was purified by flash chromatography, eluting with 1:9 
MeOH/EtOAc to give 5.16 (14 mg, 82%) as an orange gel: 
1H NMR (500 MHz, (CD3)2CO) δ 1.23-1.41 (12H, m), 1.56 (2H, m), 1.65 (2H, p, J = 7.3), 
2.27 (2H, t, J = 7.4 Hz), 2.69 (2H, t, J = 7.3 Hz), 3.27 (1H, m, CHCHH), 3.40 (1H, m, 
CHCHH), 3.51-3.67 (18H, m), 3.98 (2H, t, J = 5.0 Hz), 4.14 (2H, t, J = 4.9 Hz), 4.41 (0.8H, 
m, CHCH2 (hydrate isomer)), 4.67 (2H, t, J = 5.0 Hz), 5.25 (0.2H, m, CHCH2 (ketone 
isomer)), 6.80 (1H, s), 7.15-7.21 (2H, m), 7.25-7.38 (4H, m), 7.93 (4H, m), 8.03 (2H, m), 
2
N
H
O
CF3
O
N
N
N
N N
O
O
5
S
O
Chapter Nine: Experimental 
 
233
 
8.14 (2H, m), 8.22 (0.8H, d, J = 8.3 Hz, NH (hydrate isomer)), 8.55 (1H, s, NCH), 8.63 
(0.2H, d, J = 6.6 Hz, NH (ketone isomer). 
13C NMR (75 MHz, (CD3)2CO) δ 25.6, 29.1, 29.7, 29.9, 30.1, 30.2, 34.5, 39.3, 51.0, 64.0, 
69.7, 70.0, 71.1, 71.2, 71.2, 71.2, 71.2, 71.2, 71.2, 123.3, 124.5, 127.0, 127.2, 129.2, 129.5, 
130.2, 135.8, 136.7, 139.5, 146.7, 152.6, 155.2, 169.6, 173.7. 
 
(E)-N-(1-Benzyl-3,3,3-trifluoro-2-oxo-propyl)-4-(4-(1-(2-(2-(2-(2-(2-(2-hydroxy-
ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethyl)-1H-(1,2,3)triazol-4-yl)-phenylazo)-
benzamide 5.17:  
 
 
 
 
 
 
To a solution of alkyne 4.3 (13 mg, 0.029 mmol) and azide 5.24 (10 mg, 1.1 eq) in tBuOH 
(0.5 mL) and H2O (0.5 mL) was added sodium ascorbate (7.0 mg, 1.1 eq) then CuSO4  
(1.0 M in H2O, 32 μL, 1.1 eq) and the resulting mixture was stirred for 16 h, diluted with 
EtOAc (50 mL), washed with H2O (50 mL), brine (50 mL), dried over MgSO4 and 
concentrated.  The crude material was purified by flash chromatography, eluting with 
15:85 MeOH/EtOAc to give 5.17 (15 mg, 68%) as an orange gel: 
1H NMR (500 MHz, (CD3)2CO) δ 3.25 (1H, m, CHCHH), 3.39 (1H, m, CHCHH), 3.47-
3.66 (20H, m), 3.98 (2H, t, J = 5.0 Hz), 4.41 (1H, m, CHCH2), 4.67 (2H, t, J = 5.1 Hz), 
6.80 (1H, s), 7.15-7.21 (2H, m), 7.25-7.41 (4H, m), 7.88-7.96 (4H, m), 8.03 (2H, d, J = 8.6 
Hz), 8.14 (2H, d, J = 8.8 Hz), 8.21 (1H, d, J = 8.3 Hz), 8.56 (1H, s, NNCH). 
13C NMR (75 MHz, CDCl3) δ 33.8, 51.0, 58.5, 61.9, 70.0, 71.0, 71.1, 71.2, 73.5, 123.3, 
124.5, 127.0, 127.2, 129.2, 129.5, 130.1, 135.8, 136.7, 139.5, 146.7, 152.6, 155.2, 169.6. 
HRMS (ES): Calcd. for C37H45F3N6NaO9 (MH3O+) 797.3098, found 797.3126. 
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(S,E)-methyl 3-(4-((4-(1-(17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3- 
triazol-4-yl) phenyl)diazenyl)benzamido)-2-oxo-4-phenylbutanoate 5.18:  
 
 
 
 
 
 
 
To a solution of 4.6 (5.0 mg, 0.011 mmol) and 5.24 (4.0 mg, 1.2 eq) in tBuOH (0.5 mL) 
and H2O (0.5 mL) was added sodium ascorbate (2.0 mg, 1 eq) then CuSO4 (1.0 M in H2O, 
11 μL, 1 eq) and the resulting mixture was stirred for 16 h, diluted with EtOAc (50 mL), 
washed with H2O (50 mL), brine (50 mL), dried over MgSO4 and concentrated.  The crude 
material was purified by flash chromatography, eluting with 15:85 MeOH/EtOAc to give 
5.18 (3.0 mg, 37%) as an orange gel:  
[α]D = -70.9 º (c = 0.19, acetone) 
1H NMR (500 MHz, (CD3)2CO) δ 2.91 (0.6H, m, hydrate/hemiacetal CHCHH), 3.09-3.26 
(1H, m, hydrate/hemiacetal CHCHH and ketone CHCHH), 3.36 (0.4H, dd, J = 14.0, 5.3 
Hz, ketone CHCHH), 3.46-3.73 (28H, m), 3.81 (1H, s, hemiacetal C(OH)OMe), 3.96 (2H, 
t, J = 5.0 Hz), 4.67 (2H, t, J = 5.0 Hz), 4.79 (0.6H, m, hydrate/hemiacetal CHCH2), 5.37 
(0.4H, dd, J = 9.2, 5.5 Hz, ketone CHCH2), 7.07-7.16 (0.6H, m), 7.17-7.23 (2H, m), 7.27-
7.36 (3H, m), 7.87-7.99 (3H, m), 7.99-8.04 (3H, m), 8.09-8.15 (2H, m), 8.60 (1H, d, J = 
2.5 Hz, NNCH). 
HRMS (ES): Calcd. for C38H49N6O11 (MH+) 765.3459, found 765.3441. 
 
9.6 Experimental for work described in chapter 6 
Photoisomerisations 
 
Solutions of azobenzenes (~10 mM in d3-acetonitrile or d6-DMSO) were photoisomerised 
by irradiation with UV or visible light from a 500 W Hg arc lamp.  The light beam was 
filtered through water to reduce heat, and through a Schott UG11 filter, Corning 7-37 filter 
or Edmund optics 340 nm interference filter for UV, and a Corning 0–51 visible filter for 
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visible light.  Samples were irradiated in a darkened fumehood, then encased with foil to 
protect from ambient light and analysed by 1H NMR immediately after irradiation. NMR 
spectra were run with a delay time, d1, of 1 s.  The use of longer delay times (e.g. 10 s) did 
not significantly affect integrals, except in the case of terminal alkyne protons RCCH, 
which required d1 = 10 s to obtain a meaningful integral.  E/Z ratios were determined by 
measurement of the average E/Z integrals of appropriate non-overlapping proton 
resonances. Typically, α-H, NH and azobenzene signals were used depending on the 
degree of overlap. The major isomer was assigned the thermodynamically more stable E 
configuration based on literature precedence.36, 37 The minor Z isomer characteristically 
gave rise to upfield signals for the aryl protons which were enhanced on irradiation. 
 
1H NMR data for azobenzene E/Z isomers obtained by photoisomerisation 
 
E-2.26: 
1H NMR (500 MHz, CD3CN) δ 0.81 (3H, d, J = 6.6 Hz, CHMeMe), 0.88 (3H, d, J = 6.6 
Hz, CHMeMe), 1.42-1.54 (2H, m), 1.66 (1H, m), 3.40 (3H, s, OMe), 3.93 (1H, m, 
CHCH2), 6.21 (1H, d, J = 8.6 Hz, NH), 7.58-7.63 (3H, m), 7.94-8.03 (6H, m). 
 
Z-2.26: 
1H NMR (500 MHz, CD3CN) δ 0.78 (3H, d, J = 6.6 Hz, CHMeMe), 0.86 (3H, d, J = 6.6 
Hz, CHMeMe), 1.41-1.45 (2H, m), 1.59 (1H, m), 3.40 (3H, s, OMe), 3.83 (1H, m, 
CHCH2), 6.07 (1H, d, J = 9.1 Hz, NH), 6.86 (2H, d, J = 7.96 Hz), 6.96 (2H, d, J = 8.68 
Hz), 7.21 (1H, t, J = 7.45 Hz, CHCHCHCHCH), 7.31 (2H, t, J = 7.74 Hz, 
CHCHCHCHCH), 7.69 (2H, d, J = 8.61 Hz). 
 
E-2.41: 
1H NMR (500 MHz, CD3CN) δ 1.36-1.46 (12H, m, CMe3 and CH2Me), 3.69 (2H, d, J = 
6.0 Hz), 4.38 (2H, q, J = 7.1 Hz, CH2Me), 4.46 (2H, d, J = 6.2 Hz), 5.66 (1H, s), 7.18 (1H, 
s), 7.48 (2H, d, J = 8.2 Hz), 7.90 (2H, d, J = 8.2 Hz), 7.95 (2H, d, J = 8.7 Hz), 8.18 (2H, 
d, J = 8.7 Hz). 
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Z-2.41: 
1H NMR (500 MHz, CD3CN) δ 1.32 (3H, t, J = 7.1 Hz, CH2Me), 1.39 (9H, s, CMe3), 3.62 
(2H, d, J = 5.8 Hz), 4.26-4.33 (4H, m), 5.62 (1H, s), 6.82 (2H, d, J = 8.2 Hz), 6.90 (2H, d, 
J = 8.5 Hz), 7.03 (1H, s), 7.16 (2H, d, J = 8.2 Hz), 7.90 (2H, d, J = 8.5 Hz). 
 
E-2.7: 
1H NMR (500 MHz, CD3CN) δ 1.16-1.23 (12H, m, (CMe2)2), 2.77 (1H, m), 2.93-3.07 (2H, 
m), 7.17-7.36 (5H, m), 7.57-7.63 (3H, m), 7.88 (1H, s, NH), 7.92-8.00 (6H, m).  
 
Z-2.7: 
1H NMR (500 MHz, CD3CN) δ 1.12-1.17 (12H, m, (CMe2)2), 2.69 (1H, m), 2.87-2.99 (2H, 
m), 6.84 (2H, d, J = 7.6 Hz), 6.89 (2H, d, J = 6.9 Hz), 7.16-7.34 (7H, m), 7.67 (2H, d, J = 
6.9 Hz), 7.76 (1H, s). 
 
E-2.10: 
1H NMR (500 MHz, CD3CN) δ 1.15-1.21 (12H, m, (CMe2)2), 1.42 (9H, s, CMe3), 2.77 
(1H, dd, J = 13.9, 9.9 Hz), 2.96 (1H, dd, J = 13.9, 5.3 Hz), 3.02 (1H, m), 3.69 (2H, d, J = 
5.5 Hz), 4.46 (2H, d, J = 6.0 Hz), 5.67 (1H, s, NH), 7.15-7.38 (6H, m), 7.47 (2H, d, J = 8.1 
Hz), 7.86-7.98 (6H, m). 
 
Z-2.10: 
1H NMR (500 MHz, CD3CN) δ 1.12-1.17 (12H, m (CMe2)2), 1.39 (9H, s, CMe3), 2.8 (1H, 
m), 2.92 (2H, m), 3.62 (2H, m), 4.29 (2H, d, J = 5.9 Hz), 5.64 (1H, s, NH), 6.81 (2H, d, J = 
8.2 Hz), 6.89 (2H, d, J = 7.8 Hz), 7.06 (1H, s, NH), 7.12-7.36 (7H, m), 7.69 (2H, d, J = 8.2 
Hz), 7.86 (1H, s, NH). 
  
E-4.1: 
1H NMR (500 MHz, CD3CN) δ 1.42 (9H, s, CMe3), 3.11 (1H, m, CHCHH), 3.29 (1H, dd, 
J = 14.1, 3.3 Hz, CHCHH), 3.69 (2H, d, J = 5.4 Hz), 4.34 (0.7H, m, hydrate CHCH2), 4.45 
(2H, d, J = 6.2 Hz), 5.13 (0.3H, m), 5.35 (0.3H, m), 5.68 (1H, s), 5.94 (1H, s), 6.37 (1H, s), 
7.15-7.43 (7H, m), 7.47 (2H, d, J = 8.1 Hz), 7.74 (2H, d, J = 8.6 Hz), 7.85-7.92 (4H, m).  
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Z-4.1: 
1H NMR (500 MHz, CD3CN) δ 1.40 (9H, s, CMe3), 3.04 (1H, m, CHCHH), 3.25 (1H, dd, 
J = 13.9, 2.7 Hz, CHCHH), 3.63 (2H, d, J = 5.9 Hz), 4.23-4.33 (3H, m), 5.11 (0.3H, m), 
5.34 (1H, m), 5.64 (1H, s), 5.91 (1H, s), 6.31 (1H, s), 6.77-6.84 (4H, m), 7.08 (1H, s), 
7.15-7.30 (8H, m), 7.48 (2H, d, J = 8.4 Hz). 
 
E-4.2: 
1H NMR (500 MHz, CD3CN) δ 1.50 (3H, d, J = 7.3 Hz, Me), 2.69 (1H, t, J = 2.3 Hz, 
CH2CCH), 3.12 (1H, m, CHCHH), 3.30 (1H, dd, J = 14.1, 2.9 Hz, CHCHH), 3.50-3.60 
(12H, m), 3.66 (2H, t, J = 4.6 Hz), 4.14 (2H, m), 4.19-4.36 (3H, m), 4.61 (1H, m), 5.75 
(1H, s), 6.20 (1H, s), 7.21 (1H, m), 7.25-7.31 (4H, m), 7.34 (1H, d, J = 8.2 Hz), 7.44 (1H, 
d, J = 7.0 Hz), 7.75 (2H, d, J = 8.3 Hz), 7.92 (2H, d, J = 8.3 Hz), 7.96-8.03 (4H, m). 
 
Z-4.2: 
1H NMR (500 MHz, CD3CN) δ 1.44 (3H, d, J = 7.3 Hz), 2.79 (1H, m, CH2CCH), 3.04 
(1H, m, CHCHH), 3.23 (1H, dd, J = 14.1, 2.7 Hz, CHCHH), 3.47-3.60 (12H, m), 3.63 (2H, 
t, J = 4.5 Hz), 4.13 (2H, m), 4.15-4.36 (3H, m), 4.53 (1H, m), 5.75 (1H, s), 6.17 (1H, s), 
6.85 (2H, d, J = 8.5 Hz), 6.89 (2H, d, J = 8.4 Hz), 7.14-7.30 (7H, m), 7.46 (2H, d, J = 8.5 
Hz), 7.73 (2H, d, J = 8.4 Hz). 
 
E-4.3: 
1H NMR (500 MHz, CD3CN) δ 3.08-3.20 (1H, m, CHCHH), 3.26-3.36 (1H, m, CHCHH), 
3.61 (1H, s, CCCH), 4.31 (0.3H, m, hydrate CHCH2), 5.09 (0.7H, m, ketone CHCH2), 5.74 
(0.3H, s, hydrate OH), 6.20 (1H, s, hydrate OH), 7.18-7.37 (6H, m), 7.67-7.77 (3H, m), 
7.85-7.98 (5H, m).  
 
Z-4.3: 
The NMR spectra obtained for Z-4.3 in d3-acetonitrile contained a mixture of E- and Z- 
ketone and hydrate isomers, and peaks corresponding to each could not be fully 
determined.  The NMR spectrum is shown in Fig. 9.1, and selected Z peaks were assigned 
for determination of E/Z composition:  
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Fig. 9.1.  1H NMR spectrum of a Z-enriched sample of 4.3. 
 
Selected peaks from 1H NMR (500 MHz, CD3CN) δ 3.41-3.43 (1H, m, CCCH), 4.23 
(0.3H, m, hydrate CHCH2), 5.02 (0.7H, m, ketone CHCH2). 
 
E-4.4: 
1H NMR (500 MHz, CD3CN) δ 2.69 (1H, t, J = 2.4 Hz, CH2CCH), 3.10 (1H, m, CHCHH), 
3.29 (1H, dd, J = 14.3, 3.1 Hz, CHCHH), 3.49-3.65 (14H, m), 3.70 (2H, m), 4.14 (2H, d, J 
= 2.4 Hz, CH2CCH), 4.34 (1H, m, CHCH2), 4.43 (2H, s, OCH2CC), 5.87 (1H, s), 6.27 (1H, 
s), 7.20 (1H, m), 7.24-7.32 (4H, m), 7.38 (1H, d, J = 8.5 Hz), 7.64 (2H, d, J = 8.3 Hz), 7.75 
(2H, d, J = 8.3 Hz), 7.88-7.93 (4H, m). 
 
Z-4.4: 
1H NMR (500 MHz, CD3CN) δ 2.69 (1H, t, J = 2.3 Hz, CH2CCH), 3.04 (1H, m, CHCHH), 
3.24 (1H, dd, J = 14.0, 3.1 Hz, CHCHH), 3.51-3.67 (16H, m), 4.14 (2H, t, J = 2.3 Hz, 
CH2CCH), 4.25 (1H, m, CHCH2), 4.35 (2H, s, OCH2CC), 5.86 (1H, s), 6.26 (1H, s), 6.78-
6.85 (4H, m), 7.14-7.30 (6H, m), 7.35 (2H, d, J = 8.5 Hz), 7.47 (2H, d, J = 8.6 Hz). 
 
 
E- and Z-4.5: 
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The NMR spectra obtained for E- and Z-4.5 in d3-acetonitrile contained mixtures of E- and 
Z- ketone and hydrate isomers, and peaks corresponding to each isomer could not be fully 
determined.  1H NMR spectra are shown in Figs. 9.2 and 9.3, and E and Z CH2 peaks were 
assigned for determination of E/Z composition:  
Fig. 9.2.  1H NMR spectrum of E-4.5.  
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 4.46 (2H, d, J = 6.2 Hz). 
Fig. 9.3.  1H NMR spectrum of a Z-enriched sample of 4.5. 
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 4.29 (2H, d, J = 6.2 Hz).  
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E- and Z-4.6: 
 
The NMR spectra obtained for E- and Z-4.6 in d3-acetonitrile contained mixtures of E- and 
Z- ketone and hydrate isomers, and peaks corresponding to each isomer could not be fully 
determined.  1H NMR spectra are shown in Figs. 9.4 and 9.5, and E and Z aryl peaks were 
assigned for determination of E/Z composition:  
Fig. 9.4.  1H NMR spectrum of E-4.6. 
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 7.87-7.96 (6H, m).  
Fig. 9.5.  1H NMR spectrum of a Z-enriched sample of 4.6. 
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 6.80-6.84 (4H, m). 
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E- and Z-4.7: 
 
The NMR spectra obtained for E- and Z-4.7 in d3-acetonitrile contained mixtures of E- and 
Z- ketone and hydrate isomers, and peaks corresponding to each isomer could not be fully 
determined.  1H NMR spectra are shown in Figs. 9.6 and 9.7, and E and Z aryl peaks were 
assigned for determination of E/Z composition:  
Fig. 9.6.  1H NMR spectrum of E-4.7.  
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 7.87-7.96 (6H, m).  
Fig. 9.7.  1H NMR spectrum of a Z-enriched sample of 4.7. 
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 6.80-6.89 (4H, m). 
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E-5.17: 
1H NMR (500 MHz, CD3CN) δ 2.80 (1H, m), 3.13 (1H, m), 3.29 (1H, dd, J = 14.1, 3.1 
Hz), 3.40-3.64 (20H, m), 3.91 (2H, t, J = 5.0 Hz), 4.32 (1H, m), 4.59 (2H, t, J = 5.0 Hz), 
5.78 (1H, s), 6.25 (1H, s), 7.21 (1H, m), 7.24-7.31 (4H, m), 7.76 (1H, d, J = 8.6 Hz), 7.91 
(2H, d, J = 8.6 Hz), 8.01 (2H, d, J = 8.6 Hz), 8.08 (2H, d, J = 8.6 Hz), 8.32 (1H, s, 
NNNCH). 
 
Z-5.17: 
1H NMR (500 MHz, CD3CN) δ 2.88 (1H, t, J = 5.9 Hz), 3.04 (1H, m), 3.22 (1H, dd, J = 
13.9, 3.2 Hz), 3.40-3.64 (20H, m), 3.86 (2H, m), 4.23 (1H, m), 4.53 (2H, m), 5.81 (1H, s), 
6.22 (1H, s), 6.87 (2H, d, J = 8.6 Hz), 6.91 (2H, d, J = 8.6 Hz), 7.16-7.25 (5H, m), 7.28 
(1H, m), 7.49 (2H, d, J = 8.6 Hz), 7.77 (2H, d, J = 8.6 Hz), 8.17 (1H, s, NNNCH). 
 
E- and Z-5.18: 
 
The NMR spectra obtained for E- and Z-5.18 in d3-acetonitrile contained mixtures of E- 
and Z- ketone, hydrate, and hemiacetal isomers, and peaks corresponding to each isomer 
could not be fully determined.  1H NMR spectra are shown in Figs. 9.8 and 9.9, and E and 
Z triazole peaks were assigned for determination of E/Z composition: 
Fig. 9.8.  1H NMR spectrum of E-5.18. 
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 8.33 (1H, s, NNNCH). 
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Fig. 9.9.  1H NMR spectrum of a Z-enriched sample of 5.18. 
 
Selected peak from 1H NMR (500 MHz, CD3CN) δ 8.17 (1H, s, NNNCH). 
 
E-5.12: 
1H NMR (500 MHz, CD3CN) δ 1.35-1.46 (5H, m), 1.55-1.64 (4H, m), 1.69 (1H, m), 1.86 
(1H, m), 2.41 (1H, m), 3.08 (1H, m), 3.16 (1H, m), 3.56 (1H, m), 3.80 (2H, d, J = 5.8 Hz), 
4.38 (2H, q, J = 7.1 Hz, CH2Me), 4.45 (2H, d, J = 6.2 Hz), 6.74 (1H, s), 7.13 (1H, t, J = 5.7 
Hz), 7.47 (2H, d, J = 8.2 Hz), 7.91 (2H, d, J = 8.2 Hz), 7.95 (2H, d, J = 8.3 Hz), 8.18 (2H, 
d, J = 8.3 Hz). 
 
The NMR spectrum obtained for Z-5.12 contained only a small amount of Z-5.12, and few 
peaks corresponding to this isomer could be identified, as given below. 
 
Z-5.12: 
Selected peaks from 1H NMR (500 MHz, CD3CN) δ 3.73 (2H, d, J = 6.2 Hz), 4.25-4.32 
(4H, m), 6.82 (2H, d, J = 7.9 Hz), 6.90 (2H, d, J = 8.1 Hz).  
 
E-5.13: 
1H NMR (500 MHz, CD3CN) δ 1.18-1.35 (12H, m), 1.38 (3H, t, J = 7.1 Hz, CH2Me), 
1.47-1.56 (4H, m), 2.23-2.29 (5H, m), 2.81 (2H, m), 3.52-3.68 (10H, m), 3.89 (2H, d, J = 
6.0 Hz), 3.98 (2H, s, COCH2O), 4.12 (2H, m), 4.38 (2H, q, J = 7.1 Hz, CH2Me), 4.46 (2H, 
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d, J = 6.1 Hz), 7.18 (1H, m), 7.48 (2H, d, J = 8.4 Hz), 7.58 (1H, m), 7.91 (2H, d, J = 8.4 
Hz), 7.95 (2H, d, J = 8.6 Hz), 8.18 (2H, d, J = 8.6 Hz). 
 
Z-5.13: 
1H NMR (500 MHz, CD3CN) δ 1.23-1.35 (15H, m), 1.49-1.56 (4H, m), 2.24-2.29 (5H, m), 
2.83 (2H, m), 3.51-3.65 (10H, m), 3.83 (2H, d, J = 6.1 Hz), 3.95 (1H, s, COCH2O), 4.11 
(2H, m), 4.27-4.33 (4H, m), 6.82 (2H, d, J = 8.3 Hz), 6.90 (2H, d, J = 8.5 Hz), 7.04 (1H, 
m), 7.17 (2H, d, J = 8.3 Hz), 7.54 (1H, m), 7.91 (2H, d, J = 8.5 Hz). 
 
Isolation of Z-2.7 
 
 
 
 
 
A solution of E-2.7 (10 mg, 0.02 mmol) in 3:7 EtOAc–DCM (2.0 mL) was exposed to 
ambient indoor lighting and daylight for 2 d, giving a mixture of E- and Z-2.7 (by TLC).  
The isomers were separated by flash chromatography, eluting with 3:7 EtOAc–DCM to 
give Z-2.7 (1.0 mg, 7%, >95% Z isomer by 1H NMR): 
1H NMR (500 MHz, CDCl3) δ 1.27 (6H, s, (CMe2)2), 1.28 (6H, s, (CMe2)2), 2.76 (1H, dd, 
J = 12,14), 3.03 (1H, dd, J = 14, 4.3), 3.09 (1H, m), 6.80 (3H, m), 6.85 (2H, d, J = 8.5), 
7.18 (1H, t, J = 9.3), 7.23 (5H, m), 7.33 (2H, t, J = 7.5), 7.62 (2H, d, J = 8.5).  
 
α-Chymotrypsin assays 
 
Buffer solution (Tris): Tris(hydroxymethyl)aminomethane (12 g), CaCl2.6H2O (4.4 g) and 
Triton X-100 (0.50 g) were dissolved in Milli-Q deionised water (750 mL), adjusted to pH 
7.8 with HCl solution (1.0 M) and made up to 1.0 L with Milli-Q water.   
 
Substrate solution: N-succinyl-Ala-Ala-Pro-Phe-4-nitroanilide (21 mg) was dissolved in 
Tris buffer solution (10 mL) by ultrasonication. The solution was stored at −18 ºC for up to 
two weeks. The concentration of the solution was determined at the start of each day from 
its UV spectrum (ε315 =14 000 Lmol−1cm−1). 
N
N
N
H
O
B
O
O
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Enzyme solution: a stock solution was prepared from α-chymotrypsin (15 mg) in HCl 
solution (10 mL, pH 3, made up by dilution of conc. HCl with Milli-Q water).  The stock  
solution was stored at −18 ºC for up to 1 month.  Each day an enzyme solution was 
prepared: stock solution (200 μL, or 100 μL for assay of trifluoromethylketones and  
α-ketoesters) and Triton X-100 (25 mg) were made up to 50 mL with Milli-Q water. 
 
Inhibition of α-chymotrypsin was determined with Suc–Ala–Ala–Pro–Phe–4-nitroanilide 
as the substrate by an assay procedure developed from the technique described by 
Geiger,38 except that the order of addition of enzyme and substrate was inverted, and in 
some cases only one substrate concentration was used, in order to obtain inhibition 
constants as IC50 rather than Ki.  Inhibitors were dissolved in acetonitrile or DMSO at a 
series of dilutions ranging from 0.001 – 500 μM as appropriate for each compound (see 
assay data below for the concentrations used in each assay).  For each rate measurement, 
inhibitor solution (or acetonitrile blank, 50 μL), substrate solution (30-150 μL) and buffer 
solution (to make up the total volume to 1020 μL) were mixed in a cuvette, and incubated 
for 5 min at 25 ºC.  Enzyme solution (30 μL) was added, and the absorbance at 405 nm 
was monitored for 5 min (or 10 min for trifluoromethylketones).  An absorbance vs. time 
plot was obtained, and the slope used to find the initial rate V0 (or final rate for 
trifluoromethylketones) in μmol s-1 mg-1 (μmol of substrate hydrolysed per second per mg 
of enzyme) using the following equation: 
 
slope
ml
VslopeV
E
⋅=⋅⋅
⋅⋅= 60610
405
6
0 ε  
 
Where V is the volume of the assay solution (0.001050 L), ε405 is the molar absorptivity 
coefficient of 4-nitroaniline (10200 L mol-1 cm-1), l is the path length of the cell (1 cm) and 
mE is the mass of enzyme used in the assay (1.7 × 10-4 mg).   
 
For IC50 assays, % inhibition values were calculated from V0 (or slopes) using the 
following formula: 
 
% inhibition 100
)0]([0
0)0]([0 ⋅−=
=
=
I
I
V
VV
 
Chapter Nine: Experimental 
 
246
 
Where V0([I] = 0) is the initial rate in the absence of inhibitor. 
 
The rate data (V0 and % inhibition) was analysed to give Ki or IC50 inhibition constants.  
Details of these analyses are given in chapter 6. 
 
The uncertainty in affinity constants was not studied comprehensively, but is estimated at 
±20%, with ±10% estimated for increases/decreases in inhibition on photoisomerisation.  
These estimated errors are based on measurement uncertainties and observed discrepancies 
between E:Z compositions and IC50 values in photoswitching assays, as follows: 
 
It is apparent that the Z isomer of the trifluoromethylketone and α-ketoester inhibitors is 
the most potent (see chapter 6, Table 6.4).  Therefore, the IC50 value obtained for each 
inhibitor before irradiation (5-7% Z, see chapter 6, Table 6.2) is expected to be slightly 
higher than, and similar to, the value obtained after visible irradiation (8-21% Z, Table 6.2).  
However, some inhibitors (4.2, 4.7 and 5.17) exhibit up to 10% greater IC50 values after 
visible irradiation than obtained before irradiation.  This discrepancy must be due to 
experimental error, and is used to estimate ±10% uncertainty in IC50 increases/decreases 
on photoswitching.  This maximum observed error also gives an estimated ±10% error for 
assays, not including uncertainty in the measurement of inhibitor concentrations. 
 
The total uncertainty in affinity constants also includes measurement errors, primarily 
weighing balance uncertainties and the possible presence of solvents or minor impurities in 
inhibitor samples.  These measurement errors are estimated at ±10%, which gives a total 
estimated error of ±20% (including the 10% assay error described above).  While it is 
recognised that this estimation is not a rigorous calculation of uncertainties, the limited 
analysis was considered sufficient for the purposes of this study. 
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Assay data (slopes of absorbance vs. time plots and derived initial rates, V0) 
 
Table 9.1.  Data for assay of α-chymotrypsin. 
Substrate concentration (μM) Slope (A.U. s-1) V0 (μmol s-1 mg-1) 
83 0.0014 0.85 
170 0.0017 1.0 
250 0.0018 1.1 
330 0.0018 1.1 
420 0.0019 1.1 
 
Table 9.2.  Data for assay of α-chymotrypsin in the presence of acetonitrile. 
Substrate concentration (μM) Slope (A.U. s-1) V0 (μmol s-1 mg-1) 
83 0.0017 1.0 
170 0.0024 1.4 
250 0.0019 1.1 
330 0.0019 1.2 
420 0.0020 1.2 
 
Table 9.3.  Data for assay of α-chymotrypsin in the presence of DMSO. 
Substrate concentration (μM) Slope (A.U. s-1) V0 (μmol s-1 mg-1) 
83 0.0014 0.84 
170 0.0016 0.98 
250 0.0017 1.0 
330 0.0018 1.1 
420 0.0018 1.1 
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Table 9.4.  Data for assay of the inhibition of α-chymotrypsin by 2.12. 
Inhibitor and Substrate 
concentrations (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) 
0, 82 0.0016 0.99 
0, 170 0.0017 1.0 
0, 250 0.0018 1.1 
0, 330 0.0020 1.2 
0, 410 0.0021 1.2 
17, 82 0.00057 0.35 
17, 170 0.00088 0.54 
17, 250 0.0011 0.69 
17, 330 0.0013 0.78 
17, 410 0.0014 0.86 
35, 82 0.00037 0.22 
35, 170 0.00063 0.38 
35, 150 0.00086 0.52 
35, 330 0.00098 0.60 
35, 410 0.0011 0.69 
52, 82 0.00030 0.18 
52, 170 0.00048 0.29 
52, 250 0.00062 0.38 
52, 330 0.00076 0.46 
52, 410 0.00088 0.53 
69, 82 0.00023 0.14 
69, 170 0.00042 0.26 
69, 250 0.00056 0.34 
69, 330 0.00067 0.40 
69, 410 0.00084 0.51 
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Table 9.5.  Data for assay of the inhibition of α-chymotrypsin by 2.1. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.1 0 
15 0.0018 1.1 6.5 
 
Table 9.6.  Data for assay of the inhibition of α-chymotrypsin by 2.2. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.1 0 
25 0.0017 1.0 8.6 
 
Table 9.7.  Data for assay of the inhibition of α-chymotrypsin by 2.6. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.1 0 
200 0.0018 1.1 3.1 
 
Table 9.8.  Data for assay of the inhibition of α-chymotrypsin by 2.7. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0023 1.4 0 
0.41 0.0020 1.2 12 
0.81 0.0019 1.2 17 
1.6 0.0015 0.92 34 
3.2 0.0011 0.66 52 
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Table 9.9.  Data for assay of the inhibition of α-chymotrypsin by chromatographically 
isolated Z-2.7. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0018 1.1 0 
0.81 0.0016 0.94 16 
1.6 0.0014 0.83 26 
3.2 0.0011 0.64 43 
6.5 0.00075 0.45 60 
 
Table 9.10.  Data for assay of the inhibition of α-chymotrypsin by 2.8. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0016 0.96 0 
4.2 0.0014 0.86 10 
8.4 0.0012 0.70 27 
14 0.00079 0.48 50 
21 0.00071 0.43 55 
42 0.00050 0.30 69 
 
Table 9.11.  Data for assay of the inhibition of α-chymotrypsin by 2.9. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0016 0.96 0 
0.52 0.0011 0.67 30 
1.1 0.00090 0.55 43 
2.1 0.00059 0.36 63 
4.2 0.00036 0.22 77 
8.4 0.00022 0.14 86 
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Table 9.12.  Data for assay of the inhibition of α-chymotrypsin by 2.10. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.1 0 
5.1 0.0013 0.78 30 
10 0.00087 0.53 53 
20 0.00060 0.36 68 
41 0.00040 0.25 78 
 
Table 9.13.  Data for assay of the inhibition of α-chymotrypsin by 2.11. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0018 1.1 0 
5.5 0.0012 0.74 33 
11 0.00088 0.53 52 
22 0.00057 0.34 69 
44 0.00036 0.22 80 
88 0.00022 0.13 88 
 
Table 9.14.  Data for assay of the inhibition of α-chymotrypsin by 2.7 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0017 1.2 0 
1.7 0.0014 0.84 28 
3.5 0.0011 0.68 41 
7.0 0.00086 0.52 55 
14 0.00052 0.32 72 
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Table 9.15. Data for assay of the inhibition of α-chymotrypsin by 2.7 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.2 0 
0.87 0.0017 1.0 10 
1.7 0.0016 0.96 17 
3.5 0.0013 0.78 33 
7.0 0.00089 0.54 54 
 
Table 9.16.  Data for assay of the inhibition of α-chymotrypsin by 2.7 after UV, vis, UV 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.2 0 
2.2 0.0016 0.99 14 
4.4 0.0014 0.87 25 
8.7 0.0011 0.70 39 
17 0.00078 0.47 59 
 
Table 9.17.  Data for assay of the inhibition of α-chymotrypsin by 2.7 after UV, vis, UV, 
vis irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0016 1.1 0 
2.2 0.0015 1.0 12 
4.4 0.0013 0.93 18 
8.7 0.0011 0.80 30 
17 0.0019 0.64 44 
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Table 9.18.  Data for assay of the inhibition of α-chymotrypsin by 2.10 after UV 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.1 0 
2.6 0.0014 0.82 27 
5.1 0.0011 0.66 41 
10 0.00072 0.44 61 
20 0.00045 0.27 76 
41 0.00025 0.15 86 
 
Table 9.19.  Data for assay of the inhibition of α-chymotrypsin by 2.10 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.1 0 
5.1 0.0012 0.74 35 
10 0.0011 0.67 41 
20 0.00072 0.43 62 
41 0.00055 0.33 71 
 
Table 9.20.  Data for assay of the inhibition of α-chymotrypsin by 2.10 after UV, vis, UV 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0019 1.1 0 
5.1 0.0012 0.75 34 
10 0.00098 0.60 47 
20 0.00054 0.33 71 
41 0.00037 0.22 80 
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Table 9.21.  Data for assay of the inhibition of α-chymotrypsin by 3.3. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0013 0.80 0 
60 0.0013 0.78 1.6 
 
Table 9.22.  Data for assay of the inhibition of α-chymotrypsin by 3.4. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.0012 0.75 0 
91 0.0012 0.72 3.7 
 
Table 9.23.  Data for assay of the inhibition of α-chymotrypsin by 3.10. 
Inhibitor and Substrate 
concentrations (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) 
0, 89 0.0011 0.65 
0, 180 0.0013 0.80 
0, 270 0.0015 0.88 
0, 350 0.0015 0.90 
0, 440 0.0015 0.93 
11, 89 0.00074 0.45 
11, 180 0.0012 0.73 
11, 270 0.0013 0.77 
11, 350 0.0014 0.85 
11, 440 0.0014 0.85 
21, 89 0.00061 0.37 
21, 180 0.00088 0.53 
21, 270 0.0011 0.65 
21, 350 0.0012 0.75 
21, 440 0.0013 0.78 
 
 
 
Chapter Nine: Experimental 
 
255
 
Table 9.24.  Data for assay of the inhibition of α-chymotrypsin by 4.1. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00075 0.45 0 
4.9 0.00066 0.40 11 
9.7 0.00056 0.34 26 
19 0.00047 0.28 37 
39 0.00033 0.20 56 
 
Table 9.25.  Data for assay of the inhibition of α-chymotrypsin by 4.1 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00075 0.45 0 
4.9 0.00056 0.34 25 
9.7 0.00043 0.26 43 
19 0.00029 0.18 61 
39 0.00016 0.097 79 
 
Table 9.26.  Data for assay of the inhibition of α-chymotrypsin by 4.1 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00075 0.45 0 
4.9 0.00066 0.40 12 
9.7 0.00056 0.34 24 
19 0.00043 0.26 43 
39 0.00075 0.19 57 
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Table 9.27.  Data for assay of the inhibition of α-chymotrypsin by 4.2. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00068 0.41 0 
3.3 0.00067 0.40 1.7 
6.6 0.00054 0.33 20 
13 0.00041 0.25 39 
26 0.00026 0.16 62 
53 0.00019 0.11 73 
 
Table 9.28.  Data for assay of the inhibition of α-chymotrypsin by 4.2 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00068 0.41 0 
3.3 0.00061 0.37 10 
6.6 0.00052 0.32 23 
13 0.00036 0.22 46 
26 0.00024 0.14 65 
53 0.00016 0.095 77 
 
 
Table 9.29.  Data for assay of the inhibition of α-chymotrypsin by 4.2 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00068 0.41 0 
3.3 0.00067 0.40 1.7 
6.6 0.00056 0.34 17 
13 0.00042 0.25 38 
26 0.00027 0.16 61 
53 0.00019 0.11 72 
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Table 9.30.  Data for assay of the inhibition of α-chymotrypsin by 4.3. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00072 0.44 0 
11 0.00063 0.38 13 
21 0.00054 0.33 25 
42 0.00045 0.27 38 
85 0.00039 0.24 46 
 
Table 9.31.  Data for assay of the inhibition of α-chymotrypsin by 4.3 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00072 0.44 0 
2.7 0.00066 0.40 9 
5.3 0.00056 0.34 23 
11 0.00043 0.26 41 
21 0.00031 0.19 57 
42 0.00019 0.11 74 
85 0.00012 0.073 83 
 
Table 9.32.  Data for assay of the inhibition of α-chymotrypsin by 4.3 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00072 0.44 0 
5.3 0.00070 0.42 3.8 
11 0.00062 0.38 14 
21 0.00054 0.33 25 
42 0.00045 0.27 38 
85 0.00037 0.22 49 
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Table 9.33.  Data for assay of the inhibition of α-chymotrypsin by 4.4. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00053 0.32 0 
51 0.00029 0.17 46 
 
Table 9.34.  Data for assay of the inhibition of α-chymotrypsin by 4.4 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00053 0.32 0 
3.2 0.00046 0.28 13 
6.4 0.00036 0.22 31 
13 0.00029 0.17 46 
26 0.00017 0.10 68 
51 0.000091 0.055 83 
 
Table 9.35.  Data for assay of the inhibition of α-chymotrypsin by 4.4 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00053 0.32 0 
51 0.00031 0.19 42 
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Table 9.36.  Data for assay of the inhibition of α-chymotrypsin by 4.5. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00068 0.41 0 
0.18 0.00061 0.37 11 
0.36 0.00051 0.31 26 
0.73 0.00034 0.21 50 
1.5 0.00018 0.11 74 
2.9 0.000092 0.056 87 
15 0.0000078 0.0047 99 
 
Table 9.37.  Data for assay of the inhibition of α-chymotrypsin by 4.5 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00068 0.41 0 
0.090 0.00054 0.33 20 
0.18 0.00039 0.24 43 
0.36 0.00026 0.16 61 
0.73 0.000094 0.057 86 
1.5 0.000071 0.043 90 
 
Table 9.38.  Data for assay of the inhibition of α-chymotrypsin by 4.5 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00068 0.41 0 
0.18 0.00057 0.34 17 
0.36 0.00044 0.27 36 
0.73 0.00032 0.20 53 
1.5 0.00015 0.091 78 
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Table 9.39.  Data for assay of the inhibition of α-chymotrypsin by 4.6. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00066 0.40 0 
0.42 0.00050 0.30 24 
0.85 0.00035 0.21 48 
1.7 0.00025 0.15 63 
3.4 0.000093 0.057 86 
6.8 0.000052 0.032 92 
 
Table 9.40.  Data for assay of the inhibition of α-chymotrypsin by 4.6 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00066 0.40 0 
0.17 0.00051 0.31 23 
0.34 0.00044 0.27 34 
0.68 0.00024 0.15 64 
1.4 0.00011 0.069 83 
 
Table 9.41.  Data for assay of the inhibition of α-chymotrypsin by 4.6 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00066 0.40 0 
0.42 0.00045 0.27 32 
0.85 0.00033 0.20 50 
1.7 0.00020 0.12 69 
3.4 0.00012 0.071 82 
6.8 0.000057 0.035 91 
 
 
 
 
Chapter Nine: Experimental 
 
261
 
Table 9.42.  Data for assay of the inhibition of α-chymotrypsin by 4.7. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00059 0.36 0 
0.58 0.00048 0.29 19 
1.2 0.00038 0.23 36 
2.3 0.00029 0.18 51 
4.6 0.00015 0.089 75 
9.3 0.000062 0.038 89 
23 0.000028 0.017 95 
 
Table 9.43.  Data for assay of the inhibition of α-chymotrypsin by 4.7 after UV irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00059 0.36 0 
0.29 0.00045 0.27 25 
0.58 0.00033 0.20 44 
1.2 0.00022 0.13 63 
2.3 0.00011 0.69 81 
 
Table 9.44.  Data for assay of the inhibition of α-chymotrypsin by 4.7 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00059 0.36 0 
0.58 0.00051 0.31 14 
1.2 0.00041 0.25 31 
2.3 0.00029 0.18 51 
4.6 0.00014 0.082 77 
9.3 0.000071 0.043 81 
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Table 9.45.  Data for assay of the inhibition of α-chymotrypsin by 5.17. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00061 0.37 0 
3.0 0.00060 0.37 1.7 
5.9 0.00052 0.32 15 
12 0.00041 0.25 34 
24 0.00025 0.15 59 
47 0.00015 0.089 76 
94 0.000087 0.053 86 
 
Table 9.46.  Data for assay of the inhibition of α-chymotrypsin by 5.17 after UV 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00061 0.37 0 
3.0 0.00059 0.36 4.2 
5.9 0.00043 0.26 30 
12 0.00030 0.18 51 
24 0.00020 0.12 68 
47 0.00011 0.067 82 
 
Table 9.47.  Data for assay of the inhibition of α-chymotrypsin by 5.17 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00061 0.37 0 
5.9 0.00056 0.34 8.9 
12 0.00041 0.25 34 
24 0.00027 0.16 57 
47 0.00016 0.098 74 
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Table 9.48.  Data for assay of the inhibition of α-chymotrypsin by 5.18. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00045 0.27 0 
0.13 0.00037 0.22 19 
0.27 0.00030 0.18 34 
0.53 0.00019 0.12 58 
1.1 0.00014 0.084 69 
2.1 0.000069 0.042 85 
 
Table 9.49.  Data for assay of the inhibition of α-chymotrypsin by 5.18 after UV 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00045 0.27 0 
0.067 0.00033 0.20 28 
0.13 0.00028 0.17 38 
0.27 0.00019 0.11 59 
0.53 0.000097 0.059 78 
1.1 0.000058 0.035 87 
 
Table 9.50.  Data for assay of the inhibition of α-chymotrypsin by 5.18 after UV, vis 
irradiation. 
Inhibitor 
concentration (μM) 
Slope (A.U. s-1) V0 (μmol s-1 mg-1) % Inhibition 
0 0.00045 0.27 0 
0.13 0.00037 0.22 19 
0.27 0.00023 0.14 48 
0.53 0.00022 0.14 50 
1.1 0.00014 0.085 69 
2.1 0.000049 0.030 89 
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9.7 Experimental for work described in chapter 7 
 
Surface preparation 
 
Gold film substrates were prepared by evaporative deposition of gold onto pieces of silicon 
wafer, previously coated with titanium.  Silica samples were initially prepared by spin-
coating a Si(100) wafer with a protective layer of AZ1813 photoresist, cutting into 10 × 10 
mm squares, removing photoresist and cleaning by ultrasonication in acetone, methanol 
then isopropanol (for 5 s each), and drying under N2.  Ti (40 nm) then Au (200 nm) were 
deposited onto the wafer pieces using a Balzer vacuum evaporator.  The substrates were 
stored in a vacuum dessicator before use.   
 
A polycrystalline gold plug electrode (geometric surface area 0.3 cm2) was used in 
electrochemistry experiments.  This electrode was cleaned before use in freshly prepared 
piranha solution (1:3 H2O2/H2SO4), followed by annealing in a H2 flame then scanning 
between potentials of -0.2 V and 1.45 V in HClO4 (0.01 M) at 20 mVs-1 until a stable CV 
was obtained (several hours). 
 
Contact angle measurements 
 
Contact angle measurements were made by placing several (typically 2-3) water drops (2 
μL) on each substrate, then recording a photograph of each drop 30 s after placement.  The 
drops were analysed using an axisymmetric drop shape analysis program39 to obtain 
contact angle measurements.  All measurements for each surface were averaged.  Error is 
estimated to be ± 3º, since the standard deviations for measurements ranged from 0.4º to 
2.2º. 
 
Cyclic voltammetry 
 
Cyclic voltammetry was carried out using a computer controlled EG&G PAR 273A 
potentiostat.  Either the gold plug electrode or a gold film was used as working electrode, 
with a Pt or Au electrode as auxiliary, and a saturated calomel electrode (SCE) as 
reference.  The gold plug electrode was mounted in an electrochemical cell, in contact with 
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the solution by a hanging meniscus that exposed only the circular bottom face of the 
electrode to the solution.  Gold film electrodes were mounted in a cell that exposed a 
circular region (approximate surface area = 0.3) to the cell solution.40  Solutions were 
degassed with N2 gas for 20 min prior to any scans below -0.3 V.  All CVs were recorded 
at room temperature using a scan rate of 300 mV s-1 unless otherwise stated. 
 
Quartz crystal microbalance 
 
QCM was carried out using a Q-sense E4 instrument linked to a peristaltic pump, using 
gold coated quartz crystals.  Tris buffer (as described above for enzyme assays but without 
Triton X-100 surfactant) was used as the running buffer in all experiments, flowing at 100 
μL min-1.  Analysis of results was carried out using the Qtools software. 
 
Surface plasmon resonance 
 
SPR was carried out using a Biacore 2000 instrument.  All solutions were filtered through 
a 0.22 μM filter and centrifuged (1300 rpm, 10 sec) before use.  HEPES buffer (0.01 M, 
pH 7.4 containing 0.15 M NaCl and 3 mM EDTA) was used as the running buffer for 
surface modifications, and Tris buffer (as described above for enzyme assays except 
containing 12.5 μL P20 surfactant instead of Triton X-100) was used in all other 
experiments.  Analysis of results was carried out using BIAevaluation software. 
 
Compound 4.4 was immobilised on an SPR chip as follows: A Biacore CM5 chip was 
docked in the SPR instrument and prepared by priming and running a sensorgram in 
HEPES buffer at 100 μL min-1 flow rate then successively injecting NaOH (50 mM, 20 μL 
× 2), HCl (10 mM, 20 μL × 2), and SDS (0.1%, 20 μL × 2). Surface modification was then 
carried out at 5 μL min-1 flow rate by injection of 35 μL EDCI/NHS, followed by 7.1 (11 
mg/mL in HEPES buffer, 3 × 5 μL) then ethanolamine (1 M, pH 8.5, 35 μL). During 
attachment of 7.1, the SPR response increased by 147 RU from the initial baseline 
obtained before EDCI/NHS injection. The chip was then undocked and removed from the 
instrument and rinsed with water. A solution of 4.4 (0.30 mg, 0.44 μmol), CuBr (0.063 mg, 
0.44 μmol), 2,6-lutidine (0.094 mg, 0.88 μmol), 2,2’-bipyridine (0.14 mg, 0.88 μmol), 
sodium ascorbate (0.17 mg, 0.88 μmol) in 1:1 DMF/H2O (150 μL) was pipetted onto the 
Chapter Nine: Experimental 
 
266
 
surface and left for 1 h at room temperature. The surface was then rinsed successively with 
1:1 DMF/H2O, H2O, 0.1 M EDTA, 1:1 DMF/H2O, and H2O then redocked in the SPR 
instrument. A sensorgram was run in Tris buffer for several hours in order to obtain a 
stable baseline. A reference cell was prepared using the same method except omitting the 
injection of 7.1.  
 
Enzyme binding to this modified surface was monitored by running sensorgrams in Tris 
buffer at 30 μL min-1. For photoswitching experiments, the chip was removed from the 
instrument after regeneration, rinsed with water and irradiated with UV or visible light (as 
detailed above for solution-phase photoisomerisation) for 10 min, then replaced in the SPR 
instrument. 
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